filename,arm_name,intervention_type,screening_window,1_month,3_months,6_months,9_months,12_months,core_treatment_screening_window,core_treatment_1_month,core_treatment_3_months,core_treatment_6_months,core_treatment_9_months,core_treatment_12_months,imaging_diagnostics_screening_window,imaging_diagnostics_1_month,imaging_diagnostics_3_months,imaging_diagnostics_6_months,imaging_diagnostics_9_months,imaging_diagnostics_12_months,labs_screening_window,labs_1_month,labs_3_months,labs_6_months,labs_9_months,labs_12_months,clinic_visits_screening_window,clinic_visits_1_month,clinic_visits_3_months,clinic_visits_6_months,clinic_visits_9_months,clinic_visits_12_months,cycle_length_days,treatment_duration_rule,visit_pattern,assumptions
30516102,Trastuzumab emtansine,intervention,1,1,6,10,14,16,0,1,5,9,13,14,1,0,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,21,"14 cycles (294 days) or until progression/unacceptable toxicity, followed by a Study Drug Completion Visit.","Screening (1 day), then 14 cycles of q3w infusions (Day 1 of each cycle). One additional ECHO/MUGA visit in Cycle 2. Study Drug Completion Visit approximately 30 days after the last dose.","All screening procedures listed for 'Day -30 to -1' are assumed to occur on a single contact day within the screening window.; The 'Cycles 1 and 2 Day 14-21' ECHO/MUGA visit is assumed to occur on Day 35 (C2D14).; The 'Study Drug Completion Visit' is assumed to occur on Day 324 (Day 294 + 30 days).; PK/ATA samples are excluded from mandatory contact days as footnote 'a' on page 136 indicates they are collected in approximately 50% of patients, implying they are part of an optional sub-study.; Follow-up visits scheduled after Day 365 are not included in the 12-month window count."
30516102,Trastuzumab,control,1,1,6,10,14,16,0,1,5,9,13,14,1,0,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,21,"14 cycles (294 days) or until progression/unacceptable toxicity, followed by a Study Drug Completion Visit.","Screening (1 day), then 14 cycles of q3w infusions (Day 1 of each cycle). One additional ECHO/MUGA visit in Cycle 2. Study Drug Completion Visit approximately 30 days after the last dose.","All screening procedures listed for 'Day -30 to -1' are assumed to occur on a single contact day within the screening window.; The 'Cycles 1 and 2 Day 14-21' ECHO/MUGA visit is assumed to occur on Day 35 (C2D14).; The 'Study Drug Completion Visit' is assumed to occur on Day 324 (Day 294 + 30 days).; PK/ATA samples are excluded from mandatory contact days as footnote 'a' on page 136 indicates they are collected in approximately 50% of patients, implying they are part of an optional sub-study.; Follow-up visits scheduled after Day 365 are not included in the 12-month window count."
35660812,Arm A,intervention,2,7,17,25,39,49,0,7,17,25,38,38,1,0,0,0,0,0,1,0,0,0,1,11,0,0,0,0,0,0,RVD cycles: 21 days; Maintenance cycles: 28 days,until disease progression,"Screening (2 days); RVD Cycles 1-3 (4 days/cycle, 21-day cycle length); PBSC Mobilization (6 days); RVD Cycles 4-8 (4 days/cycle, 21-day cycle length); Maintenance (weekly for 8 weeks, then bi-weekly for 8 weeks, then monthly).","Screening procedures marked 'X' in the table (page 111/222) are assumed to occur on one dedicated screening day (Day -X), with the exception of the second pre-C1D1 pregnancy test which is explicitly stated to occur 'within 24 hours prior to initiation of lenalidomide' (Day -1) and counted as a separate contact day.; Oral drug administrations (Lenalidomide, Dexamethasone) are not counted as in-person contact days unless other trial-mandated procedures (marked 'X' in the tables) are scheduled on the same day.; For RVD cycles, only days explicitly marked 'X' in the 'Treatment Days' columns (Day 1, 4, 8, 11) are counted as contact days. Bortezomib is administered IV on these days, making them core_treatment days.; PBSC Mobilization: Cyclophosphamide IV administration is one contact day. PBSC collection is assumed to require 5 daily in-person visits for apheresis and G-CSF administration/monitoring.; PBSC Transplant (Arm B): Melphalan administration (2 days), PBSC reinfusion (1 day), and subsequent inpatient care for G-CSF administration/monitoring (6 days) are all considered in-person contact days, totaling 9 days for the transplant period.; Maintenance Therapy: The footnote on page 115/225 (new version) regarding maintenance visit frequency ('weekly for the first 2 months, once every 2 weeks for the next 2 months, and once a month thereafter') is used to determine contact days, as it specifies mandated monitoring frequency. All maintenance visits are categorized as 'labs' due to required blood draws and other assessments.; Timing of phases: Mobilization is assumed to start on Day 86 (21 days after C3D14, which is Day 52+13=Day 65). Consolidation for Arm A is assumed to start on Day 151 (60 days after mobilization ends on Day 91). Consolidation for Arm B is assumed to start on Day 165 (60 days after transplant Day 0, which is Day 105). Maintenance starts 21 days after the last consolidation cycle for both arms.; Overlap of procedures on a single day: The tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied."
35660812,Arm B,intervention,2,7,17,31,44,49,0,7,17,31,35,35,1,0,0,0,0,0,1,0,0,0,9,14,0,0,0,0,0,0,RVD cycles: 21 days; Maintenance cycles: 28 days,until disease progression,"Screening (2 days); RVD Cycles 1-3 (4 days/cycle, 21-day cycle length); PBSC Mobilization (6 days); PBSC Transplant (9 days); RVD Cycles 4-5 (4 days/cycle, 21-day cycle length); Maintenance (weekly for 8 weeks, then bi-weekly for 8 weeks, then monthly).","Screening procedures marked 'X' in the table (page 111/222) are assumed to occur on one dedicated screening day (Day -X), with the exception of the second pre-C1D1 pregnancy test which is explicitly stated to occur 'within 24 hours prior to initiation of lenalidomide' (Day -1) and counted as a separate contact day.; Oral drug administrations (Lenalidomide, Dexamethasone) are not counted as in-person contact days unless other trial-mandated procedures (marked 'X' in the tables) are scheduled on the same day.; For RVD cycles, only days explicitly marked 'X' in the 'Treatment Days' columns (Day 1, 4, 8, 11) are counted as contact days. Bortezomib is administered IV on these days, making them core_treatment days.; PBSC Mobilization: Cyclophosphamide IV administration is one contact day. PBSC collection is assumed to require 5 daily in-person visits for apheresis and G-CSF administration/monitoring.; PBSC Transplant (Arm B): Melphalan administration (2 days), PBSC reinfusion (1 day), and subsequent inpatient care for G-CSF administration/monitoring (6 days) are all considered in-person contact days, totaling 9 days for the transplant period.; Maintenance Therapy: The footnote on page 115/225 (new version) regarding maintenance visit frequency ('weekly for the first 2 months, once every 2 weeks for the next 2 months, and once a month thereafter') is used to determine contact days, as it specifies mandated monitoring frequency. All maintenance visits are categorized as 'labs' due to required blood draws and other assessments.; Timing of phases: Mobilization is assumed to start on Day 86 (21 days after C3D14, which is Day 52+13=Day 65). Consolidation for Arm A is assumed to start on Day 151 (60 days after mobilization ends on Day 91). Consolidation for Arm B is assumed to start on Day 165 (60 days after transplant Day 0, which is Day 105). Maintenance starts 21 days after the last consolidation cycle for both arms.; Overlap of procedures on a single day: The tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied."
35704479,Active Monitoring Arm,control,1,1,1,2,2,3,0,0,0,0,0,0,1,1,1,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,180,5 years follow-up (or until cancer diagnosis/death),"Screening (Day -28), Randomization (Day 0), then 6-monthly visits (Day 180, 360, etc.)","Visit 0 (Screening) is placed at Day -28 for calculation purposes, falling within the screening window.; Visit 1 (Randomization) is anchored at Day 0.; Subsequent routine visits (Visits 2, 3, etc.) occur every 6 months (Day 180, Day 360, etc.).; For any given day, the highest priority category among all procedures performed on that day is assigned to the contact day.; Anal biopsy and High Resolution Anoscopy (HRA) are categorized as imaging_diagnostics.; HIV viral load/CD4 level and Anal biopsy are performed annually (every 12 months) from Visit 2 onwards for the Active Monitoring Arm.; Optional ancillary studies (e.g., SARS-CoV-2 swab) are not counted as trial-mandated contact days."
35704479,Treatment Arm,intervention,1,3,7,9,9,10,0,3,7,7,7,7,1,0,0,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,180,until progression/unresponsive to therapy or other criteria (up to 5 years follow-up),"Screening (Day -28), Randomization (Day 0), Interim treatment/re-evaluation visits (Day 21, 30, 42, 56, 63, 84, 112), then 6-monthly visits (Day 180, 360, etc.)","Visit 0 (Screening) is placed at Day -28 for calculation purposes, falling within the screening window.; Visit 1 (Randomization) is anchored at Day 0.; The 'Treatment Arm' encompasses multiple modalities (Imiquimod/5-FU, TCA, IRC/Hyfrecation/Laser, Surgery). The contact days are calculated by taking the maximum number of unique in-person days across all these modalities within each time window, and assigning the highest priority category for that day.; For Imiquimod/5-FU, the initial application demonstration at Visit 1 is a core_treatment day. Subsequent 8-week (Day 56) and 16-week (Day 112) re-examinations are for toxicity/tolerability assessment (imaging_diagnostics, due to HRA/biopsy).; For TCA, applications are clinician-applied and occur every 3 weeks for up to 4 times within 12 weeks (Day 21, 42, 63, 84), each counted as a core_treatment day.; For IRC/Hyfrecation/Laser, initial treatment at Visit 1 is a core_treatment day. Re-treatment within 8 weeks (Day 56) is assumed as a core_treatment day.; For Surgery (TUA), scheduling at Visit 1 is a clinic_visits activity, but the surgery itself is assumed to occur around Day 30 (within 2 months of V1) and is a core_treatment day. A re-evaluation visit at 8 weeks (Day 56) is assumed for assessment (imaging_diagnostics).; For any given day where multiple treatment modalities might have a visit, the highest priority category is assigned (e.g., core_treatment takes precedence over imaging_diagnostics).; Routine follow-up visits (Visits 2, 3, etc.) occur every 6 months (Day 180, Day 360, etc.).; Anal biopsy and High Resolution Anoscopy (HRA) are categorized as imaging_diagnostics.; Anal biopsy is performed every 6 months for the Treatment Arm.; HIV viral load/CD4 level is performed annually (every 12 months) from Visit 2 onwards for the Treatment Arm.; Optional ancillary studies (e.g., SARS-CoV-2 swab) are not counted as trial-mandated contact days."
35759733,Regimen I: CT-2103 (135mg/m²),intervention,1,2,7,14,20,24,0,1,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,12,0,0,0,0,0,0,28,12 monthly cycles (12 months),"1 screening visit. 12 treatment visits (Day 0, 28, 56, ..., 308). 12 nadir lab visits (approx. Day 10, 38, 66, ..., 318).","All 'Prior to Study' assessments (History, Physical Exam, QOL, Labs, Imaging) are consolidated into a single in-person screening day. This day is categorized as imaging_diagnostics due to precedence (CT scan, X-ray, EKG).; Routine assessments listed under 'Prior to Each Course' (History, Physical Exam, CBC, Platelets, Creatinine, Bilirubin, CA-125) are assumed to be performed on the same day as the chemotherapy infusion (Day 0, 28, 56, etc.). These days are categorized as core_treatment.; Nadir labs (CBC & Differential, Platelets) are assumed to occur on a separate visit around Day 10 of each 28-day cycle (e.g., Day 10, 38, 66, etc.), as indicated by the 'Nadir (8-12 days)' column. These are categorized as labs.; Conditional visits (e.g., CT scans for symptomatic changes, Coagulation Profile for abnormal parameters) are excluded from the routine contact day count.; Quality of Life (QOL) assessments (Footnote 7) are assumed to be performed on existing contact days (screening, Day 56, 112, 168, 308).; Pre-Cycle Serum (SB01, SB02) and Whole Blood (WB01) specimen collections are assumed to be consolidated with existing contact days (screening or Day 0 for SB01/WB01, Day 28 for SB02)."
35759733,Regimen II: Paclitaxel (135mg/m²),intervention,1,2,7,14,20,24,0,1,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,12,0,0,0,0,0,0,28,12 monthly cycles (12 months),"1 screening visit. 12 treatment visits (Day 0, 28, 56, ..., 308). 12 nadir lab visits (approx. Day 10, 38, 66, ..., 318).","All 'Prior to Study' assessments (History, Physical Exam, QOL, Labs, Imaging) are consolidated into a single in-person screening day. This day is categorized as imaging_diagnostics due to precedence (CT scan, X-ray, EKG).; Routine assessments listed under 'Prior to Each Course' (History, Physical Exam, CBC, Platelets, Creatinine, Bilirubin, CA-125) are assumed to be performed on the same day as the chemotherapy infusion (Day 0, 28, 56, etc.). These days are categorized as core_treatment.; Nadir labs (CBC & Differential, Platelets) are assumed to occur on a separate visit around Day 10 of each 28-day cycle (e.g., Day 10, 38, 66, etc.), as indicated by the 'Nadir (8-12 days)' column. These are categorized as labs.; Conditional visits (e.g., CT scans for symptomatic changes, Coagulation Profile for abnormal parameters) are excluded from the routine contact day count.; Quality of Life (QOL) assessments (Footnote 7) are assumed to be performed on existing contact days (screening, Day 56, 112, 168, 308).; Pre-Cycle Serum (SB01, SB02) and Whole Blood (WB01) specimen collections are assumed to be consolidated with existing contact days (screening or Day 0 for SB01/WB01, Day 28 for SB02)."
35759733,Regimen III: No anti-cancer treatment,control,1,2,4,7,10,12,0,0,0,0,0,0,1,0,0,0,0,0,0,2,4,7,10,12,0,0,0,0,0,0,30,until disease progression (monthly surveillance for 12 months for calculation purposes),"1 screening visit. 12 monthly surveillance visits (Day 0, 30, 60, ..., 330).","All 'Prior to Study' assessments (History, Physical Exam, QOL, Labs, Imaging) are consolidated into a single in-person screening day. This day is categorized as imaging_diagnostics due to precedence (CT scan, X-ray, EKG).; Monthly surveillance visits (Day 0, 30, 60, etc.) include History, Physical Exam, and routine labs (CBC, Platelets, Creatinine, Bilirubin, CA-125). These days are categorized as labs due to precedence (blood draws over H&P/QOL).; Nadir labs are not applicable for Regimen III as there is no anti-cancer treatment.; Conditional visits (e.g., CT scans for symptomatic changes, Coagulation Profile for abnormal parameters) are excluded from the routine contact day count.; Quality of Life (QOL) assessments (Footnote 7) are assumed to be performed on existing monthly surveillance days (screening, Day 60, 120, 180, 360).; Pre-Cycle Serum (SB01, SB02) and Whole Blood (WB01) specimen collections are assumed to be consolidated with existing contact days (screening or Day 0 for SB01/WB01, Day 30 for SB02).; Although treatment is 'until progression', monthly surveillance visits are counted up to Day 330 (12th monthly visit) to cover the 12-month window, consistent with 'monthly during 1st year'."
35763704,Atezolizumab + ddAC-PacHP,intervention,1,3,10,20,25,30,0,3,10,19,23,27,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,Cycles 1-4: 14 days; Cycles 5-22: 21 days,Atezolizumab/placebo for max 22 cycles; HER2-targeted therapy for 52 weeks from C5D1; Paclitaxel for 12 weeks (C5-8).,"Screening (1 day); Neoadjuvant Phase (Cycles 1-4: Day 1 of 14-day cycles; Cycles 5-8: Day 1, Day 8, Day 15 of 21-day cycles); Pre-Surgery Visit; Surgery; Adjuvant Phase (Cycles 9-18: Day 1 of 21-day cycles); Standalone ECHO/MUGA visits.","All screening procedures are consolidated into a single in-person visit day.; The pre-surgery visit is a separate in-person day from the surgery day.; Standalone ECHO/MUGA scans (every 3 months during treatment) are counted as separate in-person contact days if they do not coincide with a scheduled treatment infusion day.; Infusion days for atezolizumab/placebo, chemotherapy, and HER2-targeted therapy are categorized as 'core_treatment'.; Biopsies (tumor tissue sample, pathologic response assessment) and imaging (mammogram, tumor staging, ECHO/MUGA, ECG) are categorized as 'imaging_diagnostics'.; All lab collections requiring in-person attendance are categorized as 'labs'.; All other general assessments (consent, history, physical exam, vital signs, weight, PROs, concomitant meds, AE) are categorized as 'clinic_visits'.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple procedures."
35763704,Placebo + ddAC-PacHP,control,1,3,10,20,25,30,0,3,10,19,23,27,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,Cycles 1-4: 14 days; Cycles 5-22: 21 days,Atezolizumab/placebo for max 22 cycles; HER2-targeted therapy for 52 weeks from C5D1; Paclitaxel for 12 weeks (C5-8).,"Screening (1 day); Neoadjuvant Phase (Cycles 1-4: Day 1 of 14-day cycles; Cycles 5-8: Day 1, Day 8, Day 15 of 21-day cycles); Pre-Surgery Visit; Surgery; Adjuvant Phase (Cycles 9-18: Day 1 of 21-day cycles); Standalone ECHO/MUGA visits.","All screening procedures are consolidated into a single in-person visit day.; The pre-surgery visit is a separate in-person day from the surgery day.; Standalone ECHO/MUGA scans (every 3 months during treatment) are counted as separate in-person contact days if they do not coincide with a scheduled treatment infusion day.; Infusion days for atezolizumab/placebo, chemotherapy, and HER2-targeted therapy are categorized as 'core_treatment'.; Biopsies (tumor tissue sample, pathologic response assessment) and imaging (mammogram, tumor staging, ECHO/MUGA, ECG) are categorized as 'imaging_diagnostics'.; All lab collections requiring in-person attendance are categorized as 'labs'.; All other general assessments (consent, history, physical exam, vital signs, weight, PROs, concomitant meds, AE) are categorized as 'clinic_visits'.; Category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied for days with multiple procedures."
35922251,Cemiplimab (experimental),intervention,1,1,6,14,20,26,0,1,4,10,14,18,1,0,2,4,5,6,0,0,0,0,0,0,0,0,0,0,1,2,42,up to 96 weeks (16 cycles of 6 weeks each),"Screening (Day -28 to -1). Treatment cycles (42 days each) with visits on Day 1, Day 22, and Day 42. Cemiplimab infusion on Day 1 and Day 22. CT/MRI on Day 42 of specific cycles.","Screening is considered a single in-person contact day, distinct from Cycle 1 Day 1, as per footnote 6.; Optional procedures (Genomics sub-study, PBMC, Genomic DNA sample) were excluded from contact day counts.; For days with multiple procedures, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; CT/MRI for Cemiplimab arm occurs on Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. For cycles without CT/MRI (e.g., C5, C7), Day 42 is counted as a clinic_visit due to concomitant medications/procedures."
35922251,IC Chemotherapy (Topotecan),control,1,5,22,54,76,98,0,5,20,50,70,90,1,0,2,4,5,6,0,0,0,0,0,0,0,0,0,0,1,2,42,up to 96 weeks (16 cycles of 6 weeks each),Screening (Day -28 to -1). Treatment cycles (42 days each) with Topotecan infusions on Day 1-5 and Day 22-26. Additional visits on Day 42 for CT/MRI or other assessments.,"Screening is considered a single in-person contact day, distinct from Cycle 1 Day 1, as per footnote 6.; For the 'IC Chemotherapy control arm', Topotecan was selected as the representative regimen due to its higher frequency of treatment days (10 days per 42-day cycle) compared to other IC options, providing a conservative estimate of contact days.; For days with multiple procedures, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits.; Topotecan infusion is administered daily for 5 consecutive days (Day 1-5 and Day 22-26) within each 42-day cycle, counted as 5 distinct core_treatment days for each block.; Vital signs, weight (Day 1 of cycle only), physical exams (complete on Day 1, limited on Day 22), hematology, blood chemistry, pregnancy test (Day 1 of cycle only), EORTC QLQ-C30 (Day 1 of cycle only), concomitant medications, and concomitant procedures are assumed to occur on the specified treatment days.; CT/MRI for IC Chemotherapy arm occurs on Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. For cycles without CT/MRI (e.g., C5, C7), Day 42 is counted as a clinic_visit due to concomitant medications/procedures."
36108662,Pembrolizumab Arm,intervention,4,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,21,"18 infusions (approximately one year), with follow-up until progression.","Screening visits include consent, physical exam, baseline imaging, and labs. Treatment involves IV infusions every 3 weeks for 18 cycles, with associated physical exams, AE assessments, hematology, serum chemistry, concomitant medication assessments, pregnancy tests, and on specific cycles: PK/ADA samples, thyroid function, urinalysis, HRQoL, and disease evaluation imaging.","Both treatment arms follow the same schedule of events.; Randomization is not an in-person contact day.; The 'Main Study' informed consent, demographics, medical history, physical exam, ECOG PS, HRQoL, PD-L1 testing, and baseline disease evaluation (CT chest/abdomen, brain CT/MRI) are performed on a single day within the 'Within 12 weeks prior to randomization' period (set to Day -28).; Hematology and serum chemistry are performed on a single day within 'Within 10 days prior to treatment initiation' (set to Day -10).; Pregnancy test is performed on a single day within 'Within 72 hours prior to treatment initiation' (set to Day -3).; PK/ADA samples for Infusion 1 are collected on a single day within 'Within 24 hours prior to treatment initiation' (set to Day -1).; All 'if clinically indicated' procedures (e.g., HIV/HBV/HCV serology, brain CT/MRI during treatment) are excluded from mandatory contact day counts.; All procedures on an infusion day are subsumed under 'core_treatment' due to the IV infusion taking precedence.; The End of Treatment (EoT) visit, scheduled 4 weeks after the last infusion (Day 357), falls outside the 12-month window (Day +365) and is therefore not counted.; Follow-up visits after treatment completion are not counted within the 12-month window as the first scheduled follow-up imaging/HRQoL/Thyroid (every 6 months in year 2) occurs after Day +365."
36108662,Placebo Arm,control,4,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,21,"18 infusions (approximately one year), with follow-up until progression.","Screening visits include consent, physical exam, baseline imaging, and labs. Treatment involves IV infusions every 3 weeks for 18 cycles, with associated physical exams, AE assessments, hematology, serum chemistry, concomitant medication assessments, pregnancy tests, and on specific cycles: PK/ADA samples, thyroid function, urinalysis, HRQoL, and disease evaluation imaging.","Both treatment arms follow the same schedule of events.; Randomization is not an in-person contact day.; The 'Main Study' informed consent, demographics, medical history, physical exam, ECOG PS, HRQoL, PD-L1 testing, and baseline disease evaluation (CT chest/abdomen, brain CT/MRI) are performed on a single day within the 'Within 12 weeks prior to randomization' period (set to Day -28).; Hematology and serum chemistry are performed on a single day within 'Within 10 days prior to treatment initiation' (set to Day -10).; Pregnancy test is performed on a single day within 'Within 72 hours prior to treatment initiation' (set to Day -3).; PK/ADA samples for Infusion 1 are collected on a single day within 'Within 24 hours prior to treatment initiation' (set to Day -1).; All 'if clinically indicated' procedures (e.g., HIV/HBV/HCV serology, brain CT/MRI during treatment) are excluded from mandatory contact day counts.; All procedures on an infusion day are subsumed under 'core_treatment' due to the IV infusion taking precedence.; The End of Treatment (EoT) visit, scheduled 4 weeks after the last infusion (Day 357), falls outside the 12-month window (Day +365) and is therefore not counted.; Follow-up visits after treatment completion are not counted within the 12-month window as the first scheduled follow-up imaging/HRQoL/Thyroid (every 6 months in year 2) occurs after Day +365."
36155117,Arm A: Palbociclib + Letrozole,intervention,2,4,8,11,14,18,0,0,0,0,0,0,1,3,6,9,12,16,0,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (1 day for assessments, 1 day for randomization), Cycle 1 (Day 1, Day 14, Day 21), Cycle 2 (Day 1, Day 14, Day 21), Cycles ≥3 (Day 1 only). Disease assessments (CT/MRI every 12 weeks, Bone Scan every 24 weeks) and Ophthalmic exams (C4D1, C7D1, C13D1) are integrated into Day 1 visits of relevant cycles.","All screening assessments (excluding randomization) are assumed to occur on a single contact day within the screening window.; Randomization is assumed to be a separate in-person contact day within the screening window (e.g., Day -1), distinct from the main screening assessment day, as per 'Baseline split' rule.; Procedures marked 'X' in the Schedule of Activities table are considered in-person contact days unless explicitly stated as optional, telephone, or home-based.; Conditional visits (e.g., 'if not completed at screening') are assumed to occur if they are part of the standard schedule and no explicit prior completion is guaranteed.; Oral drug administration (Palbociclib/Placebo, Letrozole) is not counted as a contact day.; Disease assessments (CT/MRI, Bone Scan) are performed at Screening and then every 12/24 weeks from randomization (Day 0). If a visit day coincides with a scheduled disease assessment, it is counted as one contact day and categorized by the highest precedence procedure.; The 'Cycles 1 and 2 Day 14' column for Hematology is assumed to be an in-person contact day as per the table, despite footnote 'a' for Table 4 primarily mentioning C1D14 and C1D21 for initial monitoring and then C2D1 and C2D21 for subsequent monitoring, and 'monthly monitoring at the beginning of each cycle'. The table explicitly marks C2D14 with an 'X' for Hematology and 12-Lead ECG, which is followed.; Fasting Insulin and Fasting Lipid Panel are only collected at C1D1 and C1D21 (for Fasting Insulin) as per the table, and not in subsequent cycles, as no 'X' is present in 'Cycles >=3 Day 1' column."
36155117,Arm B: Placebo + Letrozole,control,2,4,8,11,14,18,0,0,0,0,0,0,1,3,6,9,12,16,0,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (1 day for assessments, 1 day for randomization), Cycle 1 (Day 1, Day 14, Day 21), Cycle 2 (Day 1, Day 14, Day 21), Cycles ≥3 (Day 1 only). Disease assessments (CT/MRI every 12 weeks, Bone Scan every 24 weeks) and Ophthalmic exams (C4D1, C7D1, C13D1) are integrated into Day 1 visits of relevant cycles.","All screening assessments (excluding randomization) are assumed to occur on a single contact day within the screening window.; Randomization is assumed to be a separate in-person contact day within the screening window (e.g., Day -1), distinct from the main screening assessment day, as per 'Baseline split' rule.; Procedures marked 'X' in the Schedule of Activities table are considered in-person contact days unless explicitly stated as optional, telephone, or home-based.; Conditional visits (e.g., 'if not completed at screening') are assumed to occur if they are part of the standard schedule and no explicit prior completion is guaranteed.; Oral drug administration (Palbociclib/Placebo, Letrozole) is not counted as a contact day.; Disease assessments (CT/MRI every 12 weeks, Bone Scan every 24 weeks) are performed at Screening and then every 12/24 weeks from randomization (Day 0). If a visit day coincides with a scheduled disease assessment, it is counted as one contact day and categorized by the highest precedence procedure.; The 'Cycles 1 and 2 Day 14' column for Hematology is assumed to be an in-person contact day as per the table, despite footnote 'a' for Table 4 primarily mentioning C1D14 and C1D21 for initial monitoring and then C2D1 and C2D21 for subsequent monitoring, and 'monthly monitoring at the beginning of each cycle'. The table explicitly marks C2D14 with an 'X' for Hematology and 12-Lead ECG, which is followed.; Fasting Insulin and Fasting Lipid Panel are only collected at C1D1 and C1D21 (for Fasting Insulin) as per the table, and not in subsequent cycles, as no 'X' is present in 'Cycles >=3 Day 1' column."
36162037,Arm A: nivolumab 240 mg IV every 2 weeks + ipilimumab 1 mg/kg IV every 6 weeks,intervention,1,3,7,13,20,25,0,3,7,13,20,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year total duration of study medication,Nivolumab infusion every 2 weeks (Q2W) and Ipilimumab infusion every 6 weeks (Q6W). Overlapping infusions occur on the same day. All other assessments coincide with these infusion visits.,"The 'Screening Visit' listed in Table 2-1 is counted as 1 in-person contact day. The highest-priority procedure on this day is 'Tumor Tissue Samples' (diagnostic biopsy for PD-L1 status) or 'Electrocardiogram (ECG)', both categorized as imaging_diagnostics.; All visits involving administration of active study drug (nivolumab or ipilimumab) are considered in-person 'core_treatment' days. When multiple infusions occur on the same day, it counts as one 'core_treatment' day.; All other assessments (safety, labs, imaging, questionnaires, biomarker samples) are assumed to coincide with these infusion visits and are therefore subsumed under the 'core_treatment' category due to precedence rules.; Optional procedures (e.g., optional biopsies, optional microbiome samples) are not counted as mandatory contact days.; Treatment duration is for a maximum of 1 year (365 days) from Day 0. Follow-up visits occurring after Day 365 are not included in the 12-month window."
36162037,Arm B: nivolumab 480 mg IV every 4 weeks,control,1,3,7,13,20,25,0,3,7,13,20,25,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year total duration of study medication,"Nivolumab infusion every 4 weeks (Q4W), Nivolumab placebo every 4 weeks (offset by 2 weeks), and Ipilimumab placebo every 6 weeks (Q6W). Overlapping infusions occur on the same day. All other assessments coincide with these infusion/placebo infusion visits.","The 'Screening Visit' listed in Table 2-1 is counted as 1 in-person contact day. The highest-priority procedure on this day is 'Tumor Tissue Samples' (diagnostic biopsy for PD-L1 status) or 'Electrocardiogram (ECG)', both categorized as imaging_diagnostics.; All visits involving administration of active study drug (nivolumab) or placebo (nivolumab placebo, ipilimumab placebo) are considered in-person 'core_treatment' days, as placebo administration is mandated to maintain blinding. When multiple infusions (active or placebo) occur on the same day, it counts as one 'core_treatment' day.; All other assessments (safety, labs, imaging, questionnaires, biomarker samples) are assumed to coincide with these infusion/placebo infusion visits and are therefore subsumed under the 'core_treatment' category due to precedence rules.; Optional procedures (e.g., optional biopsies, optional microbiome samples) are not counted as mandatory contact days.; Treatment duration is for a maximum of 1 year (365 days) from Day 0. Follow-up visits occurring after Day 365 are not included in the 12-month window."
36265504,Enzalutamide + Docetaxel + Prednisolone,intervention,1,5,12,21,24,25,0,2,6,10,11,11,1,0,0,0,1,2,0,3,6,11,12,12,0,0,0,0,0,0,21,"until disease progression, intolerable toxicity, subject withdrawal or death","Screening (Eligibility Assessment for Period 2), then 10 cycles of docetaxel (Day 1 of each 21-day cycle), with additional lab visits at Day 7 (nadir) for all 10 cycles and Day 14 (2-week) for the first 3 cycles. After 10 docetaxel cycles, ongoing treatment visits occur at Day 253 and Day 337 (q84d intervals). ECG and Radiographic Assessments occur at Screening, Day 84, Day 168, Day 253, and Day 337. PSA and Testosterone are collected at Screening, Day 0, Day 84, Day 168, Day 253, and Day 337, and also at other scheduled visits where not explicitly excluded.","The 'Eligibility Assessment for Period 2' (Week -4 to -1) is considered the screening visit for the Period 2 treatment arms, occurring once within the screening window.; Docetaxel administration is assumed to occur for the maximum stated 10 cycles.; Treatment is assumed to continue for the full 12-month period for calculation purposes.; Additional local laboratory hematology samples for nadir count (~1 week after docetaxel) and 2-week post-docetaxel (for first 3 cycles) are counted as separate in-person lab visits.; Optional biomarker samples are not counted as contact days.; The safety follow-up visit (30 days after last IMP) falls outside the 12-month window if treatment continues until Day 365."
36265504,Placebo + Docetaxel + Prednisolone,control,1,5,12,21,24,25,0,2,6,10,11,11,1,0,0,0,1,2,0,3,6,11,12,12,0,0,0,0,0,0,21,"until disease progression, intolerable toxicity, subject withdrawal or death","Screening (Eligibility Assessment for Period 2), then 10 cycles of docetaxel (Day 1 of each 21-day cycle), with additional lab visits at Day 7 (nadir) for all 10 cycles and Day 14 (2-week) for the first 3 cycles. After 10 docetaxel cycles, ongoing treatment visits occur at Day 253 and Day 337 (q84d intervals). ECG and Radiographic Assessments occur at Screening, Day 84, Day 168, Day 253, and Day 337. PSA and Testosterone are collected at Screening, Day 0, Day 84, Day 168, Day 253, and Day 337, and also at other scheduled visits where not explicitly excluded.","The 'Eligibility Assessment for Period 2' (Week -4 to -1) is considered the screening visit for the Period 2 treatment arms, occurring once within the screening window.; Docetaxel administration is assumed to occur for the maximum stated 10 cycles.; Treatment is assumed to continue for the full 12-month period for calculation purposes.; Additional local laboratory hematology samples for nadir count (~1 week after docetaxel) and 2-week post-docetaxel (for first 3 cycles) are counted as separate in-person lab visits.; Optional biomarker samples are not counted as contact days.; The safety follow-up visit (30 days after last IMP) falls outside the 12-month window if treatment continues until Day 365."
36308441,PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy,intervention,1,6,16,25,26,27,0,3,7,13,13,13,1,0,0,1,2,3,0,0,0,0,0,0,0,3,9,11,11,11,14,"Up to 12 cycles of mFOLFOX6 (22 weeks), followed by follow-up assessments until Month 24.","Screening (Day -28), Treatment Visits (Day 1 of each 14-day cycle for 12 cycles, plus Day 2, 3, 4 for Cycles 1, 4, 7, 10), End of Treatment (EOT) Visit (Day 14 of Cycle 12), Follow-up Assessment Visits (Month 9, Month 12).","One screening visit is assumed to encompass all screening procedures listed in the 'Screening' column, occurring on Day -28, and categorized by the highest priority procedure (CT/MRI/Brain MRI).; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' on 'Days 1, 2, 3 after IMP and mFOLFOX6 infusion at Day 1' for Cycles 1, 4, 7, and 10 are interpreted as requiring separate in-person contact days (Day 2, Day 3, Day 4 of those cycles), in addition to the Day 1 visit.; The schedule reflects the planned protocol, not the impact of the clinical hold as of March 2nd, 2020, which stopped IMP but allowed mFOLFOX6 and follow-up to continue.; The 'Randomization' event is explicitly stated as 'Not a patient visit' and is therefore not counted as a contact day."
36308441,Placebo + mFOLFOX6 chemotherapy,control,1,6,16,25,26,27,0,3,7,13,13,13,1,0,0,1,2,3,0,0,0,0,0,0,0,3,9,11,11,11,14,"Up to 12 cycles of mFOLFOX6 (22 weeks), followed by follow-up assessments until Month 24.","Screening (Day -28), Treatment Visits (Day 1 of each 14-day cycle for 12 cycles, plus Day 2, 3, 4 for Cycles 1, 4, 7, 10), End of Treatment (EOT) Visit (Day 14 of Cycle 12), Follow-up Assessment Visits (Month 9, Month 12).","One screening visit is assumed to encompass all screening procedures listed in the 'Screening' column, occurring on Day -28, and categorized by the highest priority procedure (CT/MRI/Brain MRI).; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' on 'Days 1, 2, 3 after IMP and mFOLFOX6 infusion at Day 1' for Cycles 1, 4, 7, and 10 are interpreted as requiring separate in-person contact days (Day 2, Day 3, Day 4 of those cycles), in addition to the Day 1 visit.; The schedule reflects the planned protocol, not the impact of the clinical hold as of March 2nd, 2020, which stopped IMP but allowed mFOLFOX6 and follow-up to continue.; The 'Randomization' event is explicitly stated as 'Not a patient visit' and is therefore not counted as a contact day."
36322844,Standard Arm (ABVE-PC),control,1,17,41,58,59,60,1,16,39,54,54,54,0,1,2,4,4,4,0,0,0,0,1,2,0,0,0,0,0,0,21,5 cycles of chemotherapy + response-adapted radiation therapy,"Screening (Day -14); Chemotherapy cycles (C1-C5) on Days 1, 2, 3, 4, 5, 6, 7, 8 of each 21-day cycle; Assessments: Day 20 (Prior to C3), Day 61 (Prior to C4), Day 105 (Post-chemo/Pre-RT), Days 106-110, 113-117, 120-123 (RT), Day 165 (Post-RT); Follow-up: Day 213 (3-month FU), Day 303 (6-month FU).","All baseline procedures (H&P, labs, imaging, questionnaires, and bone marrow biopsy if positive) are consolidated into a single screening day. This day is categorized as 'core_treatment' due to the assumption of a bone marrow biopsy being performed.; Prednisone administration on Days 1-7 of each cycle is counted as in-person contact days, assuming IV administration or close monitoring/dispensing in clinic.; G-CSF administration is counted as 1 in-person contact day per cycle (e.g., Day 4), representing the initial administration of either Filgrastim or Pegfilgrastim.; Radiation therapy (ISRT) is assumed to be administered for 14 days (5 days/week over ~3 weeks) for all patients, as it is a conditional part of the treatment plan for slow responders or LMA. These days are categorized as 'core_treatment'.; PK blood draws for a subset of patients in the experimental arm are not included in the main contact day count as per the 'most conservative lower estimate' rule for ambiguous data (subset of patients).; Assessment days are placed at the end of the cycle/period they refer to for distinct counting, e.g., 'Prior to Cycle 3' assessment is placed on Day 20 (within Days 18-22 of Cycle 2). 'Prior to Cycle 4' assessment is placed on Day 61 (end of Cycle 3). 'After Cycle 5 or prior to RT' assessment is placed on Day 105 (post-chemo). 'End of RT' assessment is placed on Day 165 (6 weeks post-RT).; Follow-up times are calculated from the last day of RT (Day 123), which is considered the 'end of all therapy'."
36322844,Experimental Arm (Bv-AVEPC),intervention,1,17,41,58,59,60,1,16,39,54,54,54,0,1,2,4,4,4,0,0,0,0,1,2,0,0,0,0,0,0,21,5 cycles of chemotherapy + response-adapted radiation therapy,"Screening (Day -14); Chemotherapy cycles (C1-C5) on Days 1, 2, 3, 4, 5, 6, 7, 8 of each 21-day cycle; Assessments: Day 20 (Prior to C3), Day 61 (Prior to C4), Day 105 (Post-chemo/Pre-RT), Days 106-110, 113-117, 120-123 (RT), Day 165 (Post-RT); Follow-up: Day 213 (3-month FU), Day 303 (6-month FU).","All baseline procedures (H&P, labs, imaging, questionnaires, and bone marrow biopsy if positive) are consolidated into a single screening day. This day is categorized as 'core_treatment' due to the assumption of a bone marrow biopsy being performed.; Prednisone administration on Days 1-7 of each cycle is counted as in-person contact days, assuming IV administration or close monitoring/dispensing in clinic.; G-CSF administration is counted as 1 in-person contact day per cycle (e.g., Day 4), representing the initial administration of either Filgrastim or Pegfilgrastim.; Radiation therapy (ISRT) is assumed to be administered for 14 days (5 days/week over ~3 weeks) for all patients, as it is a conditional part of the treatment plan for slow responders or LMA. These days are categorized as 'core_treatment'.; PK blood draws for a subset of patients in the experimental arm are not included in the main contact day count as per the 'most conservative lower estimate' rule for ambiguous data (subset of patients).; Assessment days are placed at the end of the cycle/period they refer to for distinct counting, e.g., 'Prior to Cycle 3' assessment is placed on Day 20 (within Days 18-22 of Cycle 2). 'Prior to Cycle 4' assessment is placed on Day 61 (end of Cycle 3). 'After Cycle 5 or prior to RT' assessment is placed on Day 105 (post-chemo). 'End of RT' assessment is placed on Day 165 (6 weeks post-RT).; Follow-up times are calculated from the last day of RT (Day 123), which is considered the 'end of all therapy'."
36327426,durvalumab + tremelimumab combination therapy + standard of care (SoC) chemotherapy,intervention,1,5,13,16,19,23,0,5,13,16,19,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy phase), 28 days (maintenance phase)",until objective disease progression,"Screening (1 day). Chemotherapy (q3w): D0, D7, D14 for 4 cycles. Post-chemotherapy (q4w): D84, D112 (with additional Treme), D140, D168, D196, D224, D252, D280, D308, D336, D364. All tumor scans align with these infusion days.","SoC chemotherapy is assumed to be Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 of each 21-day cycle for Carboplatin) as it results in the most frequent visits during the chemotherapy phase.; Durvalumab and Tremelimumab infusions are administered on Day 1 of each 21-day cycle during the chemotherapy phase (Weeks 0, 3, 6, 9).; Durvalumab monotherapy and Pemetrexed maintenance (for non-squamous patients) are administered every 4 weeks (q4w) during the post-chemotherapy phase, starting Week 12.; An additional dose of tremelimumab is given at Week 16 post-chemotherapy for Arm 1.; Tumor evaluation scans (CT or MRI) are performed at Week 6, Week 12, and then every 8 weeks (q8w) until objective disease progression. All scheduled scan days align with chemotherapy or maintenance infusion days for this arm.; All procedures listed in Table 2 for a given visit day are considered to occur on that single contact day. Infusion days are categorized as 'core_treatment' due to the highest precedence.; 12-lead ECG is excluded from regular counts as it is 'as clinically indicated'.; Treatment continues until objective disease progression, and calculations are made up to Day 365."
36327426,durvalumab monotherapy + SoC chemotherapy,intervention,1,5,13,16,19,23,0,5,13,16,19,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy phase), 28 days (maintenance phase)",until objective disease progression,"Screening (1 day). Chemotherapy (q3w): D0, D7, D14 for 4 cycles. Post-chemotherapy (q4w): D84, D112, D140, D168, D196, D224, D252, D280, D308, D336, D364. All tumor scans align with these infusion days.","SoC chemotherapy is assumed to be Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 of each 21-day cycle for Carboplatin) as it results in the most frequent visits during the chemotherapy phase.; Durvalumab infusions are administered on Day 1 of each 21-day cycle during the chemotherapy phase (Weeks 0, 3, 6, 9).; Durvalumab monotherapy and Pemetrexed maintenance (for non-squamous patients) are administered every 4 weeks (q4w) during the post-chemotherapy phase, starting Week 12.; Tumor evaluation scans (CT or MRI) are performed at Week 6, Week 12, and then every 8 weeks (q8w) until objective disease progression. All scheduled scan days align with chemotherapy or maintenance infusion days for this arm.; All procedures listed in Table 2 for a given visit day are considered to occur on that single contact day. Infusion days are categorized as 'core_treatment' due to the highest precedence.; 12-lead ECG is excluded from regular counts as it is 'as clinically indicated'.; Treatment continues until objective disease progression, and calculations are made up to Day 365."
36327426,SoC chemotherapy alone,control,1,5,13,22,27,34,0,5,13,21,25,30,1,0,0,1,2,4,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy phase), 21 days (maintenance phase)",until objective disease progression,"Screening (1 day). Chemotherapy (q3w): D0, D7, D14 for 6 cycles. Post-chemotherapy (q3w): D126, D147, D168, D189, D210, D231, D252, D273, D294, D315, D336, D357. Tumor scans at Week 6 (D42), Week 12 (D84), Week 20 (D140), Week 28 (D196), Week 36 (D252), Week 44 (D308), Week 52 (D364). Days D140, D196, D308, D364 are separate imaging days.","SoC chemotherapy is assumed to be Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 of each 21-day cycle for Carboplatin) as it results in the most frequent visits during the chemotherapy phase.; Patients receive 6 cycles of q3w SoC chemotherapy (Weeks 0, 3, 6, 9, 12, 15) as 'clinically indicated' to maximize visits.; Pemetrexed maintenance (for non-squamous patients) is administered every 3 weeks (q3w) during the post-chemotherapy phase, starting after Cycle 6 (Week 18), to maximize visits.; Tumor evaluation scans (CT or MRI) are performed at Week 6, Week 12, and then every 8 weeks (q8w) until objective disease progression. Some scan days do not align with chemotherapy or maintenance infusion days for this arm, creating separate imaging contact days.; All procedures listed in Table 2 for a given visit day are considered to occur on that single contact day. Infusion days are categorized as 'core_treatment' due to the highest precedence. Separate scan days are categorized as 'imaging_diagnostics'.; 12-lead ECG is excluded from regular counts as it is 'as clinically indicated'.; Treatment continues until objective disease progression, and calculations are made up to Day 365."
36346687,Arm A: Capecitabine,intervention,1,2,6,10,11,12,0,0,0,0,0,0,1,0,0,0,0,1,0,2,5,8,8,8,0,0,1,2,3,3,21,"8 cycles (24 weeks) of capecitabine, followed by 5 years clinical follow-up.","Pre-randomization screening, 8 cycles of capecitabine treatment (Day 1 of each 21-day cycle), followed by 3-monthly and 6-monthly follow-up visits (with annual imaging) for 5 years.","All 'X' marked procedures in the 'Pre-rd' column of the Schedule of Events (SoE) table (page 24) occur on a single in-person screening day (e.g., Day -7). The highest priority procedure on this day is imaging_diagnostics.; The 'During CT' column refers to visits on Day 1 of each 21-day cycle for the 8 cycles of capecitabine treatment (Day 0, Day 21, Day 42, Day 63, Day 84, Day 105, Day 126, Day 147). The presence of hematology and biochemistry tests makes these 'labs' days.; The 'Years 1-2, Every 3 months' and 'Years 3-5, Every 6 months' follow-up schedules (page 24) are relative to Day 0 and apply to both arms, in addition to treatment-specific visits for Arm A. If a follow-up visit date coincides with a treatment visit date, it is counted as a single contact day, and the higher priority category applies.; Mammography and Chest X-ray are considered mandatory at 12-month intervals during follow-up for both arms, as stated in the text on page 31, overriding the 'diamond' (if clinically indicated) in the table. This makes the 12-month follow-up visits 'imaging_diagnostics' days.; Procedures marked with a 'diamond' (if clinically indicated) in the SoE table, such as abdominal ultrasound/CT and bone scan during follow-up, are excluded from contact day counts as per instructions.; Pharmacogenetics blood sample collection is counted as a 'labs' activity."
36346687,Arm B: Observation,control,1,0,1,2,3,4,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,2,3,3,,5 years clinical follow-up.,"Pre-randomization screening, followed by 3-monthly and 6-monthly follow-up visits (with annual imaging) for 5 years.","All 'X' marked procedures in the 'Pre-rd' column of the Schedule of Events (SoE) table (page 24) occur on a single in-person screening day (e.g., Day -7). The highest priority procedure on this day is imaging_diagnostics.; The 'Years 1-2, Every 3 months' and 'Years 3-5, Every 6 months' follow-up schedules (page 24) are relative to Day 0 and apply to both arms. For the observation arm, these are the only scheduled post-randomization visits.; Mammography and Chest X-ray are considered mandatory at 12-month intervals during follow-up for both arms, as stated in the text on page 31, overriding the 'diamond' (if clinically indicated) in the table. This makes the 12-month follow-up visits 'imaging_diagnostics' days.; Procedures marked with a 'diamond' (if clinically indicated) in the SoE table, such as abdominal ultrasound/CT and bone scan during follow-up, are excluded from contact day counts as per instructions."
36455168,Pembrolizumab plus Best Supportive Care,interventional,1,1,5,9,13,18,0,1,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progressive disease or unacceptable adverse events (up to 35 treatments, approx. 2 years)","Screening visit, followed by treatment cycles every 21 days.","All screening procedures are completed on a single day within the screening window (Day -28 to Day -1).; Treatment continues until Day +365, or the last scheduled cycle day before Day +365, as per the 'until progression' rule for fixed intervals.; The 'End of Treatment Discon', 'Safety Follow-up', 'Follow-Up Visits', and 'Survival Follow-Up' are conditional or post-treatment visits and are not included in the fixed interval counts up to 12 months, assuming treatment continues as scheduled.; Survival Follow-up is explicitly stated as being conducted via telephone and is therefore not counted as an in-person contact day.; Tumor imaging is performed Q6W (42±7 days) from Day 0, as stated in footnotes (page 37, 'p') and text (page 4, 49), overriding conflicting 'X' marks in the table for specific cycles (e.g., C4, C7).; Patient Reported Outcomes (EQ-5D, EORTC QLQ-C30) are performed at C1, C2, C3, C4, C5, C7, then every 9 weeks (Day 0, 21, 42, 63, 84, 126, 189, 252, 315) as per footnote 'f' on page 36.; Urinalysis and Thyroid function tests (T3, FT4, TSH) are performed every other cycle (C1, C3, C5, C7, C9, C11, C13, C15, C17) as per footnote 'j' on page 36.; Anti-HBc antibody, HBeAb, HBV e antigen, HBsAb are performed every 12 weeks (C1, C7, C13, C19) as per footnote 'n' on page 37.; Height is measured at Visit 1 (Screening) only.; Full Physical Examination at Discontinuation is assumed to cover Directed Physical Examination if both are marked on the same day.; On days where both core treatment (IV infusion) and imaging diagnostics (tumor imaging) occur, the day is categorized as core_treatment due to higher precedence."
36455168,Placebo plus Best Supportive Care,interventional,1,1,5,9,13,18,0,1,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progressive disease or unacceptable adverse events (up to 35 treatments, approx. 2 years)","Screening visit, followed by treatment cycles every 21 days.","All screening procedures are completed on a single day within the screening window (Day -28 to Day -1).; Treatment continues until Day +365, or the last scheduled cycle day before Day +365, as per the 'until progression' rule for fixed intervals.; The 'End of Treatment Discon', 'Safety Follow-up', 'Follow-Up Visits', and 'Survival Follow-Up' are conditional or post-treatment visits and are not included in the fixed interval counts up to 12 months, assuming treatment continues as scheduled.; Survival Follow-up is explicitly stated as being conducted via telephone and is therefore not counted as an in-person contact day.; Tumor imaging is performed Q6W (42±7 days) from Day 0, as stated in footnotes (page 37, 'p') and text (page 4, 49), overriding conflicting 'X' marks in the table for specific cycles (e.g., C4, C7).; Patient Reported Outcomes (EQ-5D, EORTC QLQ-C30) are performed at C1, C2, C3, C4, C5, C7, then every 9 weeks (Day 0, 21, 42, 63, 84, 126, 189, 252, 315) as per footnote 'f' on page 36.; Urinalysis and Thyroid function tests (T3, FT4, TSH) are performed every other cycle (C1, C3, C5, C7, C9, C11, C13, C15, C17) as per footnote 'j' on page 36.; Anti-HBc antibody, HBeAb, HBV e antigen, HBsAb are performed every 12 weeks (C1, C7, C13, C19) as per footnote 'n' on page 37.; Height is measured at Visit 1 (Screening) only.; Full Physical Examination at Discontinuation is assumed to cover Directed Physical Examination if both are marked on the same day.; On days where both core treatment (IV infusion) and imaging diagnostics (tumor imaging) occur, the day is categorized as core_treatment due to higher precedence."
36473143,Arm A: Nivolumab + Ipilimumab Arm,intervention,2,3,7,13,20,26,0,3,7,13,20,26,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression (up to 24 months),"Arm A: Nivolumab every 2 weeks, Ipilimumab every 6 weeks. All treatment-related assessments (safety, labs, imaging, PK/biomarkers, questionnaires) occur on infusion days.","Screening procedures are consolidated into 2 in-person days: one for general clinic/labs/ECG and one for imaging/biopsy. Both are categorized as imaging_diagnostics due to the highest priority procedure on those days.; All 'During Treatment Visit' procedures (safety assessments, labs, questionnaires, PK/Biomarkers, tumor assessments) are performed on the same day as drug infusions.; Treatment duration is calculated up to 12 months (Day 365), assuming continuation until progression.; For Arm A, Nivolumab is administered every 2 weeks (Q2W) and Ipilimumab every 6 weeks (Q6W). When both are given, they are on the same day.; Tumor assessments for Arm A are every 6 weeks for the first 48 weeks, coinciding with Nivo+Ipi infusion days."
36473143,Arm B: EXTREME regimen Arm,control,2,11,28,44,57,71,0,11,28,44,57,71,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Induction: 21 days; Maintenance: 7 days (for Cetuximab),Induction: 6 cycles (18 weeks); Maintenance: until progression,"Arm B: Induction (6 cycles, 21-day cycles): Cetuximab weekly, Cisplatin/Carboplatin Day 1, Fluorouracil Day 1-4. Maintenance (after 6 cycles): Cetuximab weekly. All treatment-related assessments (safety, labs, imaging, PK/biomarkers, questionnaires) occur on infusion days.","Screening procedures are consolidated into 2 in-person days: one for general clinic/labs/ECG and one for imaging/biopsy. Both are categorized as imaging_diagnostics due to the highest priority procedure on those days.; All 'During Treatment Visit' procedures (safety assessments, labs, questionnaires, PK/Biomarkers, tumor assessments) are performed on the same day as drug infusions.; Treatment duration is calculated up to 12 months (Day 365), assuming continuation until progression.; For Arm B maintenance, Cetuximab is assumed to be administered weekly, as per the protocol summary's 'weekly (or every 2 weeks)' statement, choosing the more frequent option.; Tumor assessments for Arm B are every 6 weeks for the first 48 weeks, coinciding with Cetuximab infusion days (or Cetuximab + Chemo infusion days during induction)."
36503738,BBI-608 plus biweekly FOLFIRI (Arm 1),intervention,5,3,7,13,19,27,0,3,7,13,19,27,3,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,14,until progression,"Screening visits (Day -28, -21, -14, -10, -2 for Arm 1; Day -28, -21, -14, -10 for Arm 2), followed by Day 1 of each 14-day cycle (Day 0, 14, 28, etc.) for FOLFIRI infusion and other assessments. Radiology every 8 weeks for 6 months, then every 12 weeks. QoL on specific cycle Day 1s. Sparse PK on C2D1 and C3D1 for Arm 1 only.","Randomization is Day 0 for the purpose of the screening window calculation (Day -28 to Day -1 relative to C1D1). C1D1 is Day 0.; The 'Begin BBI-608 administration' for Arm 1 (Run-in Day 1, 2 days prior to C1D1, i.e., Day -2) is counted as an in-person clinic visit for patient education/dispensing of the oral drug.; The 'Submission of representative diagnostic tumor tissue' is counted as an imaging_diagnostics day in the screening window, assuming it requires an in-person visit for a new biopsy or specific submission procedure, distinct from other screening visits. This is placed on Day -10 for calculation purposes.; All 'Day 1 of cycle' visits are considered in-person contact days.; Quality of Life (QoL) questionnaires are completed in clinic on the specified days (C1D1, C3D1, C5D1, C7D1, C9D1, C13D1).; ECG is fixed only on C1D1. 'As clinically indicated thereafter' ECGs are not counted.; Radiology and Imaging schedule: 'Every 8 weeks for 6 months and every 12 weeks thereafter'. This translates to Day 0 (C1D1), Day 56 (C5D1), Day 112 (C9D1), Day 168 (C13D1), Day 252 (C19D1), Day 336 (C25D1).; Sparse PK samples for Arm 1 are collected on C2D1 (Day 14) and C3D1 (Day 28).; All activities on Day 1 of each cycle (FOLFIRI infusion, H&P, labs, imaging, QoL, PK) occur on the same calendar day. Due to precedence, these days are categorized as 'core_treatment' because FOLFIRI infusion is a core treatment activity.; Treatment continues 'until progression' or unacceptable toxicity, so it is assumed to continue for the full 12-month period for calculation."
36503738,biweekly FOLFIRI alone (Arm 2),control,4,3,7,13,19,27,0,3,7,13,19,27,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening visits (Day -28, -21, -14, -10), followed by Day 1 of each 14-day cycle (Day 0, 14, 28, etc.) for FOLFIRI infusion and other assessments. Radiology every 8 weeks for 6 months, then every 12 weeks. QoL on specific cycle Day 1s.","Randomization is Day 0 for the purpose of the screening window calculation (Day -28 to Day -1 relative to C1D1). C1D1 is Day 0.; The 'Submission of representative diagnostic tumor tissue' is counted as an imaging_diagnostics day in the screening window, assuming it requires an in-person visit for a new biopsy or specific submission procedure, distinct from other screening visits. This is placed on Day -10 for calculation purposes.; All 'Day 1 of cycle' visits are considered in-person contact days.; Quality of Life (QoL) questionnaires are completed in clinic on the specified days (C1D1, C3D1, C5D1, C7D1, C9D1, C13D1).; ECG is fixed only on C1D1. 'As clinically indicated thereafter' ECGs are not counted.; Radiology and Imaging schedule: 'Every 8 weeks for 6 months and every 12 weeks thereafter'. This translates to Day 0 (C1D1), Day 56 (C5D1), Day 112 (C9D1), Day 168 (C13D1), Day 252 (C19D1), Day 336 (C25D1).; No Sparse PK samples are collected for Arm 2.; All activities on Day 1 of each cycle (FOLFIRI infusion, H&P, labs, imaging, QoL) occur on the same calendar day. Due to precedence, these days are categorized as 'core_treatment' because FOLFIRI infusion is a core treatment activity.; Treatment continues 'until progression' or unacceptable toxicity, so it is assumed to continue for the full 12-month period for calculation."
36521097,Arm A: nab-Paclitaxel/Gemcitabine Arm,intervention,2,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,1,0,0,0,0,0,28,"6 cycles of treatment, followed by follow-up until disease recurrence or up to 5 years.","Screening (1 day), Randomization (1 day), 6 cycles of treatment (Day 1, 8, 15 of 28-day cycle), End of Treatment visit, and follow-up imaging/labs/QoL visits every 8-12 weeks.","Screening and Randomization are distinct in-person days. Screening evaluations are assumed to occur on Day -7, and Randomization on Day -1, within the ≤14 days prior to randomization window.; The End of Treatment (EOT) visit is assumed to occur on Day 175 (mid-point of the 14-day window after Cycle 6 Day 28, which is Day 168).; Follow-up imaging, CA19-9, and Quality of Life assessments occur on Day 168 (end of Cycle 6, 24 weeks post-randomization), Day 252 (12 weeks after Day 168), and Day 336 (12 weeks after Day 252). These are distinct visits from treatment days or the EOT visit.; Follow-up for survival and anticancer therapy by telephone/record review is not counted as an in-person contact day.; Collection of tumor/blood samples for biomarker analysis at screening or disease recurrence, if from archival tissue or during an existing visit, is not counted as a separate contact day unless it is the sole purpose of a visit. Biomarker blood sample at screening is assumed to be part of the main screening visit.; QoL questionnaires are considered clinic_visits when they are the highest priority on a given day.; BSA Calculation is considered a clinic_visit as it is performed in conjunction with other clinic assessments.; Urinalysis, Pregnancy Test, Clinical Chemistry Panel, CBC, PT/PTT/INR, Biomarker blood sample, Serum CA19-9 are considered labs.; ECG, CT/MRI Scan are considered imaging_diagnostics.; IV infusions of nab-Paclitaxel and/or Gemcitabine are core_treatment."
36521097,Arm B: Gemcitabine-only Arm,control,2,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,1,0,0,0,0,0,28,"6 cycles of treatment, followed by follow-up until disease recurrence or up to 5 years.","Screening (1 day), Randomization (1 day), 6 cycles of treatment (Day 1, 8, 15 of 28-day cycle), End of Treatment visit, and follow-up imaging/labs/QoL visits every 8-12 weeks.","Screening and Randomization are distinct in-person days. Screening evaluations are assumed to occur on Day -7, and Randomization on Day -1, within the ≤14 days prior to randomization window.; The End of Treatment (EOT) visit is assumed to occur on Day 175 (mid-point of the 14-day window after Cycle 6 Day 28, which is Day 168).; Follow-up imaging, CA19-9, and Quality of Life assessments occur on Day 168 (end of Cycle 6, 24 weeks post-randomization), Day 252 (12 weeks after Day 168), and Day 336 (12 weeks after Day 252). These are distinct visits from treatment days or the EOT visit.; Follow-up for survival and anticancer therapy by telephone/record review is not counted as an in-person contact day.; Collection of tumor/blood samples for biomarker analysis at screening or disease recurrence, if from archival tissue or during an existing visit, is not counted as a separate contact day unless it is the sole purpose of a visit. Biomarker blood sample at screening is assumed to be part of the main screening visit.; QoL questionnaires are considered clinic_visits when they are the highest priority on a given day.; BSA Calculation is considered a clinic_visit as it is performed in conjunction with other clinic assessments.; Urinalysis, Pregnancy Test, Clinical Chemistry Panel, CBC, PT/PTT/INR, Biomarker blood sample, Serum CA19-9 are considered labs.; ECG, CT/MRI Scan are considered imaging_diagnostics.; IV infusions of nab-Paclitaxel and/or Gemcitabine are core_treatment."
36535566,Pembrolizumab (MK-3475),experimental,1,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression or up to 35 administrations (for Pembrolizumab),"Based on 'Trial Flow Chart' (Section 6.1, pages 27-28) for screening and treatment cycles, and associated footnotes.","All procedures listed under 'Screening (Visit 1)' in the Trial Flow Chart (Section 6.1) occur on a single in-person day.; Treatment continues until disease progression or up to 35 administrations for Pembrolizumab, but calculations are capped at 12 months (Day +365).; Oral Capecitabine administration is not considered an in-person contact day.; The 'To be repeated beyond 6 cycles' columns in the Trial Flow Chart imply the same schedule for cycles 7 through 17 (or up to Day +365).; Footnotes clarifying specific visit frequencies (e.g., Urinalysis every other cycle after C1, TSH every other cycle after C6, PK/ADA on specific cycles, EBV DNA weekly C1 then D1 subsequent cycles, Imaging every 6 weeks) have been incorporated.; Day 0 is defined as Cycle 1 Day 1 (C1D1)."
36535566,SOC - Capecitabine,control,1,4,7,11,15,20,0,0,0,0,0,0,1,0,2,4,6,8,0,4,5,7,9,12,0,0,0,0,0,0,21,until progression,"Based on 'Trial Flow Chart' (Section 6.1, pages 27-28) for screening and treatment cycles, and associated footnotes.","All procedures listed under 'Screening (Visit 1)' in the Trial Flow Chart (Section 6.1) occur on a single in-person day.; Treatment continues until disease progression, but calculations are capped at 12 months (Day +365).; Oral Capecitabine administration is not considered an in-person contact day.; The 'To be repeated beyond 6 cycles' columns in the Trial Flow Chart imply the same schedule for cycles 7 through 17 (or up to Day +365).; Footnotes clarifying specific visit frequencies (e.g., Urinalysis every other cycle after C1, TSH every other cycle after C6, PK/ADA on specific cycles, EBV DNA weekly C1 then D1 subsequent cycles, Imaging every 6 weeks) have been incorporated.; Day 0 is defined as Cycle 1 Day 1 (C1D1)."
36535566,SOC - Gemcitabine,control,1,5,10,18,26,37,0,4,9,17,25,36,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,21,until progression,"Based on 'Trial Flow Chart' (Section 6.1, pages 27-28) for screening and treatment cycles, and associated footnotes.","All procedures listed under 'Screening (Visit 1)' in the Trial Flow Chart (Section 6.1) occur on a single in-person day.; Treatment continues until disease progression, but calculations are capped at 12 months (Day +365).; The 'To be repeated beyond 6 cycles' columns in the Trial Flow Chart imply the same schedule for cycles 7 through 17 (or up to Day +365).; Footnotes clarifying specific visit frequencies (e.g., Urinalysis every other cycle after C1, TSH every other cycle after C6, PK/ADA on specific cycles, EBV DNA weekly C1 then D1 subsequent cycles, Imaging every 6 weeks) have been incorporated.; Day 0 is defined as Cycle 1 Day 1 (C1D1)."
36535566,SOC - Docetaxel,control,1,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Based on 'Trial Flow Chart' (Section 6.1, pages 27-28) for screening and treatment cycles, and associated footnotes.","All procedures listed under 'Screening (Visit 1)' in the Trial Flow Chart (Section 6.1) occur on a single in-person day.; Treatment continues until disease progression, but calculations are capped at 12 months (Day +365).; The 'To be repeated beyond 6 cycles' columns in the Trial Flow Chart imply the same schedule for cycles 7 through 17 (or up to Day +365).; Footnotes clarifying specific visit frequencies (e.g., Urinalysis every other cycle after C1, TSH every other cycle after C6, PK/ADA on specific cycles, EBV DNA weekly C1 then D1 subsequent cycles, Imaging every 6 weeks) have been incorporated.; Day 0 is defined as Cycle 1 Day 1 (C1D1)."
36541957,Ibrutinib + CIT (RICE or RVICI),intervention,1,14,33,36,37,38,0,12,28,30,30,30,1,1,2,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,"3 cycles of combination therapy, then for Arm A, 3 additional cycles of ibrutinib monotherapy, or until progression/unacceptable toxicity/transplantation, followed by follow-up until PD or up to 3 years after C1D1.","Screening (Day -1); Treatment Phase (3 cycles of 28 days each): C1D1, C1D2-5, C1D6-9, C1D14, C1D21; C2D1, C2D2-5, C2D6-9, C2D15; C3D1, C3D2-5, C3D6-9, C3D15; End-of-Treatment (Day 83). For Arm A, additional Monotherapy Phase (3 cycles of 28 days each): C4D1, C5D1, C6D1; End-of-Monotherapy (Day 168). Follow-up visits for both arms at 6, 9, 12 months.","Screening is considered a single visit day (Day -1).; Default cycle length is 28 days.; RICE/RVICI chemotherapy is administered over 9 days per cycle (Day 1-9), including Rituximab, Ifosfamide, Carboplatin, Etoposide, Mesna, Dexamethasone, IV hydration, and Triple Intrathecal Therapy. These are categorized as core_treatment.; For Arm A, ibrutinib monotherapy continues for 3 additional 28-day cycles after the initial 3 combination cycles. Ibrutinib dispensing is considered an in-person core_treatment contact day for each monotherapy cycle (Day 84, 112, 140).; For ECG/Echocardiogram/MUGA, the 'worst-case' RVICI schedule is assumed for both arms, meaning these assessments occur at Screening, End of Cycle 1 (Day 28), End of Cycle 2 (Day 56), End of Cycle 3 (Day 84), and End-of-Monotherapy (Day 168) for Arm A, and End-of-Treatment (Day 84) for Arm B. These are categorized as imaging_diagnostics.; Lumbar puncture/CSF cytologic evaluation is required at C1D1, C2D1, C3D1. Lumbar puncture and bone marrow aspirate/biopsy in follow-up phases are 'if clinically indicated' and thus excluded from standard schedule counts.; Bone marrow aspirate/biopsy at C2D1 and C3D1 are 'if clinically indicated' and thus excluded from standard schedule counts.; Weekly hematology and chemistry labs are counted for Cycle 1 (Day 0, 7, 14, 21). For Cycle 2 and 3, labs are counted on Day 1 and one day between Day 14-21 (assumed Day 15). These are categorized as labs.; PK samples for Arm A are collected on C1D1, C1D7/8 (assumed Day 7), C2D1, C3D1. Biomarker blood samples for Arm A are collected on C1D1, C1D14 (preferred over C2D1), C3D1. These are categorized as labs.; The 'Early withdrawal/End-of-Treatment visit' in Table 2 is counted as one day at the end of the 3 combination cycles (Day 83). The 'End-of-Monotherapy visit' in Table 3 is counted as one day after 3 monotherapy cycles (Day 168).; Follow-up visits at 6, 9, 12 months are counted as distinct in-person days if procedures are listed in Tables 3 and 4.; Procedures occurring on the same calendar day are assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits)."
36541957,CIT (RICE or RVICI) alone,control,1,14,32,33,34,35,0,12,27,27,27,27,1,1,2,3,4,5,0,1,3,3,3,3,0,0,0,0,0,0,28,"3 cycles of combination therapy, or until progression/unacceptable toxicity/transplantation, followed by follow-up until PD or up to 3 years after C1D1.","Screening (Day -1); Treatment Phase (3 cycles of 28 days each): C1D1, C1D2-5, C1D6-9, C1D14, C1D21; C2D1, C2D2-5, C2D6-9, C2D15; C3D1, C3D2-5, C3D6-9, C3D15; End-of-Treatment (Day 83). Follow-up visits at 6, 9, 12 months.","Screening is considered a single visit day (Day -1).; Default cycle length is 28 days.; RICE/RVICI chemotherapy is administered over 9 days per cycle (Day 1-9), including Rituximab, Ifosfamide, Carboplatin, Etoposide, Mesna, Dexamethasone, IV hydration, and Triple Intrathecal Therapy. These are categorized as core_treatment.; For ECG/Echocardiogram/MUGA, the 'worst-case' RVICI schedule is assumed for both arms, meaning these assessments occur at Screening, End of Cycle 1 (Day 28), End of Cycle 2 (Day 56), End of Cycle 3 (Day 84), and End-of-Treatment (Day 84). These are categorized as imaging_diagnostics.; Lumbar puncture/CSF cytologic evaluation is required at C1D1, C2D1, C3D1. Lumbar puncture and bone marrow aspirate/biopsy in follow-up phases are 'if clinically indicated' and thus excluded from standard schedule counts.; Bone marrow aspirate/biopsy at C2D1 and C3D1 are 'if clinically indicated' and thus excluded from standard schedule counts.; Weekly hematology and chemistry labs are counted for Cycle 1 (Day 0, 7, 14, 21). For Cycle 2 and 3, labs are counted on Day 1 and one day between Day 14-21 (assumed Day 15). These are categorized as labs.; The 'Early withdrawal/End-of-Treatment visit' in Table 2 is counted as one day at the end of the 3 combination cycles (Day 83).; Follow-up visits at 6, 9, 12 months are counted as distinct in-person days if procedures are listed in Tables 3 and 4.; Procedures occurring on the same calendar day are assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits)."
36623230,Arm A: 45 Gy twice daily for 3 weeks,intervention,3,19,29,41,42,43,0,18,24,34,34,34,1,0,2,4,5,6,1,1,3,3,3,3,1,0,0,0,0,0,21,"4 cycles of chemotherapy (12 weeks) and concurrent radiotherapy (Arm A: 3 weeks; Arm B: 7 weeks), followed by PCI (2 weeks), then follow-up until progression.","Screening (H&P/Labs, Imaging/PFT, Registration). Chemotherapy (4 cycles, 21-day cycle: Days 1, 2, 3 for etoposide; Day 1 for cisplatin/carboplatin; Day 8 for labs). Concurrent Radiotherapy (Arm A: 3 weeks, M-F, BID; Arm B: 7 weeks, M-F, QD). Restaging imaging after Cycle 2 and Cycle 4. PCI (2 weeks, M-F) with prior MRI/CT Brain. Follow-up visits with imaging at 3, 6, 9, 12 months (PFT at 12 months).","Radiotherapy for both arms is assumed to start on Cycle 1 Day 1 (C1D1).; Radiotherapy is administered Monday-Friday.; Screening procedures (H&P, initial labs, initial imaging/PFT) are assumed to occur on 2 distinct days within the screening window, separate from the registration day.; Prophylactic cranial irradiation (PCI) is assumed to be initiated approximately 3-6 weeks after the end of chemoRT (Day 84), with an MRI/CT Brain scan occurring prior to PCI. Day 100 is used for MRI/CT Brain, and Day 105 for PCI start.; Quality of Life (QOL) substudy (CALGB 70702) is noted as closed to accrual as of August 30, 2017, and patients registered after one cycle of chemotherapy are not eligible. Given the protocol version date (08/02/18), QOL visits are excluded.; Correlative Studies (CALGB 150712) plasma collections are assumed to coincide with existing scheduled visits (screening, chemotherapy cycles, follow-up) and therefore do not add new contact days, but contribute to the 'labs' category on those days.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was strictly applied for days with multiple activities."
36623230,Arm B: 70 Gy once daily for 7 weeks,intervention,3,23,42,54,55,56,0,23,38,48,48,48,1,0,2,4,5,6,1,0,2,2,2,2,1,0,0,0,0,0,21,"4 cycles of chemotherapy (12 weeks) and concurrent radiotherapy (Arm A: 3 weeks; Arm B: 7 weeks), followed by PCI (2 weeks), then follow-up until progression.","Screening (H&P/Labs, Imaging/PFT, Registration). Chemotherapy (4 cycles, 21-day cycle: Days 1, 2, 3 for etoposide; Day 1 for cisplatin/carboplatin; Day 8 for labs). Concurrent Radiotherapy (Arm A: 3 weeks, M-F, BID; Arm B: 7 weeks, M-F, QD). Restaging imaging after Cycle 2 and Cycle 4. PCI (2 weeks, M-F) with prior MRI/CT Brain. Follow-up visits with imaging at 3, 6, 9, 12 months (PFT at 12 months).","Radiotherapy for both arms is assumed to start on Cycle 1 Day 1 (C1D1).; Radiotherapy is administered Monday-Friday.; Screening procedures (H&P, initial labs, initial imaging/PFT) are assumed to occur on 2 distinct days within the screening window, separate from the registration day.; Arm B includes a 'second simulation' for PTV-2, which is assumed to occur around Day 24 (one week prior to PTV-2 initiation, which is after 4.4 weeks of RT). This day also has RT, so it is categorized as core_treatment.; Prophylactic cranial irradiation (PCI) is assumed to be initiated approximately 3-6 weeks after the end of chemoRT (Day 84), with an MRI/CT Brain scan occurring prior to PCI. Day 100 is used for MRI/CT Brain, and Day 105 for PCI start.; Quality of Life (QOL) substudy (CALGB 70702) is noted as closed to accrual as of August 30, 2017, and patients registered after one cycle of chemotherapy are not eligible. Given the protocol version date (08/02/18), QOL visits are excluded.; Correlative Studies (CALGB 150712) plasma collections are assumed to coincide with existing scheduled visits (screening, chemotherapy cycles, follow-up) and therefore do not add new contact days, but contribute to the 'labs' category on those days.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits was strictly applied for days with multiple activities."
36669140,Regimen A (vincristine/doxorubicin/cyclophosphamide (VDC) and ifosfamide/etoposide (IE)),intervention,1,9,22,43,52,59,0,9,22,43,50,55,1,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,2,14,"Fixed duration for Induction (12 weeks), Local Control, Consolidation (16 weeks), and Metastatic Site Radiation (5 days), followed by scheduled follow-up.","Screening: 1 day for baseline evaluations. Induction (6 cycles, 14-day cycle): VDC on Day 0, 28, 56 (each 2 days); IE on Day 14-18, 42-46, 70-74 (each 5 days). End of Induction evaluations on Day 84. Local Control: Surgery on Day 84. Consolidation (8 cycles, 14-day cycle, starting Day 98): VDC on Day 98, 140, 154, 182 (each 2 days); IE on Day 112-116, 126-130, 168-172, 196-200 (each 5 days). End of Consolidation evaluations on Day 209. Metastatic Site Radiation: SBRT on Day 315-319 (5 days) with weekly clinic visit on Day 322 and post-radiation clinic visit on Day 349. Follow-up: 3-month evaluation on Day 299.","Baseline evaluations are assumed to occur on one day (Day -7) within the screening window.; Local Control phase is assumed to include one day for surgery (Day 84), which overlaps with the End of Induction evaluations. Core treatment takes precedence for this day.; Metastatic Site Radiation (SBRT) is assumed to be 5 consecutive days, starting 3 weeks after the start of Consolidation Week 15 (Day 315).; Follow-up visits are anchored to the end of Consolidation (Day 209) as stated in Section 7.3.1, even though Metastatic Site Radiation occurs later. The 6-month follow-up visit (Day 389) falls outside the 12-month window (Day 0 to Day +365) and is not counted.; Each chemotherapy infusion day (VCR, CPM, IFOS, ETOP, DXRZ, DOXO, MESNA) is counted as one contact day. Multi-day infusions (like IFOS/ETOP/MESNA over 5 days) are counted as 5 separate contact days.; For days with multiple procedures, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied."
36669140,Regimen B (VDC/IE plus ganitumab),intervention,1,9,22,43,52,59,0,9,22,43,50,55,1,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,2,14,"Fixed duration for Induction (12 weeks), Local Control, Consolidation (16 weeks), and Metastatic Site Radiation (5 days), followed by scheduled follow-up.","Screening: 1 day for baseline evaluations. Induction (6 cycles, 14-day cycle): VDC on Day 0, 28, 56 (each 2 days); IE on Day 14-18, 42-46, 70-74 (each 5 days). End of Induction evaluations on Day 84. Local Control: Surgery on Day 84. Consolidation (8 cycles, 14-day cycle, starting Day 98): VDC on Day 98, 140, 154, 182 (each 2 days); IE on Day 112-116, 126-130, 168-172, 196-200 (each 5 days). End of Consolidation evaluations on Day 209. Metastatic Site Radiation: SBRT on Day 315-319 (5 days) with weekly clinic visit on Day 322 and post-radiation clinic visit on Day 349. Follow-up: 3-month evaluation on Day 299.","As per the protocol amendment (May 1, 2019), ganitumab administration was discontinued for all patients on Regimen B as of March 20, 2019. Therefore, the schedule of events for Regimen B is identical to Regimen A.; Baseline evaluations are assumed to occur on one day (Day -7) within the screening window.; Local Control phase is assumed to include one day for surgery (Day 84), which overlaps with the End of Induction evaluations. Core treatment takes precedence for this day.; Metastatic Site Radiation (SBRT) is assumed to be 5 consecutive days, starting 3 weeks after the start of Consolidation Week 15 (Day 315).; Follow-up visits are anchored to the end of Consolidation (Day 209) as stated in Section 7.3.1, even though Metastatic Site Radiation occurs later. The 6-month follow-up visit (Day 389) falls outside the 12-month window (Day 0 to Day +365) and is not counted.; Each chemotherapy infusion day (VCR, CPM, IFOS, ETOP, DXRZ, DOXO, MESNA) is counted as one contact day. Multi-day infusions (like IFOS/ETOP/MESNA over 5 days) are counted as 5 separate contact days.; For days with multiple procedures, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied."
36764316,Sotorasib (AMG 510),intervention,1,6,14,27,39,54,0,3,6,10,14,19,1,0,0,0,0,0,0,3,8,17,25,35,0,0,0,0,0,0,21,until progression,"Screening (1 day); Treatment cycles (21 days each) with in-person visits on Day 1, Day 5, and Day 8. AMG 510 dosing on C1D1, C1D8, and Day 1 of all subsequent cycles. Docetaxel dosing on Day 1 of all cycles. CT/MRI every 6 weeks from C1D1.","Screening is counted as 1 day, categorized as imaging_diagnostics due to CT/MRI and ECG.; Cycle length is 21 days.; Treatment is assumed to continue until Day +365 for the purpose of calculating visits within the 12-month window.; Visits on 'Day 5' and 'Day 8' in the Schedule of Activities tables are interpreted as C1D5 (Day +4) and C1D8 (Day +7) for Cycle 1, and then for subsequent cycles, they are relative to the start of that cycle (e.g., C2D5 is Day +25, C2D8 is Day +28).; CT/MRI for tumor assessment is scheduled 'every 6 weeks from cycle 1 day 1' (Day 0), meaning on Day +42 (C3D1), Day +84 (C5D1), Day +126 (C7D1), Day +168 (C9D1), Day +210 (C11D1), Day +252 (C13D1), Day +294 (C15D1), Day +336 (C17D1). When CT/MRI falls on a dosing day (Day 1 of a cycle), the day is categorized as core_treatment due to higher precedence.; ECG is performed at screening, C1D1, C2D1, and SFU. For subsequent cycles (Cycles 2-4, 5+), the table indicates 'X' under 'Day 1', implying ECG is performed on Day 1 of every cycle. These days are categorized based on the highest priority procedure.; AMG 510 dosing is oral and administered in clinic on C1D1, C1D8, and C2D1. For subsequent cycles, it is administered in clinic on Day 1 of each cycle, but taken at home on other days (e.g., Day 8 of C2+).; PK samples for AMG 510 are collected on C1D1, C1D8, and C2D1. For Cycles 2-4 and 5+, PK is collected on Day 1 and Day 8 of every cycle. These days are categorized based on the highest priority procedure.; Biomarker samples (Plasma DNA, Serum protein, Paxgene RNA) are collected on C1D1, then every cycle for cycles 1-5, then every other cycle starting from cycle 5. For Day 8, they are collected on C1D8, then every other cycle starting from cycle 5 (e.g., C6D8, C8D8). These days are categorized based on the highest priority procedure.; Thyroid function tests are performed at screening, and pre-dose on Day 1 of every cycle (except C1). So, from C2D1 onwards. These days are categorized based on the highest priority procedure.; Cholesterol and Triglycerides are collected at screening, and pre-dose on Day 1 of every other cycle (e.g., C1D1, C3D1, C5D1). These days are categorized based on the highest priority procedure.; PRO/QOL assessments (FACT-G GP5, PRO-CTCAE, BPI, QLQ-C30, QLQ-LC13, PGIS, EQ-5D-5L) are collected at clinic visits. EQ-5D-5L is also collected at home via phone for non-clinic days (Day 5 of C1, C2, C3) and during LTFU, which are not counted as in-person contact days.; The Safety Follow-up (SFU) visit occurs 30 days (± 7 days) after the last dose. Assuming treatment continues until Day 365, the SFU visit would fall outside the 12-month window and is therefore not included in the counts for the fixed intervals."
36764316,Docetaxel,control,1,6,14,27,39,54,0,2,5,9,13,18,1,0,0,0,0,0,0,4,9,18,26,36,0,0,0,0,0,0,21,until progression,"Screening (1 day); Treatment cycles (21 days each) with in-person visits on Day 1, Day 5, and Day 8. Docetaxel dosing on Day 1 of all cycles. CT/MRI every 6 weeks from C1D1.","Screening is counted as 1 day, categorized as imaging_diagnostics due to CT/MRI and ECG.; Cycle length is 21 days.; Treatment is assumed to continue until Day +365 for the purpose of calculating visits within the 12-month window.; Visits on 'Day 5' and 'Day 8' in the Schedule of Activities tables are interpreted as C1D5 (Day +4) and C1D8 (Day +7) for Cycle 1, and then for subsequent cycles, they are relative to the start of that cycle (e.g., C2D5 is Day +25, C2D8 is Day +28).; CT/MRI for tumor assessment is scheduled 'every 6 weeks from cycle 1 day 1' (Day 0), meaning on Day +42 (C3D1), Day +84 (C5D1), Day +126 (C7D1), Day +168 (C9D1), Day +210 (C11D1), Day +252 (C13D1), Day +294 (C15D1), Day +336 (C17D1). When CT/MRI falls on a dosing day (Day 1 of a cycle), the day is categorized as core_treatment due to higher precedence.; ECG is performed at screening, C1D1, C2D1, and SFU. For subsequent cycles (Cycles 2-4, 5+), the table indicates 'X' under 'Day 1', implying ECG is performed on Day 1 of every cycle. These days are categorized based on the highest priority procedure.; Docetaxel is administered intravenously on Day 1 of each cycle.; Biomarker samples (Plasma DNA, Serum protein, Paxgene RNA) are collected on C1D1, then every cycle for cycles 1-5, then every other cycle starting from cycle 5. For Day 8, they are collected on C1D8, then every other cycle starting from cycle 5 (e.g., C6D8, C8D8). These days are categorized based on the highest priority procedure.; Thyroid function tests are performed at screening, and pre-dose on Day 1 of every cycle (except C1). So, from C2D1 onwards. These days are categorized based on the highest priority procedure.; Cholesterol and Triglycerides are collected at screening, and pre-dose on Day 1 of every other cycle (e.g., C1D1, C3D1, C5D1). These days are categorized based on the highest priority procedure.; PRO/QOL assessments (FACT-G GP5, PRO-CTCAE, BPI, QLQ-C30, QLQ-LC13, PGIS, EQ-5D-5L) are collected at clinic visits. EQ-5D-5L is also collected at home via phone for non-clinic days (Day 5 of C1, C2, C3) and during LTFU, which are not counted as in-person contact days.; The Safety Follow-up (SFU) visit occurs 30 days (± 7 days) after the last dose. Assuming treatment continues until Day 365, the SFU visit would fall outside the 12-month window and is therefore not included in the counts for the fixed intervals."
36795891,Rucaparib (600 mg BID),intervention,3,3,6,9,12,16,0,2,3,4,6,9,2,1,2,4,5,6,1,0,1,1,1,1,0,0,0,0,0,0,"Not a single fixed cycle length for all visits; treatment dispensation is every 28 days after Day 15, other assessments vary.",until radiographic disease progression,"Screening: 3 days (optional biopsy, main screening with imaging, follow-up labs/PRO). Treatment Phase: Day 1, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 253, Day 281, Day 309, Day 337, Day 365.","Assumed 3 distinct screening days: 1 for optional biopsy for mutation testing, 1 for comprehensive screening including imaging, and 1 for follow-up labs/PRO. The optional biopsy is considered 'imaging_diagnostics'.; For Rucaparib, Abiraterone Acetate, and Enzalutamide, 'Study Drug Dispensation' is considered 'core_treatment' as these are targeted therapies and dispensing involves patient interaction/counseling/accountability as part of treatment delivery.; Treatment is assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule, to maximize visits within the 12-month window.; Visit days are based on Table 5 (Amendment 4, page 70) for Rucaparib/AR-directed therapies. The 'Day 57 & every 28 days thereafter' column implies visits on Day 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. The 'Study Day 15' and 'Study Day 43' columns represent additional visits in the earlier cycles.; Tumor assessments (TA) are explicitly scheduled on Day 1, 57, 113, 169, 253, 337 (footnote j/k on page 112/113, Amendment 4) and take precedence for categorization on those days.; PK samples are collected on Day 29, 57, 85, 113 (footnote t on page 113, Amendment 4)."
36795891,Physician's Choice: Abiraterone Acetate or Enzalutamide,control,3,3,6,9,12,16,0,2,3,4,6,9,2,1,2,4,5,6,1,0,1,1,1,1,0,0,0,0,0,0,"Not a single fixed cycle length for all visits; treatment dispensation is every 28 days after Day 15, other assessments vary.",until radiographic disease progression,"Screening: 3 days (optional biopsy, main screening with imaging, follow-up labs/PRO). Treatment Phase: Day 1, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225, Day 253, Day 281, Day 309, Day 337, Day 365.","Assumed 3 distinct screening days: 1 for optional biopsy for mutation testing, 1 for comprehensive screening including imaging, and 1 for follow-up labs/PRO. The optional biopsy is considered 'imaging_diagnostics'.; For Rucaparib, Abiraterone Acetate, and Enzalutamide, 'Study Drug Dispensation' is considered 'core_treatment' as these are targeted therapies and dispensing involves patient interaction/counseling/accountability as part of treatment delivery.; Treatment is assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule, to maximize visits within the 12-month window.; Visit days are based on Table 5 (Amendment 4, page 70) for Rucaparib/AR-directed therapies. The 'Day 57 & every 28 days thereafter' column implies visits on Day 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. The 'Study Day 15' and 'Study Day 43' columns represent additional visits in the earlier cycles.; Tumor assessments (TA) are explicitly scheduled on Day 1, 57, 113, 169, 253, 337 (footnote j/k on page 112/113, Amendment 4) and take precedence for categorization on those days.; PK samples are collected on Day 29, 57, 85, 113 (footnote t on page 113, Amendment 4)."
36795891,Physician's Choice: Docetaxel,control,3,3,7,14,16,19,0,2,5,10,10,10,2,0,1,2,3,4,1,1,1,2,3,5,0,0,0,0,0,0,Docetaxel administration is 21-day cycles (max 10 cycles). Other assessments are 28-day or 56/84-day schedules.,up to a maximum of 10 cycles,"Screening: 3 days (optional biopsy, main screening with imaging, follow-up labs/PRO). Treatment Phase: Docetaxel administration on Day 1, 22, 43, 64, 85, 106, 127, 148, 169, 190. PRO/General assessments on Day 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Tumor assessments on Day 57, 113, 169, 253, 337.","Assumed 3 distinct screening days: 1 for optional biopsy for mutation testing, 1 for comprehensive screening including imaging, and 1 for follow-up labs/PRO. The optional biopsy is considered 'imaging_diagnostics'.; Docetaxel administration is 'core_treatment'.; Docetaxel treatment is for a maximum of 10 cycles (21-day cycles), so the last treatment day is Day 190. Assessments continue until Day 365.; Visit days are based on Table 6 (Amendment 4, page 73) for Docetaxel. The table columns 'Study Day 1 and every 21 days thereafter', 'Study Day 1 and every 28 days thereafter', and 'Study Day 57 and every 56 days thereafter' are interpreted as distinct visit schedules, with procedures marked 'X' in a column occurring on that schedule. If a day falls under multiple schedules, the highest priority category applies.; Tumor assessments (TA) are explicitly scheduled on Day 57, 113, 169, 253, 337 (footnote j/k on page 115/116, Amendment 4) and take precedence for categorization on those days, unless Docetaxel administration occurs on the same day (e.g., Day 169), in which case 'core_treatment' takes precedence."
36969338,BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1),intervention,3,4,10,20,30,40,1,4,10,20,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated up to Day 365),"Screening (Day -14, Day -2 (Arm 1 only), Day -1). Treatment cycles (28 days) with visits on Day 1, Day 8, and Day 15. Imaging every 56 days. QoL, pregnancy tests, and correlative blood draws on various schedules, often coinciding with treatment days.","Randomization (Day 0) is the anchor.; Initial baseline assessments (e.g., Physical Exam, CT/MRI, initial labs) are assumed to occur on one day in the screening window (e.g., Day -14).; Additional baseline testing (< 72 hours prior to randomization) is assumed to occur on a separate day in the screening window (e.g., Day -1).; For Arm 1, BBI-608 administration begins 2 days prior to C1D1 (Run-in Day 1 and Run-in Day 2). Assuming randomization is Day 0, Run-in Day 1 is Day -2 and Run-in Day 2 is Day -1.; For Arm 2, there is no BBI-608 run-in period.; Treatment cycles are 28 days.; Treatment continues 'until progression' for the purpose of calculating days up to Day 365.; All treatment days (Day 1, 8, 15 of each cycle) include IV infusions (nab-paclitaxel and gemcitabine) and for Arm 1, BBI-608 dispensing, which are categorized as 'core_treatment'. Any other assessments on these days are subsumed by 'core_treatment' due to precedence.; Radiology & Imaging (CT/MRI scan) scheduled every 8 weeks (Day 56, 112, etc.) fall on Cycle Day 1 visits, and are therefore subsumed by 'core_treatment'.; QoL assessments, pregnancy tests, and correlative blood draws that fall on treatment days are subsumed by 'core_treatment'."
36969338,nab-paclitaxel with gemcitabine (Arm 2),control,2,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated up to Day 365),"Screening (Day -14, Day -1). Treatment cycles (28 days) with visits on Day 1, Day 8, and Day 15. Imaging every 56 days. QoL, pregnancy tests, and correlative blood draws on various schedules, often coinciding with treatment days.","Randomization (Day 0) is the anchor.; Initial baseline assessments (e.g., Physical Exam, CT/MRI, initial labs) are assumed to occur on one day in the screening window (e.g., Day -14).; Additional baseline testing (< 72 hours prior to randomization) is assumed to occur on a separate day in the screening window (e.g., Day -1).; For Arm 1, BBI-608 administration begins 2 days prior to C1D1 (Run-in Day 1 and Run-in Day 2). Assuming randomization is Day 0, Run-in Day 1 is Day -2 and Run-in Day 2 is Day -1.; For Arm 2, there is no BBI-608 run-in period.; Treatment cycles are 28 days.; Treatment continues 'until progression' for the purpose of calculating days up to Day 365.; All treatment days (Day 1, 8, 15 of each cycle) include IV infusions (nab-paclitaxel and gemcitabine) and for Arm 1, BBI-608 dispensing, which are categorized as 'core_treatment'. Any other assessments on these days are subsumed by 'core_treatment' due to precedence.; Radiology & Imaging (CT/MRI scan) scheduled every 8 weeks (Day 56, 112, etc.) fall on Cycle Day 1 visits, and are therefore subsumed by 'core_treatment'.; QoL assessments, pregnancy tests, and correlative blood draws that fall on treatment days are subsumed by 'core_treatment'."
36996380,Arm A: Enzalutamide alone,intervention,1,2,5,10,14,20,0,0,0,0,0,0,1,0,1,3,4,6,0,2,4,7,10,14,0,0,0,0,0,0,28,until progression,"One screening visit. Cycle 1 Day 1 (Day 0) visit. Subsequent cycle Day 1 visits every 28 days. Imaging visits for tumor assessment occur at Week 9, 17, 25, 33, 41, 49. Correlative and PK blood draws are integrated into these visits.","All 'Prior to Registration' procedures are assumed to occur on a single day within the screening window.; All 'Day 1 of each cycle' procedures are assumed to occur on a single day.; Treatment monitoring imaging visits (Week 9, 17, 25, 33, 41, 49) are assumed to be separate in-person visits from the Day 1 of cycle visits, as their nominal dates do not align with Day 1 of cycle dates.; Correlative blood samples and PK samples are collected on existing visit days (either screening or Day 1 of cycle visits) and do not add new contact days.; Treatment continues until progression, so visits are enumerated up to Day +365."
36996380,"Arm B: Enzalutamide, Abiraterone, and Prednisone",intervention,1,3,8,13,17,23,0,0,0,0,0,0,1,0,1,3,4,6,0,3,7,10,13,17,0,0,0,0,0,0,28,until progression,"One screening visit. Cycle 1 Day 1 (Day 0) visit. Subsequent cycle Day 1 visits every 28 days. Additional bi-weekly lab visits for the first 3 months (Day 14, 42, 70). Imaging visits for tumor assessment occur at Week 9, 17, 25, 33, 41, 49. Correlative and PK blood draws are integrated into these visits.","All 'Prior to Registration' procedures are assumed to occur on a single day within the screening window.; All 'Day 1 of each cycle' procedures are assumed to occur on a single day.; Treatment monitoring imaging visits (Week 9, 17, 25, 33, 41, 49) are assumed to be separate in-person visits from the Day 1 of cycle visits, as their nominal dates do not align with Day 1 of cycle dates.; Arm B specific labs (AST/ALT, Alk. Phos., Bili) every two weeks for the first 3 months (Day 14, 42, 70) are assumed to be additional in-person visits.; Correlative blood samples and PK samples are collected on existing visit days (either screening or Day 1 of cycle visits) and do not add new contact days.; Treatment continues until progression, so visits are enumerated up to Day +365."
37069359,BL-8040 + G-CSF,intervention,1,13,42,43,44,45,0,9,9,9,9,9,1,1,1,2,2,2,0,3,32,32,33,34,0,0,0,0,0,0,,Fixed mobilization/transplant period followed by scheduled post-transplant visits up to 12 months.,"Single screening visit, daily G-CSF for 8 days, BL-8040 administration on Day 4 and Day 6 (conditional), apheresis on Day 5, 6, 7, 8 (conditional), followed by a pre-transplant visit, transplant day, 29 days of daily post-transplant monitoring, and then scheduled visits at Day 30, 60, 100, 180, 270, 360 post-transplant.","Screening visit is counted as 1 day, assumed to occur on Day -10.; G-CSF is administered daily for 8 days (Day 1-8).; BL-8040 is administered on Day 4 (evening) and Day 6 (evening), assuming the collection goal was not met after the first apheresis.; Apheresis sessions occur on Day 5, 6, 7, 8, assuming the collection goal was not met after previous sessions, as these are protocol-mandated actions based on objective criteria.; Visit 9 (Conditioning Pre-transplantation) is assumed to occur on Study Day 21 (3 weeks after Day 0, within 5 weeks of last apheresis).; Visit 10 (Transplantation Day) is assumed to occur on Study Day 28 (1 week after Visit 9).; Daily post-transplant monitoring for 'Day 1 to 29 Post-transplant' is interpreted as 29 distinct daily contact days, occurring from Study Day 29 to Study Day 57.; Subsequent visits (Visit 11, 12, 13, 14, 15, 16) are counted as single contact days on their nominal post-transplant days (Day 30, 60, 100, 180, 270, 360 relative to transplant day, which is Study Day 28).; Procedures designated as 'Part 2 only' are included in the counts for this arm, as they represent in-person contact and Part 1 subjects follow the same schedule.; Category assignment for days with multiple procedures is based on the tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37069359,Placebo + G-CSF,control,1,13,42,43,44,45,0,9,9,9,9,9,1,1,1,2,2,2,0,3,32,32,33,34,0,0,0,0,0,0,,Fixed mobilization/transplant period followed by scheduled post-transplant visits up to 12 months.,"Single screening visit, daily G-CSF for 8 days, Placebo administration on Day 4 and Day 6 (conditional), apheresis on Day 5, 6, 7, 8 (conditional), followed by a pre-transplant visit, transplant day, 29 days of daily post-transplant monitoring, and then scheduled visits at Day 30, 60, 100, 180, 270, 360 post-transplant.","Screening visit is counted as 1 day, assumed to occur on Day -10.; G-CSF is administered daily for 8 days (Day 1-8).; Placebo is administered on Day 4 (evening) and Day 6 (evening), assuming the collection goal was not met after the first apheresis.; Apheresis sessions occur on Day 5, 6, 7, 8, assuming the collection goal was not met after previous sessions, as these are protocol-mandated actions based on objective criteria.; Visit 9 (Conditioning Pre-transplantation) is assumed to occur on Study Day 21 (3 weeks after Day 0, within 5 weeks of last apheresis).; Visit 10 (Transplantation Day) is assumed to occur on Study Day 28 (1 week after Visit 9).; Daily post-transplant monitoring for 'Day 1 to 29 Post-transplant' is interpreted as 29 distinct daily contact days, occurring from Study Day 29 to Study Day 57.; Subsequent visits (Visit 11, 12, 13, 14, 15, 16) are counted as single contact days on their nominal post-transplant days (Day 30, 60, 100, 180, 270, 360 relative to transplant day, which is Study Day 28).; Procedures designated as 'Part 2 only' are included in the counts for this arm.; Category assignment for days with multiple procedures is based on the tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37071094,mFOLFOX6 + Panitumumab,intervention,2,9,18,39,57,78,0,9,18,39,57,78,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,until progression (guided duration of 12 months),"Screening: 1 day for labs/clinic, 1 day for imaging. Treatment cycles (14-day cycle): Day 1 (infusion, clinical assessment, labs, plus imaging/tumor markers every 56 days), Day 2 (infusion), Day 3 (infusion).","One dedicated screening visit for all initial labs and clinic assessments (ICF, patient background, clinical findings, height/body weight, ECOG PS, hematology, serum chemistry, urinalysis, immunological tests, RAS status) is assumed to occur on a single day within the screening window, categorized as 'labs' due to precedence.; One separate screening visit for imaging (thoracoabdominal-pelvic CT/MRI) is assumed to occur on a different day within the screening window, categorized as 'imaging_diagnostics'.; Treatment is assumed to continue for at least 12 months (until Day +365) as per the 'until discontinuation criteria are met' rule, with 'lack of efficacy (exacerbation) when PD is evident' being a discontinuation criterion, implying 'until progression'.; All Day 1, Day 2, and Day 3 of each 14-day cycle involve in-person administration of core treatment (infusions), thus counted as 'core_treatment' days.; Clinical findings, ECOG PS, and routine laboratory tests performed on Day 1 of each cycle are subsumed under 'core_treatment' due to the co-occurrence of infusions.; Imaging (CT/MRI) and tumor markers performed on Day 1 of cycles 1, 5, 9, 13, 17, 21, 25 (every 56 days) are subsumed under 'core_treatment' due to the co-occurrence of infusions."
37071094,mFOLFOX6 + Bevacizumab,intervention,2,9,18,39,57,78,0,9,18,39,57,78,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,until progression (guided duration of 12 months),"Screening: 1 day for labs/clinic, 1 day for imaging. Treatment cycles (14-day cycle): Day 1 (infusion, clinical assessment, labs, plus imaging/tumor markers every 56 days), Day 2 (infusion), Day 3 (infusion).","One dedicated screening visit for all initial labs and clinic assessments (ICF, patient background, clinical findings, height/body weight, ECOG PS, hematology, serum chemistry, urinalysis, immunological tests, RAS status) is assumed to occur on a single day within the screening window, categorized as 'labs' due to precedence.; One separate screening visit for imaging (thoracoabdominal-pelvic CT/MRI) is assumed to occur on a different day within the screening window, categorized as 'imaging_diagnostics'.; Treatment is assumed to continue for at least 12 months (until Day +365) as per the 'until discontinuation criteria are met' rule, with 'lack of efficacy (exacerbation) when PD is evident' being a discontinuation criterion, implying 'until progression'.; All Day 1, Day 2, and Day 3 of each 14-day cycle involve in-person administration of core treatment (infusions), thus counted as 'core_treatment' days.; Clinical findings, ECOG PS, and routine laboratory tests performed on Day 1 of each cycle are subsumed under 'core_treatment' due to the co-occurrence of infusions.; Imaging (CT/MRI) and tumor markers performed on Day 1 of cycles 1, 5, 9, 13, 17, 21, 25 (every 56 days) are subsumed under 'core_treatment' due to the co-occurrence of infusions."
37075781,Pembrolizumab plus Gemcitabine and Cisplatin,experimental,2,4,9,18,26,36,0,4,9,18,26,36,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,"Pembrolizumab up to 35 administrations, Cisplatin up to 8 cycles, Gemcitabine until progression.","Screening (2 days), then Day 1 and Day 8 of each 21-day cycle.","Screening procedures are consolidated into 2 distinct in-person days: one for imaging/biopsy and physical assessments (imaging_diagnostics), and one for all routine labs (labs).; The 'X' in the Schedule of Activities table indicates an in-person procedure.; Visits explicitly noted as potentially remote (e.g., 'If a clinic visit is not feasible, follow-up information may be obtained via other means of contact') are excluded from contact days.; Optional visits or visits 'if clinically indicated' (e.g., brain MRI/CT, bone scan) are excluded from routine contact day counts, except for audiometry at screening.; Genetic analysis samples marked with 'X' are assumed to be in-person collections.; Cycle length is 21 days.; Pembrolizumab is administered on Day 1 of each cycle for up to 35 administrations. For the 12-month window, this covers 18 cycles (Day 0 to Day 364).; Cisplatin is administered on Day 1 and Day 8 of each cycle for a maximum of 8 cycles (up to C8D8, Day 154).; Gemcitabine is administered on Day 1 and Day 8 of each cycle until disease progression or unacceptable toxicity. For the 12-month calculation, it is assumed to continue for the full 12-month period (18 cycles).; All Day 1 and Day 8 visits during the intervention phase involve intravenous infusions (Pembrolizumab/Placebo, Gemcitabine, and/or Cisplatin). Therefore, all these days are categorized as 'core_treatment' due to tie-breaker precedence, even if other procedures (imaging, labs, clinic visits) also occur.; Tumor imaging (CT/MRI) occurs on Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, 18 within the 12-month window. These days are already categorized as 'core_treatment' due to infusions.; The '30 Days After Last Dose' (Safety FUb) visit and subsequent Efficacy/Survival FU visits are assumed to occur after the 12-month treatment period if treatment continues for the full duration, and thus are not included in the 12-month contact day counts."
37075781,Placebo plus Gemcitabine and Cisplatin,control,2,4,9,18,26,36,0,4,9,18,26,36,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,"Placebo up to 35 administrations, Cisplatin up to 8 cycles, Gemcitabine until progression.","Screening (2 days), then Day 1 and Day 8 of each 21-day cycle.","Screening procedures are consolidated into 2 distinct in-person days: one for imaging/biopsy and physical assessments (imaging_diagnostics), and one for all routine labs (labs).; The 'X' in the Schedule of Activities table indicates an in-person procedure.; Visits explicitly noted as potentially remote (e.g., 'If a clinic visit is not feasible, follow-up information may be obtained via other means of contact') are excluded from contact days.; Optional visits or visits 'if clinically indicated' (e.g., brain MRI/CT, bone scan) are excluded from routine contact day counts, except for audiometry at screening.; Genetic analysis samples marked with 'X' are assumed to be in-person collections.; Cycle length is 21 days.; Placebo is administered on Day 1 of each cycle for up to 35 administrations. For the 12-month window, this covers 18 cycles (Day 0 to Day 364).; Cisplatin is administered on Day 1 and Day 8 of each cycle for a maximum of 8 cycles (up to C8D8, Day 154).; Gemcitabine is administered on Day 1 and Day 8 of each cycle until disease progression or unacceptable toxicity. For the 12-month calculation, it is assumed to continue for the full 12-month period (18 cycles).; All Day 1 and Day 8 visits during the intervention phase involve intravenous infusions (Placebo, Gemcitabine, and/or Cisplatin). Therefore, all these days are categorized as 'core_treatment' due to tie-breaker precedence, even if other procedures (imaging, labs, clinic visits) also occur.; Tumor imaging (CT/MRI) occurs on Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17, 18 within the 12-month window. These days are already categorized as 'core_treatment' due to infusions.; The '30 Days After Last Dose' (Safety FUb) visit and subsequent Efficacy/Survival FU visits are assumed to occur after the 12-month treatment period if treatment continues for the full duration, and thus are not included in the 12-month contact day counts."
37080222,Arm A (Tislelizumab + chemotherapy doublet),intervention,2,12,30,50,70,95,1,10,25,45,65,90,0,0,0,0,0,0,1,2,5,5,5,5,0,0,0,0,0,0,21,"until disease progression, intolerable toxicity, or withdrawal","Screening (2 days); Treatment Cycles (21-day cycle length): Days 1-5 for core treatment, Day 8 and 15 for labs/clinic in Cycles 1-3. Day 1-5 for core treatment in Cycles 4+. Additional assessments (imaging, labs) integrated into these days.","A fresh tumor biopsy is assumed to be performed during screening, contributing one 'core_treatment' day. All other screening procedures (imaging, ECG, PFT, clinic visits, labs) are consolidated into this day or a separate 'labs' day based on precedence.; The Platinum + 5-FU chemotherapy doublet is assumed for both arms, as it results in the highest number of in-person contact days (5 days per cycle for infusions: Day 1-5).; Day 8 and Day 15 visits for Cycles 1-3 are counted as in-person contact days due to 'X' in the Schedule of Assessments table for various procedures (e.g., labs, physical exam), despite a footnote mentioning telephone calls for AE/concomitant medication review.; Tumor assessments are scheduled every 6 weeks for the first 48 weeks, then every 9 weeks, as per the text description (Page 6, 11, 36, 64). These assessments fall on Day 1 of specific cycles and are subsumed under 'core_treatment' due to drug administration on those days.; Optical Coherence Tomography (OCT) and visual acuity tests are scheduled approximately every 15 weeks (Page 58, Note 10). These fall on Day 1 of specific cycles and are subsumed under 'core_treatment'.; Thyroid function tests are performed at Screening and every 3 cycles (C4, C7, C10, C13, C16) on Day 1. These are subsumed under 'core_treatment' on Day 1 of those cycles.; HBV/HCV tests are performed at Screening and every 4 cycles (C5, C9, C13, C17) on Day 1. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Pharmacokinetics (PK) and Anti-Tislelizumab Antibodies (ADA) samples are collected on Day 1 of Cycles 1, 2, 5, 9, and 17. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Patient-Reported Outcomes (PROs) are collected on Day 1 of Cycles 1-6, then every other cycle thereafter. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Treatment is assumed to continue until Day +365 for the purpose of calculating visits within the 12-month window, based on the 'until progression' rule."
37080222,Arm B (Placebo + chemotherapy doublet),control,2,12,30,50,70,95,1,10,25,45,65,90,0,0,0,0,0,0,1,2,5,5,5,5,0,0,0,0,0,0,21,"until disease progression, intolerable toxicity, or withdrawal","Screening (2 days); Treatment Cycles (21-day cycle length): Days 1-5 for core treatment, Day 8 and 15 for labs/clinic in Cycles 1-3. Day 1-5 for core treatment in Cycles 4+. Additional assessments (imaging, labs) integrated into these days.","A fresh tumor biopsy is assumed to be performed during screening, contributing one 'core_treatment' day. All other screening procedures (imaging, ECG, PFT, clinic visits, labs) are consolidated into this day or a separate 'labs' day based on precedence.; The Platinum + 5-FU chemotherapy doublet is assumed for both arms, as it results in the highest number of in-person contact days (5 days per cycle for infusions: Day 1-5).; Day 8 and Day 15 visits for Cycles 1-3 are counted as in-person contact days due to 'X' in the Schedule of Assessments table for various procedures (e.g., labs, physical exam), despite a footnote mentioning telephone calls for AE/concomitant medication review.; Tumor assessments are scheduled every 6 weeks for the first 48 weeks, then every 9 weeks, as per the text description (Page 6, 11, 36, 64). These assessments fall on Day 1 of specific cycles and are subsumed under 'core_treatment' due to drug administration on those days.; Optical Coherence Tomography (OCT) and visual acuity tests are scheduled approximately every 15 weeks (Page 58, Note 10). These fall on Day 1 of specific cycles and are subsumed under 'core_treatment'.; Thyroid function tests are performed at Screening and every 3 cycles (C4, C7, C10, C13, C16) on Day 1. These are subsumed under 'core_treatment' on Day 1 of those cycles.; HBV/HCV tests are performed at Screening and every 4 cycles (C5, C9, C13, C17) on Day 1. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Pharmacokinetics (PK) and Anti-Tislelizumab Antibodies (ADA) samples are collected on Day 1 of Cycles 1, 2, 5, 9, and 17. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Patient-Reported Outcomes (PROs) are collected on Day 1 of Cycles 1-6, then every other cycle thereafter. These are subsumed under 'core_treatment' on Day 1 of those cycles.; Treatment is assumed to continue until Day +365 for the purpose of calculating visits within the 12-month window, based on the 'until progression' rule."
37080223,Arm A - Control Arm,control,3,23,35,36,37,38,0,23,33,33,33,33,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,1,2,3,21,"until progression or 5 years follow-up, whichever is earlier","Screening (3 days); 6 weeks of concurrent chemoradiation (30 EBRT days, 5 weekly cisplatin infusions, 6 weekly clinical/lab assessments, 3 brachytherapy insertions with imaging); End of Treatment visit. Arm B additionally receives 4 cycles of 3-weekly adjuvant carboplatin/paclitaxel chemotherapy and an End of Adjuvant Treatment visit. Follow-up visits occur every 3 months for 2 years, then every 6 months, with imaging at 6 months post-randomization.","Baseline assessments (clinic, imaging, labs) are assumed to occur on 3 distinct days during the screening window.; Chemoradiation starts on Day 0 (Randomisation Day).; External Beam Radiation Therapy (EBRT) is 5 days/week for 6 weeks, totaling 30 fractions. These are assumed to occur on weekdays (Day 0-4, 7-11, 14-18, 21-25, 28-32, 35-39).; Cisplatin is given weekly for 5 doses, coinciding with 5 of the EBRT days (Day 0, 7, 14, 21, 28).; Weekly clinical reviews and labs during chemoradiation are assumed to coincide with the 5 cisplatin days and one additional EBRT day (Day 35), totaling 6 weekly assessment days.; Brachytherapy consists of 3 fractions, assumed to occur after EBRT completion and on days distinct from EBRT (e.g., Day 42, 45, 48). Imaging is assumed to be performed on these brachytherapy days.; End of Treatment (EoT) visit for Arm A is assumed to occur on Day 56 (within 4 weeks of last radiation treatment).; Adjuvant chemotherapy for Arm B starts on Day 70 (within 4 weeks of last radiation treatment on Day 48).; Adjuvant chemotherapy cycles for Arm B are on Day 70, 91, 112, 133.; End of Adjuvant Treatment visit for Arm B is assumed to occur on Day 140 (after the last adjuvant chemotherapy).; Follow-up visits are scheduled at Day 90, 180, 270, 365, etc. as per protocol.; For Arm B, the 3-month follow-up visit (Day 90) is omitted as it falls within the adjuvant chemotherapy treatment period, as per Footnote A.; For Arm B, the 6-month follow-up visit (Day 180) is considered a distinct visit from the End of Adjuvant Treatment visit (Day 140), as the gap is significant (40 days).; Optional visits or 'if clinically indicated' procedures (e.g., follow-up bloods) are not counted as contact days unless explicitly mandated for all patients at a specific time point (e.g., baseline imaging if available).; Quality of Life questionnaires are assumed to be completed during clinic visits."
37080223,Arm B - Intervention Arm,intervention,3,23,34,39,40,41,0,23,34,37,37,37,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,2,21,"until progression or 5 years follow-up, whichever is earlier","Screening (3 days); 6 weeks of concurrent chemoradiation (30 EBRT days, 5 weekly cisplatin infusions, 6 weekly clinical/lab assessments, 3 brachytherapy insertions with imaging); End of Treatment visit. Arm B additionally receives 4 cycles of 3-weekly adjuvant carboplatin/paclitaxel chemotherapy and an End of Adjuvant Treatment visit. Follow-up visits occur every 3 months for 2 years, then every 6 months, with imaging at 6 months post-randomization.","Baseline assessments (clinic, imaging, labs) are assumed to occur on 3 distinct days during the screening window.; Chemoradiation starts on Day 0 (Randomisation Day).; External Beam Radiation Therapy (EBRT) is 5 days/week for 6 weeks, totaling 30 fractions. These are assumed to occur on weekdays (Day 0-4, 7-11, 14-18, 21-25, 28-32, 35-39).; Cisplatin is given weekly for 5 doses, coinciding with 5 of the EBRT days (Day 0, 7, 14, 21, 28).; Weekly clinical reviews and labs during chemoradiation are assumed to coincide with the 5 cisplatin days and one additional EBRT day (Day 35), totaling 6 weekly assessment days.; Brachytherapy consists of 3 fractions, assumed to occur after EBRT completion and on days distinct from EBRT (e.g., Day 42, 45, 48). Imaging is assumed to be performed on these brachytherapy days.; End of Treatment (EoT) visit for Arm A is assumed to occur on Day 56 (within 4 weeks of last radiation treatment).; Adjuvant chemotherapy for Arm B starts on Day 70 (within 4 weeks of last radiation treatment on Day 48).; Adjuvant chemotherapy cycles for Arm B are on Day 70, 91, 112, 133.; End of Adjuvant Treatment visit for Arm B is assumed to occur on Day 140 (after the last adjuvant chemotherapy).; Follow-up visits are scheduled at Day 90, 180, 270, 365, etc. as per protocol.; For Arm B, the 3-month follow-up visit (Day 90) is omitted as it falls within the adjuvant chemotherapy treatment period, as per Footnote A.; For Arm B, the 6-month follow-up visit (Day 180) is considered a distinct visit from the End of Adjuvant Treatment visit (Day 140), as the gap is significant (40 days).; Optional visits or 'if clinically indicated' procedures (e.g., follow-up bloods) are not counted as contact days unless explicitly mandated for all patients at a specific time point (e.g., baseline imaging if available).; Quality of Life questionnaires are assumed to be completed during clinic visits."
37104748,Arm 1: Dose-escalated RT alone,intervention,1,23,45,46,47,48,0,23,45,45,45,45,1,0,0,0,0,0,0,0,0,1,2,3,0,0,0,0,0,0,28,until progression,"1 screening day, 45 daily RT days (Mon-Fri for 9 weeks), followed by 4 post-RT follow-up visits at 3, 6, 9, and 12 months.","All screening procedures are consolidated into a single in-person contact day, categorized by the highest priority procedure (imaging_diagnostics).; Day 0 is the start of Radiation Therapy (RT).; Radiation Therapy (RT) consists of 44 fractions (79.2 Gy / 1.8 Gy/fraction) delivered 5 days/week (Monday-Friday), resulting in 9 weeks of treatment (Day 0 to Day 44), totaling 45 core_treatment days.; Weekly performance status and AE evaluations during RT (Page 42) are assumed to coincide with RT treatment days.; QOL assessments and blood for banking during the last week of RT (Page 42) are assumed to coincide with RT treatment days.; Follow-up visits at 3, 6, 9, and 12 months post RT (Page 43) include physical exam, DRE, and PSA. PSA is a lab, making these days 'labs' category.; Conditional brachytherapy-specific assessments (Transrectal ultrasound, AUA, CBC w/ diff & ANC for brachy patients) are not included as they are not universally mandated for all patients in this arm."
37104748,Arm 2: Dose-escalated RT combined with short-term (6 months) androgen blockade (LHRH agonist + anti-androgen),intervention,1,23,48,50,51,52,0,23,48,50,50,50,1,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,28,until progression,"1 screening day, 6 monthly ADT injection days (starting Day -56), 45 daily RT days (Mon-Fri for 9 weeks, starting Day 0), followed by 3 post-RT follow-up visits at 6, 9, and 12 months.","All screening procedures are consolidated into a single in-person contact day, categorized by the highest priority procedure (imaging_diagnostics).; Day 0 is the start of Radiation Therapy (RT).; Androgen Deprivation Therapy (ADT) starts 8 weeks (Day -56) prior to RT start and continues for 6 months (180 days). LHRH agonist injections are given monthly, resulting in 6 injection days (Day -56, -26, 4, 34, 64, 94). These are core_treatment days.; Monthly liver function tests (AST/ALT/alk phos) and serum testosterone for Arm 2 during ADT are assumed to coincide with LHRH agonist injection days.; Radiation Therapy (RT) consists of 44 fractions (79.2 Gy / 1.8 Gy/fraction) delivered 5 days/week (Monday-Friday), resulting in 9 weeks of treatment (Day 0 to Day 44), totaling 45 core_treatment days.; Weekly performance status and AE evaluations during RT (Page 42) are assumed to coincide with RT treatment days.; QOL assessments during Week 3 of RT and QOL assessments and blood for banking during the last week of RT (Page 42) are assumed to coincide with RT treatment days.; Follow-up visits at 6, 9, and 12 months post RT (Page 43) include physical exam, DRE, and PSA. Serum testosterone is also collected at 6 and 12 months post RT. PSA and serum testosterone are labs, making these days 'labs' category.; Conditional brachytherapy-specific assessments (Transrectal ultrasound, AUA, CBC w/ diff & ANC for brachy patients) are not included as they are not universally mandated for all patients in this arm."
37141294,Pembrolizumab (MK-3475),intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progression (capped at 35 administrations or 2 years for Pembrolizumab, assumed similar for Docetaxel)","Screening: 1 day (imaging_diagnostics) within Day -28 to Day -1. Treatment: Infusion on Day 1 of each 21-day cycle, with associated labs, clinic visits, and imaging (every 9 weeks).","All screening procedures that can be performed on a single day are consolidated into one contact day, with the highest priority procedure (tumor imaging/biopsy) determining the category.; Optional visits (e.g., consent for future biomedical research, optional biopsies) are excluded.; Treatment continues until progression; for the purpose of calculating within the 12-month window, treatment is assumed to continue through Day 357 (Cycle 18 Day 1).; The 'Discontinuation Visit' and 'Post-Treatment Follow-up Phase' visits are assumed to occur after Day 365 if treatment continues until Day 357, and thus are not included in the 12-month window.; The 'Second Course Phase' is considered a re-treatment phase after progression on the initial treatment and is not included in the primary 12-month calculation for the initial treatment arm.; All cycle visits (Day 1 of each 21-day cycle) are considered a single contact day. The presence of an IV infusion (core_treatment) on these days assigns the entire day to the 'core_treatment' category, overriding other procedures like labs, clinic visits, or imaging.; Laboratory samples for Cycle 1 Day 1 are assumed to be collected on Day 1. For subsequent cycles, even if samples can be collected up to 72 hours prior, they are considered part of the main treatment visit day for simplicity and consistency with the schedule table."
37141294,Docetaxel,control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until progression (per local standard of care, assumed similar to Pembrolizumab arm for calculation purposes)","Screening: 1 day (imaging_diagnostics) within Day -28 to Day -1. Treatment: Infusion on Day 1 of each 21-day cycle, with associated labs, clinic visits, and imaging (every 9 weeks).","All screening procedures that can be performed on a single day are consolidated into one contact day, with the highest priority procedure (tumor imaging/biopsy) determining the category.; Optional visits (e.g., consent for future biomedical research, optional biopsies) are excluded.; Treatment continues until progression; for the purpose of calculating within the 12-month window, treatment is assumed to continue through Day 357 (Cycle 18 Day 1).; The 'Discontinuation Visit' and 'Post-Treatment Follow-up Phase' visits are assumed to occur after Day 365 if treatment continues until Day 357, and thus are not included in the 12-month window.; All cycle visits (Day 1 of each 21-day cycle) are considered a single contact day. The presence of an IV infusion (core_treatment) on these days assigns the entire day to the 'core_treatment' category, overriding other procedures like labs, clinic visits, or imaging.; Laboratory samples for Cycle 1 Day 1 are assumed to be collected on Day 1. For subsequent cycles, even if samples can be collected up to 72 hours prior, they are considered part of the main treatment visit day for simplicity and consistency with the schedule table."
37257422,"All Arms (Arm A, Arm B, Arm C)",intervention,2,23,36,43,49,56,0,23,36,43,49,56,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression (assumed full 12 cycles of adjuvant therapy for calculation up to Day 365),"Screening (1 day), Randomization (1 day). Chemoradiation Phase (Day 0 to Day 46): Radiation Therapy (35 days, 5 days/week for 7 weeks), Depatuxizumab Mafodotin IV infusion on Day 0, Day 14, Day 28. Adjuvant Phase (Day 77 to Day 357): Depatuxizumab Mafodotin IV infusion on Day 1 and Day 15 of each 28-day cycle for 11 cycles (21 days within 12 months). Other assessments (interviews, labs, exams, vitals, weight, pregnancy tests) are integrated into these contact days.","All three treatment arms (Arm A: Standard Steroids, Arm B: Standard Steroids + Vasoconstrictor + Cold Compress, Arm C: Enhanced Steroids + Vasoconstrictor + Cold Compress) have identical in-person healthcare contact schedules, as the prophylactic eye treatments are self-administered and do not require additional in-person visits.; The Chemoradiation Phase is assumed to be exactly 7 weeks (49 days) for radiation therapy and temozolomide administration, followed by a 4-week recovery period.; Radiation therapy is administered 5 days per week (Monday-Friday) for 7 weeks, totaling 35 contact days.; The Adjuvant Phase is assumed to start 28 days after the last day of chemoradiation (Day 49 + 28 = Day 77).; Adjuvant Phase treatment is assumed to continue for the full 12 cycles (28 days/cycle) as specified, with visits counted up to Day +365.; Screening and Randomization are treated as two distinct in-person contact days based on their separate columns in the Schedule of Events (SoE) table.; Oral Temozolomide administration and self-administered prophylactic eye treatments (eye drops, ointment, cold compress) are not counted as in-person contact days.; Phone calls (e.g., Week 9 Day 1 CEAE assessment, Day 49 Follow-Up if unable to return) are not counted as in-person contact days.; Procedures labeled 'if clinically indicated' (e.g., Physical exam) are assumed to occur on all scheduled visit days where they are listed, as these are routine treatment/assessment visits.; The 'Tumor sample for EGFR amplification testing (required)' at Screening is classified as 'imaging_diagnostics' as it is a diagnostic biopsy for eligibility assessment, not part of treatment delivery.; The 'Archival Tumor Sample (optional)' is excluded from contact day counts.; For visits with multiple procedures, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign the primary category for the day."
37272516,AG-881 (Vorasidenib),intervention,3,2,6,9,12,16,1,0,0,0,0,0,1,2,5,8,11,15,0,0,1,1,1,1,1,0,0,0,0,0,28,"until centrally confirmed radiographic PD by the BIRC; development of unacceptable toxicity; need for initiation of chemotherapy, radiotherapy, or other anticancer therapy...; confirmed pregnancy; death; withdrawal of consent from treatment; lost to follow-up; or Sponsor ending the study, whichever occurs first.","Prescreening (biopsy, consent), Screening (MRI, ECHO, ECG, labs, clinic), then continuous 28-day cycles with D1 and D15 visits. D1 visits include various assessments (clinic, labs, PK, ECG, MRI every 3 cycles). D15 visits include labs and clinic, with PK and ECG only in C1. For C2D15, there are labs and clinic visits but no PK/ECG. From C4D1 onwards, all D1 visits include ECG and PK blood sampling.","A fresh tumor biopsy is performed during prescreening (Day -40) for eligibility, categorized as core_treatment.; Prescreening informed consent (Day -30) and Main study informed consent (Day -7) are distinct in-person visits.; All Screening procedures (D -28 to D -1) occur on a single day (Day -7).; All Cycle D1 and D15 procedures occur on a single day for that specific cycle day.; ECG procedures (imaging_diagnostics) take precedence over PK blood draws (labs) when both occur on the same day.; Other lab collections (Hematology, Serum Chemistry, Urinalysis, Pregnancy Test, 1p19q status) take precedence over clinic visits.; Treatment duration is assumed to continue for at least 12 months for fixed interval calculations.; Optional visits (buccal swab) are excluded.; For cycles 4-36, all D1 visits include ECG and PK blood sampling, as per Table 2 footnotes indicating 'every first and second cycle' and 'every third cycle' for C4D1 through C37D1."
37272516,Placebo,control,3,2,6,9,12,16,1,0,0,0,0,0,1,2,5,8,11,15,0,0,1,1,1,1,1,0,0,0,0,0,28,"until centrally confirmed radiographic PD by the BIRC; development of unacceptable toxicity; need for initiation of chemotherapy, radiotherapy, or other anticancer therapy...; confirmed pregnancy; death; withdrawal of consent from treatment; lost to follow-up; or Sponsor ending the study, whichever occurs first.","Prescreening (biopsy, consent), Screening (MRI, ECHO, ECG, labs, clinic), then continuous 28-day cycles with D1 and D15 visits. D1 visits include various assessments (clinic, labs, PK, ECG, MRI every 3 cycles). D15 visits include labs and clinic, with PK and ECG only in C1. For C2D15, there are labs and clinic visits but no PK/ECG. From C4D1 onwards, all D1 visits include ECG and PK blood sampling.","A fresh tumor biopsy is performed during prescreening (Day -40) for eligibility, categorized as core_treatment.; Prescreening informed consent (Day -30) and Main study informed consent (Day -7) are distinct in-person visits.; All Screening procedures (D -28 to D -1) occur on a single day (Day -7).; All Cycle D1 and D15 procedures occur on a single day for that specific cycle day.; ECG procedures (imaging_diagnostics) take precedence over PK blood draws (labs) when both occur on the same day.; Other lab collections (Hematology, Serum Chemistry, Urinalysis, Pregnancy Test, 1p19q status) take precedence over clinic visits.; Treatment duration is assumed to continue for at least 12 months for fixed interval calculations.; Optional visits (buccal swab) are excluded.; For cycles 4-36, all D1 visits include ECG and PK blood sampling, as per Table 2 footnotes indicating 'every first and second cycle' and 'every third cycle' for C4D1 through C37D1."
37276510,SGI-110,intervention,2,11,27,45,64,82,0,8,20,35,50,65,1,0,0,0,0,0,0,3,7,10,14,17,1,0,0,0,0,0,28,until progression,"Screening: 2 days (1 for screening procedures including imaging/labs, 1 for randomization). Cycles 1-2 (28-day cycles): Day 1 (drug, ECG, PK, assessments), D2-5 (drug, vitals, AEs), D8, D15, D22 (labs, AEs). Cycles >=3 (28-day cycles): D1 (drug, assessments, BM biopsy if scheduled), D2-5 (drug, vitals, AEs), D15 (labs, AEs). BM aspirate/biopsy: Screening, C3D1, C5D1, C7D1, C10D1, C13D1. ECG: Screening, C1D1. PK: C1D1, C1D5.","Treatment continues for the full 12 months (365 days), which corresponds to 13 cycles.; Screening and Randomization are two distinct in-person days within the screening window.; BM aspirate/biopsy and Molecular genetics/cytogenetics on C1D1 in Table 16 are superseded by text indicating they are screening or later cycle procedures.; PK samples are counted as in-person lab days.; Long-term follow-up visits are not counted as treatment continues for 12 months.; BM aspirate/biopsy on Day 1 of cycles (C3, C5, C7, C10, C13) are categorized as 'core_treatment' due to drug administration on the same day, following tie-breaker precedence."
37276510,Treatment Choice (TC),control,2,15,42,78,112,145,0,13,37,70,100,130,1,0,0,0,0,0,0,2,5,8,12,15,1,0,0,0,0,0,28,until progression,"Screening: 2 days (1 for screening procedures including imaging/labs, 1 for randomization). Cycles 1-2 (28-day cycles): Day 1 (drug, ECG, assessments), Dosing Days (drug, vitals, AEs), D8, D15, D22 (labs, AEs). Cycles >=3 (28-day cycles): D1 (drug, assessments, BM biopsy if scheduled), Dosing Days (drug, vitals, AEs), D15 (labs, AEs). BM aspirate/biopsy: Screening, C3D1, C5D1, C7D1, C10D1, C13D1. ECG: Screening, C1D1. PK: C1D1, C1D5 (Decitabine only). (Pattern reflects the maximum burden from Cytarabine regimen for dosing days).","Treatment continues for the full 12 months (365 days), which corresponds to 13 cycles.; Screening and Randomization are two distinct in-person days within the screening window.; BM aspirate/biopsy and Molecular genetics/cytogenetics on C1D1 in Table 16 are superseded by text indicating they are screening or later cycle procedures.; PK samples are counted as in-person lab days (only for Decitabine).; Long-term follow-up visits are not counted as treatment continues for 12 months.; For the 'Treatment Choice' arm, the maximum number of contact days among the three possible regimens (Cytarabine, Decitabine, Azacitidine) is reported for each time window, as this represents the highest potential burden for a participant in this arm. Cytarabine consistently had the highest number of contact days.; 'BID' for Cytarabine means 1 contact day per calendar date, not 2.; 'IV or SC' for Azacitidine means it's an in-person administration.; BM aspirate/biopsy on Day 1 of cycles (C3, C5, C7, C10, C13) are categorized as 'core_treatment' due to drug administration on the same day, following tie-breaker precedence."
37284847,Group 1: Olanzapine + Fosaprepitant/Aprepitant + 5-HT3 Receptor Antagonist + Dexamethasone,intervention,1,4,4,4,4,4,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,maximum of 4 cycles (24 days),"1 screening visit. 4 treatment cycles, each 6 days long. In-person visits only occur on Day 1 of each cycle. Days 2-6 involve self-reported questionnaires and phone contacts, which are not counted as in-person contact days.","Chemotherapy administration is an in-person core_treatment activity on Day 1 of each cycle.; IV drug administration (5-HT3 RA, Fosaprepitant/Aprepitant or Placebo) requires an in-person visit.; Oral drug administration (Olanzapine, Dexamethasone) on Day 1 is assumed to be in-person as part of the Day 1 clinic visit for chemotherapy and IV drugs. On subsequent days (Days 2-4), oral drugs are taken at home and do not count as contact days.; Questionnaires completed in clinic on Day 1 are in-person clinic_visits, but are superseded by core_treatment on Day 1 due to precedence.; Daily Nurse Telephone Contact (Days 2-6) is explicitly a phone call and not an in-person contact day.; Adverse Event Assessments on Day 1 of each cycle are in-person as part of the chemotherapy visit, but are superseded by core_treatment on Day 1 due to precedence.; The maximum study duration of 24 days (4 cycles of 6 days) is strictly followed, and no further visits occur after Day +23."
37284847,Group 2: Olanzapine + Placebo (IV) + 5-HT3 Receptor Antagonist + Dexamethasone,control,1,4,4,4,4,4,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,maximum of 4 cycles (24 days),"1 screening visit. 4 treatment cycles, each 6 days long. In-person visits only occur on Day 1 of each cycle. Days 2-6 involve self-reported questionnaires and phone contacts, which are not counted as in-person contact days.","Chemotherapy administration is an in-person core_treatment activity on Day 1 of each cycle.; IV drug administration (5-HT3 RA, Fosaprepitant/Aprepitant or Placebo) requires an in-person visit.; Oral drug administration (Olanzapine, Dexamethasone) on Day 1 is assumed to be in-person as part of the Day 1 clinic visit for chemotherapy and IV drugs. On subsequent days (Days 2-4), oral drugs are taken at home and do not count as contact days.; Questionnaires completed in clinic on Day 1 are in-person clinic_visits, but are superseded by core_treatment on Day 1 due to precedence.; Daily Nurse Telephone Contact (Days 2-6) is explicitly a phone call and not an in-person contact day.; Adverse Event Assessments on Day 1 of each cycle are in-person as part of the chemotherapy visit, but are superseded by core_treatment on Day 1 due to precedence.; The maximum study duration of 24 days (4 cycles of 6 days) is strictly followed, and no further visits occur after Day +23."
37290035,Arm 1 (Pembrolizumab Plus Olaparib),intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (up to 35 cycles for Pembrolizumab),"Screening (Day -28), then Cycle Day 1 visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357).","Screening visit is assumed to occur on Day -28.; Cycle length is 21 days (Q3W). Cycle Day 1 visits are assumed to occur on Day 0, Day 21, Day 42, etc.; Treatment is assumed to continue for at least 35 cycles (approximately 2 years) or until discontinuation criteria are met. All visits within the 365-day window are counted.; The 'End of Treatment Visit' and 'Safety Follow-up' visits are assumed to occur after the 12-month window (Day +365) if treatment continues for 35 cycles, and are therefore not included in the counts.; Per Amendment 06, 'Second Course Phase' treatment, ePRO assessments (FACT-P, EQ-5D-5L, BPI-SF, Analgesic Log), and all biomarker sample collections (CTC count, genetic analysis, RNA analysis, plasma/serum biomarker analysis, ctDNA analysis) are discontinued and excluded from contact day counts.; For Arm 1, Pembrolizumab is administered via IV infusion on Day 1 of each cycle, making these days 'core_treatment'. Dispensing/return of Olaparib containers on these days are subsumed under 'core_treatment'.; For Arm 2, Abiraterone/Enzalutamide are oral, self-administered. Dispensing/return of containers are considered 'clinic_visits' but the day's category is determined by the highest priority procedure performed on that day.; The 'Telephone contact or visit on Cycle 1 Day 8' is noted as optional ('An unscheduled visit can occur at any time if deemed necessary by the investigator') and is therefore excluded."
37290035,Arm 2 (Abiraterone Acetate or Enzalutamide),control,1,2,5,9,13,18,0,0,0,0,0,0,1,1,4,6,9,12,0,1,1,3,4,6,0,0,0,0,0,0,21,until progression,"Screening (Day -28), then Cycle Day 1 visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357).","Screening visit is assumed to occur on Day -28.; Cycle length is 21 days (Q3W). Cycle Day 1 visits are assumed to occur on Day 0, Day 21, Day 42, etc.; Treatment is assumed to continue for at least 35 cycles (approximately 2 years) or until discontinuation criteria are met. All visits within the 365-day window are counted.; The 'End of Treatment Visit' and 'Safety Follow-up' visits are assumed to occur after the 12-month window (Day +365) if treatment continues for 35 cycles, and are therefore not included in the counts.; Per Amendment 06, 'Second Course Phase' treatment, ePRO assessments (FACT-P, EQ-5D-5L, BPI-SF, Analgesic Log), and all biomarker sample collections (CTC count, genetic analysis, RNA analysis, plasma/serum biomarker analysis, ctDNA analysis) are discontinued and excluded from contact day counts.; For Arm 1, Pembrolizumab is administered via IV infusion on Day 1 of each cycle, making these days 'core_treatment'. Dispensing/return of Olaparib containers on these days are subsumed under 'core_treatment'.; For Arm 2, Abiraterone/Enzalutamide are oral, self-administered. Dispensing/return of containers are considered 'clinic_visits' but the day's category is determined by the highest priority procedure performed on that day.; The 'Telephone contact or visit on Cycle 1 Day 8' is noted as optional ('An unscheduled visit can occur at any time if deemed necessary by the investigator') and is therefore excluded."
37290461,Atezolizumab + Cabozantinib,intervention,2,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,"until disease progression, unacceptable toxicity, or symptomatic deterioration","Screening: 2 days (biopsy, main screening). On-treatment: Day 1 of each 21-day cycle (C1D1 to C18D1 within 12 months).","Treatment continues for the full 12-month period (18 cycles) for calculation purposes, as treatment is 'until disease progression, unacceptable toxicity, or symptomatic deterioration'.; A separate screening day is counted for the mandatory tumor tissue biopsy, which must occur at least 10 days prior to C1D1.; The main screening visit (including CT/MRI scans and ECG) is counted as a single day.; For Arm 1, all Day 1 visits of each cycle are categorized as 'core_treatment' due to the Atezolizumab IV infusion.; For Arm 2, only C1D1 is 'core_treatment' due to in-clinic Cabozantinib administration. Subsequent Cabozantinib doses are taken at home and are not counted as contact days.; For Arm 2, subsequent Day 1 visits are categorized based on the highest priority procedure present (imaging_diagnostics > labs > clinic_visits).; Survival follow-up visits are assumed not to be mandated in-person contact days for all patients, as they can be conducted via telephone or medical records."
37290461,Cabozantinib alone,control,2,2,5,9,13,18,0,1,1,1,1,1,2,1,3,4,6,8,0,0,1,4,6,9,0,0,0,0,0,0,21,"until disease progression, unacceptable toxicity, or symptomatic deterioration","Screening: 2 days (biopsy, main screening). On-treatment: Day 1 of each 21-day cycle (C1D1 to C18D1 within 12 months).","Treatment continues for the full 12-month period (18 cycles) for calculation purposes, as treatment is 'until disease progression, unacceptable toxicity, or symptomatic deterioration'.; A separate screening day is counted for the mandatory tumor tissue biopsy, which must occur at least 10 days prior to C1D1.; The main screening visit (including CT/MRI scans and ECG) is counted as a single day.; For Arm 1, all Day 1 visits of each cycle are categorized as 'core_treatment' due to the Atezolizumab IV infusion.; For Arm 2, only C1D1 is 'core_treatment' due to in-clinic Cabozantinib administration. Subsequent Cabozantinib doses are taken at home and are not counted as contact days.; For Arm 2, subsequent Day 1 visits are categorized based on the highest priority procedure present (imaging_diagnostics > labs > clinic_visits).; Survival follow-up visits are assumed not to be mandated in-person contact days for all patients, as they can be conducted via telephone or medical records."
37315297,Arm 1: External Beam Radiation Therapy and then Brachytherapy,intervention,5,23,27,29,30,31,0,23,26,26,26,26,3,0,1,1,1,1,1,0,0,2,3,4,1,0,0,0,0,0,N/A,"Fixed follow-up schedule for the first year, then every six months until five years post-implant, then annually thereafter.","Screening (5 days: clinic, diagnostic biopsy, labs, TRUS, pelvic CT/MRI). Arm 1: EBRT (25 days over 5 weeks, Mon-Fri), Brachytherapy implant (1 day, 2-4 weeks post-EBRT), Post-implant imaging/initial FU (1 day, 3-5 weeks post-implant). Arm 2: Brachytherapy implant (1 day, 2-4 weeks post-enrollment), Post-implant imaging/initial FU (1 day, 3-5 weeks post-implant). Both arms: Follow-up visits at 4, 6, 9, 12 months (each 1 day for labs/clinic).","Screening visits are assumed to occur on distinct days.; Brachytherapy implant for Arm 1 is assumed to occur on Day 56 (midpoint of 2-4 weeks after 5 weeks of EBRT).; Post-implant imaging for Arm 1 is assumed to occur on Day 84 (midpoint of 3-5 weeks after implant).; Brachytherapy implant for Arm 2 is assumed to occur on Day 21 (midpoint of 2-4 weeks after study enrollment).; Post-implant imaging for Arm 2 is assumed to occur on Day 49 (midpoint of 3-5 weeks after implant).; All listed activities for a given follow-up visit (H&P, Zubrod, Tumor Measurement, Questionnaires, Toxicity Evaluation, Labs) occur on the same calendar day.; Weekly radiation oncologist visits and weekly verification films during EBRT are assumed to coincide with EBRT treatment days.; Optional visits (flexible cystoscopy, weekly blood tests during RT, bone scan, needle biopsy if disease worsens) are excluded."
37315297,Arm 2: Brachytherapy Alone,intervention,5,1,2,4,5,6,0,1,1,1,1,1,3,0,1,1,1,1,1,0,0,2,3,4,1,0,0,0,0,0,N/A,"Fixed follow-up schedule for the first year, then every six months until five years post-implant, then annually thereafter.","Screening (5 days: clinic, diagnostic biopsy, labs, TRUS, pelvic CT/MRI). Arm 1: EBRT (25 days over 5 weeks, Mon-Fri), Brachytherapy implant (1 day, 2-4 weeks post-EBRT), Post-implant imaging/initial FU (1 day, 3-5 weeks post-implant). Arm 2: Brachytherapy implant (1 day, 2-4 weeks post-enrollment), Post-implant imaging/initial FU (1 day, 3-5 weeks post-implant). Both arms: Follow-up visits at 4, 6, 9, 12 months (each 1 day for labs/clinic).","Screening visits are assumed to occur on distinct days.; Brachytherapy implant for Arm 1 is assumed to occur on Day 56 (midpoint of 2-4 weeks after 5 weeks of EBRT).; Post-implant imaging for Arm 1 is assumed to occur on Day 84 (midpoint of 3-5 weeks after implant).; Brachytherapy implant for Arm 2 is assumed to occur on Day 21 (midpoint of 2-4 weeks after study enrollment).; Post-implant imaging for Arm 2 is assumed to occur on Day 49 (midpoint of 3-5 weeks after implant).; All listed activities for a given follow-up visit (H&P, Zubrod, Tumor Measurement, Questionnaires, Toxicity Evaluation, Labs) occur on the same calendar day.; Weekly radiation oncologist visits and weekly verification films during EBRT are assumed to coincide with EBRT treatment days.; Optional visits (flexible cystoscopy, weekly blood tests during RT, bone scan, needle biopsy if disease worsens) are excluded."
37331369,Fruquintinib + BSC,intervention,2,3,7,13,19,27,0,3,7,13,19,26,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening (Day -28), Randomization (Day -1), then C_D1 and C_D21 every 28 days for treatment cycles (3 weeks on, 1 week off), followed by an End of Treatment visit 7 days after the last dose.","Screening and Randomization are considered distinct contact days (Day -28 and Day -1 respectively).; Visits explicitly marked with 'X' in Table 1 are in-person contact days, with footnotes providing specific scheduling details overriding general 'X' marks (e.g., Echocardiogram, Tumor Imaging, Tumor Markers, Urine Pregnancy Test, 12-lead ECG).; Drug Dispense/Return and Study Treatment on C_D1 and C_D21 are categorized as core_treatment days.; Adverse Event checks are implicitly part of other visits and do not add separate contact days.; Survival Follow-up (every 12 weeks from EOT) is by telephone (Footnote 26) and thus not a contact day.; PK/ECG visits from Table 2 and Table 3 are for a subset of patients and are not included in the general arm counts.; Treatment continues such that the last full cycle (C13) is completed, and the End of Treatment (EOT) visit occurs at Day 363 (7 days after C13D21), allowing the EOT visit to fall within the 12-month window."
37331369,Placebo + BSC,control,2,3,7,13,19,27,0,3,7,13,19,26,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening (Day -28), Randomization (Day -1), then C_D1 and C_D21 every 28 days for treatment cycles (3 weeks on, 1 week off), followed by an End of Treatment visit 7 days after the last dose.","Screening and Randomization are considered distinct contact days (Day -28 and Day -1 respectively).; Visits explicitly marked with 'X' in Table 1 are in-person contact days, with footnotes providing specific scheduling details overriding general 'X' marks (e.g., Echocardiogram, Tumor Imaging, Tumor Markers, Urine Pregnancy Test, 12-lead ECG).; Drug Dispense/Return and Study Treatment on C_D1 and C_D21 are categorized as core_treatment days.; Adverse Event checks are implicitly part of other visits and do not add separate contact days.; Survival Follow-up (every 12 weeks from EOT) is by telephone (Footnote 26) and thus not a contact day.; PK/ECG visits from Table 2 and Table 3 are for a subset of patients and are not included in the general arm counts.; Treatment continues such that the last full cycle (C13) is completed, and the End of Treatment (EOT) visit occurs at Day 363 (7 days after C13D21), allowing the EOT visit to fall within the 12-month window."
37342922,Tacrolimus/Methotrexate (Tac/MTX),intervention,4,9,17,19,20,21,0,5,5,5,5,5,1,0,0,1,1,2,2,4,12,13,14,14,1,0,0,0,0,0,Not applicable; fixed schedule post-transplant.,"1 year post-PBSC transplant for main study follow-up, with specific drug durations (MTX: Day +1, +3, +6, +11; Tacrolimus: Day -3 to Day 180).","Pre-transplant: Day -28, Day -20, Day -10, Day -1. Post-transplant: Day 0, Day +1, Day +3, Day +6, Day +7, Day +11, Day +14, Day +21, Day +28, Day +35, Day +42, Day +49, Day +56, Day +63, Day +70, Day +77, Day +84, Day +98, Day +180, Day +270, Day +365.","Pre-conditioning and pre-infusion visits for Mi-Immune samples are considered distinct in-person contact days.; General pre-transplant evaluations are consolidated into two distinct days (Day -28 for clinic/labs, Day -20 for imaging/diagnostics) within the screening window.; Tacrolimus administration is oral/IV, but its weekly blood level monitoring from Day +7 until Day 180 requires in-person visits and is categorized as 'labs'.; Mycophenolate mofetil (MMF) is oral and does not require in-person contact for administration.; All scheduled visits in Table 4.6B and mandatory/required Mi-Immune sample collections/assessments are counted as in-person contact days.; Optional stool/urine collections for Mi-Immune study are assumed to occur on days already scheduled for other mandatory assessments, thus not adding new contact days.; If multiple activities occur on the same calendar day, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied for categorization.; Patient Reported Outcomes (PRO) at Day 100 are assumed to be covered by the Day 98 visit.; CMV monitoring and antimicrobial medication data collection are assumed to be integrated into existing scheduled visits and categorized based on the highest priority activity on that day."
37342922,Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil (PTCy/Tac/MMF),intervention,4,7,15,17,18,19,0,3,3,3,3,3,1,0,0,1,1,2,2,4,12,13,14,14,1,0,0,0,0,0,Not applicable; fixed schedule post-transplant.,"1 year post-PBSC transplant for main study follow-up, with specific drug durations (PTCy: Day +3, +4; MMF: Day +5 to +35; Tacrolimus: Day +5 to Day 180).","Pre-transplant: Day -28, Day -20, Day -10, Day -1. Post-transplant: Day 0, Day +3, Day +4, Day +7, Day +14, Day +21, Day +28, Day +35, Day +42, Day +49, Day +56, Day +63, Day +70, Day +77, Day +84, Day +98, Day +180, Day +270, Day +365.","Pre-conditioning and pre-infusion visits for Mi-Immune samples are considered distinct in-person contact days.; General pre-transplant evaluations are consolidated into two distinct days (Day -28 for clinic/labs, Day -20 for imaging/diagnostics) within the screening window.; Tacrolimus administration is oral/IV, but its weekly blood level monitoring from Day +7 until Day 180 requires in-person visits and is categorized as 'labs'.; Mycophenolate mofetil (MMF) is oral and does not require in-person contact for administration.; All scheduled visits in Table 4.6B and mandatory/required Mi-Immune sample collections/assessments are counted as in-person contact days.; Optional stool/urine collections for Mi-Immune study are assumed to occur on days already scheduled for other mandatory assessments, thus not adding new contact days.; If multiple activities occur on the same calendar day, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied for categorization.; Patient Reported Outcomes (PRO) at Day 100 are assumed to be covered by the Day 98 visit.; CMV monitoring and antimicrobial medication data collection are assumed to be integrated into existing scheduled visits and categorized based on the highest priority activity on that day."
37379502,Lazertinib,intervention,1,4,7,9,11,13,0,4,7,9,11,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), Cycle 1 Day 1 (Day 0), Cycle 1 Day 8 (Day +7), Cycle 1 Day 15 (Day +14), Cycle 2 Day 1 (Day +21), Cycle 3 Day 1 (Day +42), Cycle 4 Day 1 (Day +63), Cycle 5 Day 1 (Day +84), then Day 1 of every other cycle (C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) for general activities. Specific assessments (ECG, Echo, PK, RECIST, cfDNA, Q, HRU) follow their own frequencies as per footnotes.","Randomization is not a separate contact day; Cycle 1 Day 1 (Day 0) is the first on-treatment visit after randomization.; Optional assessments ('As clinically required' or 'Optionally') such as Ophthalmologic assessment and CSF (BM only) are excluded.; The frequency for RECIST v1.1 assessment, Blood samples for cfDNA and blood-borne biomarkers, Questionnaires, and Health resource use module is based on the specific footnotes (20, 21, 22) stating 'Every 6 weeks for the first 18 months and then every 12 weeks relative to date of randomization' rather than the 'X' in every C1D1 column from C2 onwards in Table 5, as the footnotes provide more specific scheduling information. This is a more conservative interpretation.; All listed 'Laboratory tests' (Clinical chemistry, Hematology, Urinalysis, Pregnancy test) are assumed to be in-person phlebotomy/sample collection visits.; 'EGFR mutation test (Tissue biopsy)' at screening is considered an imaging_diagnostics activity (diagnostic biopsy).; 'Tumor and blood samples for central laboratory' at screening is considered a labs activity.; '12-lead ECG' and 'Echocardiography/MUGA' are considered imaging_diagnostics activities.; 'RECIST v1.1 assessment' involves imaging (CT/MRI) and is thus considered an imaging_diagnostics activity.; 'PK blood samples' are considered labs activities.; 'Blood samples for cfDNA and blood-borne biomarkers' are are considered labs activities.; 'Questionnaires' and 'Health resource use module' are considered clinic_visits activities.; 'Informed consent, Demographics & baseline characteristics, Height, Medical and surgical history, Inclusion/Exclusion criteria, Physical examination, WHO Performance Status, Vital signs, Adverse events, Prior/concomitant medication' are considered clinic_visits activities.; The tie-breaker precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied for categorizing days. All treatment days include 'Dispense study treatment' and 'Dose with study treatment' (core_treatment), making them core_treatment days. The screening day includes diagnostic imaging and biopsy, making it an imaging_diagnostics day."
37379502,Gefitinib,intervention,1,4,7,9,11,13,0,4,7,9,11,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), Cycle 1 Day 1 (Day 0), Cycle 1 Day 8 (Day +7), Cycle 1 Day 15 (Day +14), Cycle 2 Day 1 (Day +21), Cycle 3 Day 1 (Day +42), Cycle 4 Day 1 (Day +63), Cycle 5 Day 1 (Day +84), then Day 1 of every other cycle (C7D1, C9D1, C11D1, C13D1, C15D1, C17D1) for general activities. Specific assessments (ECG, Echo, PK, RECIST, cfDNA, Q, HRU) follow their own frequencies as per footnotes.","Randomization is not a separate contact day; Cycle 1 Day 1 (Day 0) is the first on-treatment visit after randomization.; Optional assessments ('As clinically required' or 'Optionally') such as Ophthalmologic assessment and CSF (BM only) are excluded.; The frequency for RECIST v1.1 assessment, Blood samples for cfDNA and blood-borne biomarkers, Questionnaires, and Health resource use module is based on the specific footnotes (20, 21, 22) stating 'Every 6 weeks for the first 18 months and then every 12 weeks relative to date of randomization' rather than the 'X' in every C1D1 column from C2 onwards in Table 5, as the footnotes provide more specific scheduling information. This is a more conservative interpretation.; All listed 'Laboratory tests' (Clinical chemistry, Hematology, Urinalysis, Pregnancy test) are assumed to be in-person phlebotomy/sample collection visits.; 'EGFR mutation test (Tissue biopsy)' at screening is considered an imaging_diagnostics activity (diagnostic biopsy).; 'Tumor and blood samples for central laboratory' at screening is considered a labs activity.; '12-lead ECG' and 'Echocardiography/MUGA' are considered imaging_diagnostics activities.; 'RECIST v1.1 assessment' involves imaging (CT/MRI) and is thus considered an imaging_diagnostics activity.; 'PK blood samples' are considered labs activities.; 'Blood samples for cfDNA and blood-borne biomarkers' are are considered labs activities.; 'Questionnaires' and 'Health resource use module' are considered clinic_visits activities.; 'Informed consent, Demographics & baseline characteristics, Height, Medical and surgical history, Inclusion/Exclusion criteria, Physical examination, WHO Performance Status, Vital signs, Adverse events, Prior/concomitant medication' are considered clinic_visits activities.; The tie-breaker precedence rule (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied for categorizing days. All treatment days include 'Dispense study treatment' and 'Dose with study treatment' (core_treatment), making them core_treatment days. The screening day includes diagnostic imaging and biopsy, making it an imaging_diagnostics day."
37423228,Atezolizumab,intervention,2,2,6,10,14,19,0,2,5,9,13,18,2,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,21,until disease progression,Screening (2 days). Treatment: Atezolizumab IV infusion every 21 days (Day 1 of each cycle). Additional lab visit at Day 49 (Week 7).,"Assumed 2 distinct in-person screening days: one for general assessments (including ECG, labs, PE, PRO, history, consent) and one for tumor imaging/biopsy (if not archival). Both days are categorized as imaging_diagnostics due to precedence.; Treatment duration is assumed to continue through the 12-month window ('until disease progression').; Follow-up visits are not counted as mandatory in-person contact days as they are described as 'telephone calls and/or clinic visits' and 'as needed' for serious side effects, indicating optionality for in-person attendance.; For Atezolizumab, all scheduled tumor assessments (every 6 weeks for 48 weeks) and TSH assessments (Cycles 5, 9, 13, etc.) fall on Day 1 of a treatment cycle, and thus are covered by the core_treatment day.; Plasma for exploratory biomarkers at Week 7 (Day 49) is an additional in-person lab day, as it does not coincide with a treatment day."
37423228,Chemotherapy (Vinorelbine or Gemcitabine),control,2,4,12,23,34,44,0,4,10,20,30,39,2,0,1,2,3,4,0,0,1,1,1,1,0,0,0,0,0,0,28,until disease progression,"Screening (2 days). Treatment: Chemotherapy administered on Day 1, Day 8, and Day 15 of each 28-day cycle. Additional lab visit at Day 49 (Week 7). Additional tumor assessment visits at Day 42, 126, 210, 294.","Assumed 2 distinct in-person screening days: one for general assessments (including ECG, labs, PE, PRO, history, consent) and one for tumor imaging/biopsy (if not archival). Both days are categorized as imaging_diagnostics due to precedence.; Treatment duration is assumed to continue through the 12-month window ('until disease progression').; Follow-up visits are not counted as mandatory in-person contact days as they are described as 'telephone calls and/or clinic visits' and 'as needed' for serious side effects, indicating optionality for in-person attendance.; For chemotherapy, the d1/8/15 q28d regimen (3 treatment days per 28-day cycle) was assumed to provide a conservative (higher) estimate of contact days, as both 21-day and 28-day cycles are mentioned as options for vinorelbine/gemcitabine.; For chemotherapy, Day 1, Day 8, and Day 15 of each cycle are considered core_treatment days due to drug administration. Other assessments (PE, ECOG, Vitals, ECG, labs, PRO, pregnancy test, coagulation) occurring on these days are subsumed under core_treatment due to precedence.; Plasma for exploratory biomarkers at Week 7 (Day 49) is an additional in-person lab day, as it does not coincide with a treatment day.; Tumor response assessments (every 6 weeks for 48 weeks) that do not fall on a chemotherapy treatment day (Day 1, 8, or 15 of a 28-day cycle) are counted as additional imaging_diagnostics days (specifically Day 42, 126, 210, 294)."
37478390,"zanubrutinib (Arm A, 160 mg twice daily)",intervention,1,4,12,21,30,40,0,2,2,2,2,2,1,0,1,3,4,5,0,2,9,16,24,33,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycles 1-13: D1, D1+4, D1+7 (3 visits/cycle); Cycle 14: D1 (1 visit). Specific assessments (Imaging, ECG, QOL, BM biopsy, Conditional Labs, PK) occur on certain D1 visits.","The 'Day of cycle' row in Table 3 indicates specific visit days within each cycle column (e.g., Cycle 1 has D1, D1+4, D1+7 visits). This pattern of 3 visits per cycle (D1, D1+4, D1+7) is applied to all cycles (C1-C14) within the 12-month window.; All screening procedures are consolidated into a single in-person visit day. Randomization is considered part of this screening visit.; Initial study drug administration on C1D1 is an in-person core_treatment event for all arms. For Arms A and C, C2D1 is also a core_treatment day due to in-clinic PK sampling and drug administration.; Study drug administration marked 'X' in the table for days other than C1D1 and C2D1 (for Arms A/C) is for dispensing/accountability and categorized as clinic_visits. However, due to higher precedence activities on those days (e.g., labs), the day is categorized as 'labs'.; Conditional labs (Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) are assumed to be abnormal at screening to maximize contact days, thus performed on D1 of C1-C13.; QOL assessments are only for Arms A and B, as per text on page 45, point 17. Their presence does not change the overall day category due to higher precedence activities.; Follow-up visits (EOT, Safety Follow-up, every 12 weeks) are not included in the 12-month treatment period as they occur after treatment discontinuation."
37478390,"ibrutinib (Arm B, 420 mg once daily)",intervention,1,4,12,21,30,40,0,2,2,2,2,2,1,0,1,3,4,5,0,2,9,16,24,33,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycles 1-13: D1, D1+4, D1+7 (3 visits/cycle); Cycle 14: D1 (1 visit). Specific assessments (Imaging, ECG, QOL, BM biopsy, Conditional Labs) occur on certain D1 visits.","The 'Day of cycle' row in Table 3 indicates specific visit days within each cycle column (e.g., Cycle 1 has D1, D1+4, D1+7 visits). This pattern of 3 visits per cycle (D1, D1+4, D1+7) is applied to all cycles (C1-C14) within the 12-month window.; All screening procedures are consolidated into a single in-person visit day. Randomization is considered part of this screening visit.; Initial study drug administration on C1D1 is an in-person core_treatment event for all arms. For Arm B, C2D1 is also categorized as core_treatment due to initial drug administration and ECG.; Study drug administration marked 'X' in the table for days other than C1D1 and C2D1 (for Arms A/C) is for dispensing/accountability and categorized as clinic_visits. However, due to higher precedence activities on those days (e.g., labs), the day is categorized as 'labs'.; Conditional labs (Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) are assumed to be abnormal at screening to maximize contact days, thus performed on D1 of C1-C13.; QOL assessments are only for Arms A and B, as per text on page 45, point 17. Their presence does not change the overall day category due to higher precedence activities.; Follow-up visits (EOT, Safety Follow-up, every 12 weeks) are not included in the 12-month treatment period as they occur after treatment discontinuation."
37478390,"zanubrutinib (Arm C, 160 mg twice daily)",intervention,1,4,12,21,30,40,0,2,2,2,2,2,1,0,1,3,4,5,0,2,9,16,24,33,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycles 1-13: D1, D1+4, D1+7 (3 visits/cycle); Cycle 14: D1 (1 visit). Specific assessments (Imaging, ECG, BM biopsy, Conditional Labs, PK) occur on certain D1 visits.","The 'Day of cycle' row in Table 3 indicates specific visit days within each cycle column (e.g., Cycle 1 has D1, D1+4, D1+7 visits). This pattern of 3 visits per cycle (D1, D1+4, D1+7) is applied to all cycles (C1-C14) within the 12-month window.; All screening procedures are consolidated into a single in-person visit day. Randomization is considered part of this screening visit.; Initial study drug administration on C1D1 is an in-person core_treatment event for all arms. For Arms A and C, C2D1 is also a core_treatment day due to in-clinic PK sampling and drug administration.; Study drug administration marked 'X' in the table for days other than C1D1 and C2D1 (for Arms A/C) is for dispensing/accountability and categorized as clinic_visits. However, due to higher precedence activities on those days (e.g., labs), the day is categorized as 'labs'.; Conditional labs (Cold agglutinins, Cryoglobulin, Anti-MAG, Serum viscosity) are assumed to be abnormal at screening to maximize contact days, thus performed on D1 of C1-C13.; QOL assessments are only for Arms A and B, as per text on page 45, point 17. Their absence for Arm C does not change the overall day category due to higher precedence activities.; Follow-up visits (EOT, Safety Follow-up, every 12 weeks) are not included in the 12-month treatment period as they occur after treatment discontinuation."
37499670,Experimental Arm: Camrelizumab + Rivoceranib,intervention,3,3,7,13,20,27,0,3,7,13,20,27,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,"until intolerable toxicity, withdrawal of consent, or disease progression confirmed by BIRC","Screening: Day -28, Day -14, Day -7. Treatment: D1 and D15 of each 28-day cycle for the first 3 cycles. From Cycle 4 onwards, D1 and D15 of each 28-day cycle for the experimental arm, and D1 only for the control arm. Tumor imaging on Day 56, 112, 168, 224, 280, 336.","Treatment continues for the full 12-month duration for calculation purposes.; Screening Period [1], [2], and [3] are distinct in-person contact days (Day -28, Day -14, Day -7).; Tumor imaging evaluation on Day -28 is counted as an in-person contact day, assuming it is performed if not recently completed prior to consent.; Fresh biopsy for tissue sample on Day -28 is counted as an in-person contact day, assuming it is performed if archived tissue is not available or insufficient.; Randomization occurs on C1D1 (Day 0) and is an in-person event.; All D1 and D15 visits during the treatment period are considered in-person contact days due to trial-mandated procedures including drug administration, safety assessments, and/or sample collections.; Oral drug administration (rivoceranib/sorafenib) on D1/D15 is considered 'active treatment delivery' for category assignment, as it is a trial-mandated in-person contact for drug administration/check.; Only the first Safety Follow-up visit (30 days after the last dose) is explicitly stated as in-person. Assuming treatment continues until Day 365, this visit would fall outside the 12-month window (around Day 395) and is therefore not counted.; All procedures occurring on a day with 'core_treatment' are superseded by 'core_treatment' for category assignment due to precedence rules."
37499670,Control Arm: Sorafenib,control,3,3,7,10,13,17,0,3,7,10,13,17,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,"until intolerable toxicity, withdrawal of consent, or disease progression confirmed by BIRC","Screening: Day -28, Day -14, Day -7. Treatment: D1 and D15 of each 28-day cycle for the first 3 cycles. From Cycle 4 onwards, D1 only of each 28-day cycle. Tumor imaging on Day 56, 112, 168, 224, 280, 336.","Treatment continues for the full 12-month duration for calculation purposes.; Screening Period [1], [2], and [3] are distinct in-person contact days (Day -28, Day -14, Day -7).; Tumor imaging evaluation on Day -28 is counted as an in-person contact day, assuming it is performed if not recently completed prior to consent.; Fresh biopsy for tissue sample on Day -28 is counted as an in-person contact day, assuming it is performed if archived tissue is not available or insufficient.; Randomization occurs on C1D1 (Day 0) and is an in-person event.; All D1 and D15 visits during the treatment period are considered in-person contact days due to trial-mandated procedures including drug administration, safety assessments, and/or sample collections.; Oral drug administration (rivoceranib/sorafenib) on D1/D15 is considered 'active treatment delivery' for category assignment, as it is a trial-mandated in-person contact for drug administration/check.; Only the first Safety Follow-up visit (30 days after the last dose) is explicitly stated as in-person. Assuming treatment continues until Day 365, this visit would fall outside the 12-month window (around Day 395) and is therefore not counted.; All procedures occurring on a day with 'core_treatment' are superseded by 'core_treatment' for category assignment due to precedence rules."
37524096,Everolimus,intervention,2,1,3,5,7,9,0,0,0,0,0,0,1,0,0,1,2,2,1,1,3,4,5,7,0,0,0,0,0,0,42,until progression or completion of 9 cycles (54 weeks),"Screening: 2 days (1 for labs/physical, 1 for CT scan). Treatment: Visits at the start of each 6-week cycle (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) including physical exam, labs, and toxicity assessment. Recurrence CT scans are at Day 126 and Day 252.","All screening labs, physical exam, weight, performance status, and hepatitis B/C screening (including HBV DNA/HCV RNA-PCR) are consolidated into one contact day during the screening window, categorized as 'labs' due to the extensive blood draws.; The screening CT scan is considered a separate contact day during the screening window, categorized as 'imaging_diagnostics'.; Weekly toxicity assessments during Cycle 1 (WK 2-6) are assumed to be phone calls as per footnote Ω (Page 29) and thus are not counted as in-person contact days.; Cycle-start visits (physical exam, weight, performance status, toxicity assessment, and routine labs) are consolidated into one contact day at the beginning of each 6-week cycle (Day 0, 42, 84, 126, 168, 210, 252, 294, 336). These are categorized as 'labs' due to the blood draws for routine labs and translational medicine specimens (Buffy Coat, Plasma, Whole Blood for Trough Levels) at Day 0, 42, 84.; Recurrence assessments, which consist of physical exams and CT scans, are performed 'every eighteen weeks' (Page 15, Section 7.2; Page 42, bullet 5; Page 29, footnote Ж). This means CT scans occur at Day 126 and Day 252 within the 12-month window. These CT scan days are consolidated with the cycle-start visit and categorized as 'imaging_diagnostics' due to precedence.; The calendar's 'X' for CT Scan and Recurrence Assessment at WK 13->18 (Day 84) is overridden by the explicit text stating 'every eighteen weeks' for recurrence assessments, starting after 3 cycles (Day 126)."
37524096,Placebo,control,2,1,3,5,7,9,0,0,0,0,0,0,1,0,0,1,2,2,1,1,3,4,5,7,0,0,0,0,0,0,42,until progression or completion of 9 cycles (54 weeks),"Screening: 2 days (1 for labs/physical, 1 for CT scan). Treatment: Visits at the start of each 6-week cycle (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) including physical exam, labs, and toxicity assessment. Recurrence CT scans are at Day 126 and Day 252.","All screening labs, physical exam, weight, performance status, and hepatitis B/C screening (including HBV DNA/HCV RNA-PCR) are consolidated into one contact day during the screening window, categorized as 'labs' due to the extensive blood draws.; The screening CT scan is considered a separate contact day during the screening window, categorized as 'imaging_diagnostics'.; Weekly toxicity assessments during Cycle 1 (WK 2-6) are assumed to be phone calls as per footnote Ω (Page 29) and thus are not counted as in-person contact days.; Cycle-start visits (physical exam, weight, performance status, toxicity assessment, and routine labs) are consolidated into one contact day at the beginning of each 6-week cycle (Day 0, 42, 84, 126, 168, 210, 252, 294, 336). These are categorized as 'labs' due to the blood draws for routine labs and translational medicine specimens (Buffy Coat, Plasma, Whole Blood for Trough Levels) at Day 0, 42, 84.; Recurrence assessments, which consist of physical exams and CT scans, are performed 'every eighteen weeks' (Page 15, Section 7.2; Page 42, bullet 5; Page 29, footnote Ж). This means CT scans occur at Day 126 and Day 252 within the 12-month window. These CT scan days are consolidated with the cycle-start visit and categorized as 'imaging_diagnostics' due to precedence.; The calendar's 'X' for CT Scan and Recurrence Assessment at WK 13->18 (Day 84) is overridden by the explicit text stating 'every eighteen weeks' for recurrence assessments, starting after 3 cycles (Day 126)."
37604981,Intensive Chemotherapy: Glasdegib/Placebo + Cytarabine/Daunorubicin,intervention,1,13,28,38,41,46,0,9,16,19,19,19,1,2,5,9,12,17,0,0,0,0,0,0,0,2,7,10,10,10,28,"up to 2 years post-randomization, or until disease progression","Screening (1 day); Induction 1 (Days 0-6, 7, 10, 14, 21); Remission Assessment (Day 42); Consolidation (4 cycles, Days 1, 3, 5, 6, 11, 22 of each 28-day cycle); Following Consolidation (Day 1 of each 28-day cycle, with BM every 3 months); End of Treatment Visit (Day 365).","HSCT does not occur within the first 12 months.; Induction 2 is not needed for the Intensive Arm.; Consolidation is assumed to be 4 cycles.; PK samples at 0, 1, and 4 hours on the same calendar day are counted as a single contact day, with the highest priority procedure determining the category for that day.; Bone marrow assessments during 'Following Consolidation' are assumed to be every 3 months (Day 1 of C6, C9, C12, C14).; End of Treatment Visit is assumed to occur on Day 365."
37604981,Non-Intensive Chemotherapy: Glasdegib/Placebo + Azacitidine,intervention,1,10,34,62,90,118,0,8,28,48,69,90,1,2,6,14,21,28,0,0,0,0,0,0,0,0,0,0,0,0,28,up to 2 years post randomization or until disease progression,"Screening (1 day); Cycle 1 (Days 0-7, 15); Subsequent Cycles (Days 1-7, 8, 16 of each 28-day cycle); BM assessment after Cycle 6 (C7D1); End of Treatment Visit (Day 365).","HSCT does not occur within the first 12 months.; PK samples at 0, 1, and 4 hours on the same calendar day are counted as a single contact day, with the highest priority procedure determining the category for that day.; PK samples are collected on C1D1, C1D15, and C2D1 only, as per Table 4, Footnote 3.; Azacitidine is administered on Days 1-7 of each 28-day cycle.; BM assessment after Cycle 6 is assumed to be on C7D1 (Day 168).; End of Treatment Visit is assumed to occur on Day 365."
37646660,Arm A (Melflufen + Daratumumab + Dexamethasone),intervention,2,4,9,15,18,21,0,4,9,15,18,21,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening: 1 day (imaging_diagnostics), Randomization: 1 day (clinic_visits). Treatment cycles (28-day): Cycle 1 (Day 1, Day 4, Day 15), Cycle 2 (Day 1, Day 15), Cycle 3 (Day 1, Day 4, Day 15), Cycles 4-6 (Day 1, Day 15), Cycle 7+ (Day 1).","Screening and Randomization are considered two distinct in-person days within the screening window, as per protocol guidance on randomization timing and 'Baseline split' rule.; Treatment is assumed to continue until Day +365 (13 cycles) for the 12-month window calculation, as per 'until progression' rule.; Day 8 and Day 22 visits are considered conditional and thus excluded from the count for all cycles, based on the statement 'patients who have not required any dose modification or delays, G-CSF and transfusions during the last two cycles may skip visits at Day 8 and Day 22' (page 68).; Oral Dexamethasone administration is not counted as a separate contact day but is considered part of the in-person visit for other procedures (Melflufen/Daratumumab administration and patient compliance review).; Specific PK/Immunogenicity/Immunoprofiling schedules detailed in footnotes (v, w, x, y) on page 19 are followed over general 'X' marks in the SoA table for Day 8, 15, 22, especially since Day 8 and Day 22 visits are excluded.; All treatment days (Day 1, Day 4, Day 15) are categorized as 'core_treatment' due to Melflufen and/or Daratumumab administration."
37646660,Arm B (Daratumumab Monotherapy),control,2,4,9,15,18,21,0,4,9,15,18,21,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening: 1 day (imaging_diagnostics), Randomization: 1 day (clinic_visits). Treatment cycles (28-day): Cycle 1 (Day 1, Day 4, Day 15), Cycle 2 (Day 1, Day 15), Cycle 3 (Day 1, Day 4, Day 15), Cycles 4-6 (Day 1, Day 15), Cycle 7+ (Day 1).","Screening and Randomization are considered two distinct in-person days within the screening window, as per protocol guidance on randomization timing and 'Baseline split' rule.; Treatment is assumed to continue until Day +365 (13 cycles) for the 12-month window calculation, as per 'until progression' rule.; Day 8 and Day 22 visits are considered conditional and thus excluded from the count for all cycles, based on the statement 'patients who have not required any dose modification or delays, G-CSF and transfusions during the last two cycles may skip visits at Day 8 and Day 22' (page 68).; Dexamethasone premedication for Daratumumab administration in Arm B is considered part of the Daratumumab administration day, which is categorized as 'core_treatment'. No separate 'Dexamethasone administration and review of patient compliance' visit is counted for Arm B.; Specific PK/Immunogenicity/Immunoprofiling schedules detailed in footnotes (v, w, x, y) on page 19 are followed over general 'X' marks in the SoA table for Day 8, 15, 22, especially since Day 8 and Day 22 visits are excluded.; All treatment days (Day 1, Day 4, Day 15) are categorized as 'core_treatment' due to Daratumumab administration."
37647576,Nimotuzumab + Gemcitabine,intervention,2,5,13,26,39,53,0,5,13,26,39,53,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until disease progression or intolerable toxicity,"Screening (2 days), then weekly drug administration (Nimotuzumab/Placebo) with Gemcitabine on Day 1, Day 8, and Day 15 of each 28-day cycle. Efficacy evaluations (including imaging) occur every 8 weeks, coinciding with a Day 1 of a cycle.","Screening Period (I) and (II) are considered two distinct in-person contact days, as they are listed in separate columns in the Schedule of Events and describe different sets of procedures.; The 'Baseline visit' (Section 6.1.3) is assumed to be combined with Cycle 1 Day 1 (C1D1), as the protocol states that if screening results are within the time window, they do not need to be repeated at baseline, and C1D1 is the first treatment day.; Efficacy evaluation visits ('Every 8 weeks') coincide with C X D1 visits (e.g., C3D1, C5D1, etc.). On these days, both core treatment (drug administration) and imaging diagnostics (CT/MRI) occur. According to the tie-breaker precedence, these days are categorized as 'core_treatment'.; Follow-up visits ('Every 3 months') are not counted as in-person contact days, as the protocol mentions follow-up by telephone for some items and does not explicitly mandate in-person procedures for these visits in the SoE table.; Treatment is assumed to continue for the full 12-month duration for calculation purposes, based on the 'until disease progression or intolerable toxicity' rule."
37647576,Placebo + Gemcitabine,control,2,5,13,26,39,53,0,5,13,26,39,53,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until disease progression or intolerable toxicity,"Screening (2 days), then weekly drug administration (Placebo) with Gemcitabine on Day 1, Day 8, and Day 15 of each 28-day cycle. Efficacy evaluations (including imaging) occur every 8 weeks, coinciding with a Day 1 of a cycle.","Screening Period (I) and (II) are considered two distinct in-person contact days, as they are listed in separate columns in the Schedule of Events and describe different sets of procedures.; The 'Baseline visit' (Section 6.1.3) is assumed to be combined with Cycle 1 Day 1 (C1D1), as the protocol states that if screening results are within the time window, they do not need to be repeated at baseline, and C1D1 is the first treatment day.; Efficacy evaluation visits ('Every 8 weeks') coincide with C X D1 visits (e.g., C3D1, C5D1, etc.). On these days, both core treatment (drug administration) and imaging diagnostics (CT/MRI) occur. According to the tie-breaker precedence, these days are categorized as 'core_treatment'.; Follow-up visits ('Every 3 months') are not counted as in-person contact days, as the protocol mentions follow-up by telephone for some items and does not explicitly mandate in-person procedures for these visits in the SoE table.; Treatment is assumed to continue for the full 12-month duration for calculation purposes, based on the 'until disease progression or intolerable toxicity' rule."
37704166,Experimental Arm A: OSE2101,intervention,1,3,6,10,13,17,0,2,5,7,8,10,1,0,0,2,4,6,0,1,1,1,1,1,0,0,0,0,0,0,"21 days for 6 cycles, then 56 days (8 weeks) for the remainder of year one, then 84 days (12 weeks) beyond year one.",until progression,"Pre-screening (Day -35), Screening/Randomization (Day -1). Treatment cycles: Cycle 1-6 are 21-day cycles (Day 1, Day 15). Cycles 7-9 are 8-week (56-day) cycles (Day 1). Cycles >=10 are 12-week (84-day) cycles (Day 1). Tumor assessments every 6 weeks from C1D1. All Day 1 visits include OSE2101 administration, labs, clinic visits, and ECG from C2D1. C1D15 includes labs.","Pre-screening (Day -35) is considered a distinct visit for HLA-A2 testing and consent, but falls outside the defined screening window (Day -28 to Day -1) and is therefore not counted in the output.; Screening and Randomization (Day -1) is counted as one in-person day.; Optional visits for translational study consent and biomarker collection are excluded from contact day counts.; Post-treatment survival follow-up visits are excluded as the protocol states 'telephone contact is acceptable'.; The 'End of Treatment' visit is not included as a fixed visit within the 12-month window, as treatment is assumed to continue 'until progression' through Day +365.; Tumor assessments are scheduled 'every 6 weeks (± 1-week allowance) after Day 1 Cycle 1' (Footnote 7). These are fixed on Day 0, Day 42, Day 84, Day 126, Day 168, Day 210, Day 252, Day 294, Day 336. If these days do not coincide with a treatment administration day, they are counted as separate imaging_diagnostics days. If they coincide with a treatment day, the day is categorized as core_treatment due to precedence.; 12-lead ECGs are marked in the SoE table for Day 1 of Cycles 2 and onwards. These days coincide with core_treatment days and are thus categorized as core_treatment."
37704166,Control Arm B: Docetaxel or Pemetrexed,control,1,3,6,10,14,19,0,2,5,9,13,18,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,21,until progression,"Pre-screening (Day -35), Screening/Randomization (Day -1). Treatment cycles: All cycles are 21-day cycles (Day 1, Day 15). All Day 1 visits include Docetaxel/Pemetrexed administration, labs, clinic visits, and ECG from C2D1. C1D15 includes labs. Tumor assessments every 6 weeks from C1D1.","Pre-screening (Day -35) is considered a distinct visit for HLA-A2 testing and consent, but falls outside the defined screening window (Day -28 to Day -1) and is therefore not counted in the output.; Screening and Randomization (Day -1) is counted as one in-person day.; Optional visits for translational study consent and biomarker collection are excluded from contact day counts.; Post-treatment survival follow-up visits are excluded as the protocol states 'telephone contact is acceptable'.; The 'End of Treatment' visit is not included as a fixed visit within the 12-month window, as treatment is assumed to continue 'until progression' through Day +365.; Tumor assessments are scheduled 'every 6 weeks (± 1-week allowance) after Day 1 Cycle 1' (Footnote 7). These are fixed on Day 0, Day 42, Day 84, Day 126, Day 168, Day 210, Day 252, Day 294, Day 336. For Arm B, all these scan days coincide with a Day 1 treatment administration, so they are categorized as core_treatment due to precedence.; 12-lead ECGs are marked in the SoE table for Day 1 of Cycles 2 and onwards. These days coincide with core_treatment days and are thus categorized as core_treatment."
37708904,Arm 1: irinotecan liposome injection+oxaliplatin+5-FU/LV,intervention,1,6,17,33,50,65,0,5,14,26,40,52,1,0,0,0,0,0,0,1,3,7,10,13,0,0,0,0,0,0,28,"until radiologically determined progressive disease, unacceptable study medication-related toxicity, or withdrawal from study","Screening (Day -7). Treatment cycles (28-day): Day 1 (core_treatment), Day 3 (core_treatment for pump removal), Day 8 (labs), Day 15 (core_treatment), Day 17 (core_treatment for pump removal). Q8W imaging coincides with D1 of C3, C5, C7, C9, C11, C13.","One consolidated screening visit is assumed on Day -7 for all screening procedures (CT/MRI, ECG, labs, clinic visits). The highest priority procedure on this day is imaging_diagnostics.; Randomisation is assumed to occur on Day 0 (C1D1) and is an in-person clinic visit.; 5-FU pump removal on D3 and D17 of each cycle for Arm 1 is considered an in-person core_treatment day, as per footnote [r] for C1D3.; Optional biobanking samples are excluded from mandatory contact days.; Q2M survival follow-up visits are assumed to be remote (telephone/email) unless explicitly stated as mandatory clinic visits, and thus are not counted as in-person contact days.; End of Treatment (EoT) visit is assumed to occur after Day +365 if treatment continues for 12 months, and therefore is not included in the 12-month window counts.; ECG procedures for Arm 1 (C1D1, C1D15) and Arm 2 (C1D1, C2D1, C3D1, C4D1) fall on core_treatment days, so core_treatment takes precedence.; PK sampling for Arm 1 (C1D1, C1D3, C1D15) falls on core_treatment days, so core_treatment takes precedence.; CA19-9 collection on D1 of every other cycle (C1, C3, C5, etc.) falls on core_treatment days, so core_treatment takes precedence.; Q8W Disease Evaluation (CT/MRI) visits fall on core_treatment days (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1), so core_treatment takes precedence."
37708904,Arm 2: nab-paclitaxel+gemcitabine,intervention,1,6,17,33,50,65,0,4,10,20,30,39,1,0,0,0,0,0,0,2,7,13,20,26,0,0,0,0,0,0,28,"until radiologically determined progressive disease, unacceptable study medication-related toxicity, or withdrawal from study","Screening (Day -7). Treatment cycles (28-day): Day 1 (core_treatment), Day 3 (labs), Day 8 (core_treatment), Day 15 (core_treatment), Day 17 (labs). Q8W imaging coincides with D1 of C3, C5, C7, C9, C11, C13.","One consolidated screening visit is assumed on Day -7 for all screening procedures (CT/MRI, ECG, labs, clinic visits). The highest priority procedure on this day is imaging_diagnostics.; Randomisation is assumed to occur on Day 0 (C1D1) and is an in-person clinic visit.; Optional biobanking samples are excluded from mandatory contact days.; Q2M survival follow-up visits are assumed to be remote (telephone/email) unless explicitly stated as mandatory clinic visits, and thus are not counted as in-person contact days.; End of Treatment (EoT) visit is assumed to occur after Day +365 if treatment continues for 12 months, and therefore is not included in the 12-month window counts.; ECG procedures for Arm 1 (C1D1, C1D15) and Arm 2 (C1D1, C2D1, C3D1, C4D1) fall on core_treatment days, so core_treatment takes precedence.; CA19-9 collection on D1 of every other cycle (C1, C3, C5, etc.) falls on core_treatment days, so core_treatment takes precedence.; Q8W Disease Evaluation (CT/MRI) visits fall on core_treatment days (C3D1, C5D1, C7D1, C9D1, C11D1, C13D1), so core_treatment takes precedence."
37722354,Treatment Arm A (Background Chemotherapy + Placebo),control,4,4,8,13,14,16,0,4,8,12,12,12,4,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,BR: 28 days; R-CHOP: 21 days (BR regimen used for calculation),until progression,"Screening (4 days) -> 6 cycles of BR chemotherapy (Day 1 & 2 every 28 days) -> Post-chemotherapy period (Every 8 weeks, plus Wk24 and Wk40 CT/MRI/labs).","The protocol specifies two background chemotherapy regimens (BR and R-CHOP) with different cycle lengths and visit schedules. To provide an 'exact number' as requested, and following the 'most conservative lower estimate' rule, the Bendamustine and Rituximab (BR) regimen (28-day cycles) schedule was used for calculating contact days for both arms, as it consistently results in fewer contact days than the R-CHOP regimen.; Screening involves an initial visit (Day -X) for consent, H&P, vitals, basic labs, ECG, Echo/MUGA, and three separate visits (Day -Y, -Z, -W) for CT/MRI, PET, and Bone Marrow Aspirate/Biopsy, given the 60-day window allowed for these procedures and their typical scheduling as distinct appointments.; Prednisone administration on Days 1-5 for R-CHOP cycles is assumed to require daily in-person contact.; The 'Posttreatment Follow-up Phase' visits are not included, as the study drug (ibrutinib/placebo) is assumed to continue 'until progression' within the 365-day window, meaning subjects remain in the 'Treatment Phase - Post-Chemotherapy Period'.; If multiple procedures occur on the same day, the day is assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits).; PK samples on Day 1 of C1, C2, C3, Biomarker samples on Day 1 of C1, C2, and MRD blood sample on Day 1 of C1 are assumed to occur on the same day as chemotherapy administration.; CT/MRI and Serum Ig/beta 2-microglobulin visits (Wk12, Wk24, Wk40) are considered separate visits unless they explicitly coincide with a chemotherapy day or a Post-Chemotherapy 'Every 8 weeks' visit. If they coincide, the highest precedence category is applied for that day."
37722354,Treatment Arm B (Background Chemotherapy + 560 mg Ibrutinib),intervention,4,4,8,13,14,16,0,4,8,12,12,12,4,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,BR: 28 days; R-CHOP: 21 days (BR regimen used for calculation),until progression,"Screening (4 days) -> 6 cycles of BR chemotherapy (Day 1 & 2 every 28 days) -> Post-chemotherapy period (Every 8 weeks, plus Wk24 and Wk40 CT/MRI/labs).","The protocol specifies two background chemotherapy regimens (BR and R-CHOP) with different cycle lengths and visit schedules. To provide an 'exact number' as requested, and following the 'most conservative lower estimate' rule, the Bendamustine and Rituximab (BR) regimen (28-day cycles) schedule was used for calculating contact days for both arms, as it consistently results in fewer contact days than the R-CHOP regimen.; Screening involves an initial visit (Day -X) for consent, H&P, vitals, basic labs, ECG, Echo/MUGA, and three separate visits (Day -Y, -Z, -W) for CT/MRI, PET, and Bone Marrow Aspirate/Biopsy, given the 60-day window allowed for these procedures and their typical scheduling as distinct appointments.; Prednisone administration on Days 1-5 for R-CHOP cycles is assumed to require daily in-person contact.; The 'Posttreatment Follow-up Phase' visits are not included, as the study drug (ibrutinib/placebo) is assumed to continue 'until progression' within the 365-day window, meaning subjects remain in the 'Treatment Phase - Post-Chemotherapy Period'.; If multiple procedures occur on the same day, the day is assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits).; PK samples on Day 1 of C1, C2, C3, Biomarker samples on Day 1 of C1, C2, and MRD blood sample on Day 1 of C1 are assumed to occur on the same day as chemotherapy administration.; CT/MRI and Serum Ig/beta 2-microglobulin visits (Wk12, Wk24, Wk40) are considered separate visits unless they explicitly coincide with a chemotherapy day or a Post-Chemotherapy 'Every 8 weeks' visit. If they coincide, the highest precedence category is applied for that day."
37748693,Arm A: Avelumab 10 mg/kg IV once every 2 weeks,intervention,1,3,7,13,20,27,0,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening (1 day) + Avelumab IV infusion every 2 weeks (Day 0, 14, 28, ..., 364).","Avelumab treatment continues 'until progression' for the full 12-month period, so no post-treatment follow-up visits are included in the 12-month window.; Screening is considered one in-person day, with the highest priority procedure (tumor evaluation/staging) determining the category.; All treatment visits for Arm A involve Avelumab infusion, which is categorized as core_treatment. Other procedures on these days are subsumed under this category.; Tumor evaluations (every 6 weeks from randomization) fall on scheduled treatment days for Arm A, and thus are subsumed under core_treatment."
37748693,Arm B: Investigator's choice platinum-containing chemotherapy,control,2,4,11,17,19,21,0,4,9,12,12,12,1,0,2,5,7,9,0,0,0,0,0,0,1,0,0,0,0,0,21,maximum of 6 cycles,Screening (1 day) + Pemetrexed premedication (1 day) + Chemotherapy (Gemcitabine regimen: Day 1 and Day 8 of a 21-day cycle for 6 cycles) + Safety Follow-up Visit (30 days after last treatment) + Post-treatment tumor evaluations (every 6 weeks from randomization).,"For Arm B, the Gemcitabine regimen schedule (Day 1 and Day 8 of a 21-day cycle) was used for treatment days as it results in more frequent visits compared to other chemotherapy regimens, maximizing contact days.; Chemotherapy treatment is assumed to continue for the maximum of 6 cycles.; A separate screening visit day is counted for Pemetrexed premedication (oral folic acid, vitamin B12 IM injection) as it occurs 'in the week before first dose of chemotherapy' and 'prior to randomization', categorized as clinic_visits.; Screening is considered one in-person day, with the highest priority procedure (tumor evaluation/staging) determining the category.; Post-treatment tumor evaluations (every 6 weeks from randomization) and the Safety Follow-up Visit (30 days after last treatment) are included as separate contact days if they do not coincide with a treatment day, as treatment stops after 6 cycles."
37748693,"Arm C: Avelumab 10 mg/kg IV once weekly for 12 weeks, followed by 10 mg/kg once every 2 weeks",intervention,1,5,13,20,26,33,0,5,13,20,26,33,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"Weekly for 12 weeks, then 14 days thereafter",until progression,"Screening (1 day) + Avelumab IV infusion once weekly for 12 weeks (Day 1, 8, ..., 78) followed by Avelumab IV infusion once every 2 weeks (Day 85, 99, ..., 365).","Avelumab treatment continues 'until progression' for the full 12-month period, so no post-treatment follow-up visits are included in the 12-month window.; Screening is considered one in-person day, with the highest priority procedure (tumor evaluation/staging) determining the category.; All treatment visits for Arm C involve Avelumab infusion, which is categorized as core_treatment. Other procedures on these days are subsumed under this category.; Tumor evaluations (every 6 weeks from randomization) fall on scheduled treatment days for Arm C, and thus are subsumed under core_treatment."
37788412,Canakinumab 200 mg sc,intervention,1,5,13,26,39,52,0,2,5,9,13,18,1,0,0,0,0,0,0,3,8,17,26,34,0,0,0,0,0,0,21,"18 cycles or until disease recurrence, unacceptable toxicity, treatment discontinuation, death, or lost to follow-up. Assumed 18 cycles for calculation.","One screening visit. Treatment phase consists of 18 cycles (21 days each). Cycle 1 has visits on Day 1, Day 8, Day 15. Subsequent cycles (C2-C18) have visits on Day 1, Day 8, Day 15. Imaging is performed at screening and then every 12 weeks for the first year (on C_D1 visits).","Cycle length is 21 days.; Treatment continues for 18 cycles (until Day 357).; Procedures marked 'As clinically indicated (X)' or 'if clinically indicated' are excluded as non-mandated contact days.; Assessments marked 'S' (source documentation only) or 'X' (clinical database) in Table 7-1 are considered in-person procedures if they are not explicitly remote or optional.; IRT Screening, IRT Randomization, and IRT study drug dispensation are considered part of the visit day they are listed under.; Adverse events and Prior/concomitant medications are considered continuous data collection, not specific contact days.; EORTC QLQ-C30 and EQ-5D-5L questionnaires are considered clinic_visits.; Imaging assessments at Day 84 (C5D1), Day 168 (C9D1), Day 252 (C13D1), and Day 336 (C17D1) coincide with core treatment (drug administration) days and are thus categorized as 'core_treatment' due to precedence.; PK/IG/IL-1b collections on C_D1 visits (Day 0, 21, 63, 105, 168, 231, 357) coincide with core treatment (drug administration) days and are thus categorized as 'core_treatment' due to precedence.; PK samples are collected on C1D8 and C1D15, but not on subsequent C_D8 or C_D15 visits.; Immunogenicity (IG) and IL-1β (PD) samples are collected on specific C_D1 visits as per Table 7-1."
37788412,Placebo,control,1,5,13,26,39,52,0,2,5,9,13,18,1,0,0,0,0,0,0,3,8,17,26,34,0,0,0,0,0,0,21,"18 cycles or until disease recurrence, unacceptable toxicity, treatment discontinuation, death, or lost to follow-up. Assumed 18 cycles for calculation.","One screening visit. Treatment phase consists of 18 cycles (21 days each). Cycle 1 has visits on Day 1, Day 8, Day 15. Subsequent cycles (C2-C18) have visits on Day 1, Day 8, Day 15. Imaging is performed at screening and then every 12 weeks for the first year (on C_D1 visits).","Cycle length is 21 days.; Treatment continues for 18 cycles (until Day 357).; Procedures marked 'As clinically indicated (X)' or 'if clinically indicated' are excluded as non-mandated contact days.; Assessments marked 'S' (source documentation only) or 'X' (clinical database) in Table 7-1 are considered in-person procedures if they are not explicitly remote or optional.; IRT Screening, IRT Randomization, and IRT study drug dispensation are considered part of the visit day they are listed under.; Adverse events and Prior/concomitant medications are considered continuous data collection, not specific contact days.; EORTC QLQ-C30 and EQ-5D-5L questionnaires are considered clinic_visits.; Imaging assessments at Day 84 (C5D1), Day 168 (C9D1), Day 252 (C13D1), and Day 336 (C17D1) coincide with core treatment (drug administration) days and are thus categorized as 'core_treatment' due to precedence.; PK/IG/IL-1b collections on C_D1 visits (Day 0, 21, 63, 105, 168, 231, 357) coincide with core treatment (drug administration) days and are thus categorized as 'core_treatment' due to precedence.; PK samples are collected on C1D8 and C1D15, but not on subsequent C_D8 or C_D15 visits.; Immunogenicity (IG) and IL-1β (PD) samples are collected on specific C_D1 visits as per Table 7-1."
37792130,MYL-1402O / Avastin,intervention,3,5,13,21,25,28,0,2,5,9,13,15,1,0,0,0,0,0,1,3,8,12,12,13,1,0,0,0,0,0,21,"up to 6 cycles of combination therapy, followed by bevacizumab monotherapy until disease progression, discontinuation, or study termination (calculated up to Week 42/Day 294 for treatment, with SFU at Day 322, within 47-week maximum study participation).","Screening (Day -28), Randomization (Day -3), Baseline (Day -1). Treatment cycles every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294). Additional PK sampling days for Cycles 1-6 (Day 7, 14, 28, 35, 49, 56, 70, 77, 91, 98, 112, 119). Safety Follow-Up Visit (Day 322). Tumor imaging on Day 42, 84, 126, 210, 294.","Both arms (MYL-1402O and Avastin) have identical schedules and procedures, so they are combined into a single arm for contact day calculation.; Screening is assumed to be one contact day (e.g., Day -28).; Randomization is assumed to be a separate contact day (e.g., Day -3) as it has its own column in the SoE table.; Baseline assessments are assumed to be a separate contact day (e.g., Day -1) as they are distinct from Day 0 procedures and randomization.; PK samples collected between Days 3-8 and Days 10-18 for Cycles 1-6 are counted as separate in-person contact days (one day for each specified range, e.g., Day 7 and Day 14 for Cycle 1).; Tumor assessments and brain/bone imaging are assumed to occur if indicated by 'Xo' or 'Xp' in the SoE table or described in the text.; For the Safety Follow-Up (SFU) visit, it is assumed to occur 28 days after the last treatment dose at Week 42 (Day 294), placing it on Day 322. This aligns with the 'approximately 47 weeks' maximum study participation. Tumor assessments and brain imaging are not assumed to be needed at the SFU visit, making it primarily a labs day.; BSA calculation is assumed to be part of a clinic visit and does not add a separate contact day if other procedures are already scheduled.; Pre-medications for paclitaxel are considered part of the core_treatment day."
37845511,Nivolumab 480 mg Q4W,intervention,1,2,4,7,11,15,0,2,4,7,10,13,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from first dose of study treatment,One screening visit. Infusions every 28 days for 12 months (13 doses). Body imaging at approximately 26 weeks and 52 weeks from Day 0.,"Treatment duration is assumed to be the maximum of 12 months (Day 0 to Day 365) for the blinded phase, as stated in the protocol summary and study design.; Cycle length is 28 days (Q4W).; The 'Screening Visit (Before Day 1, prior to Randomization)' is counted as a single contact day, with all listed procedures occurring on that day. The highest priority procedure (Body Imaging/ECG) determines the category for this day.; Body imaging scheduled 'Every 26 weeks (± 14 days)' is interpreted as separate contact days from the infusion days, as their nominal dates do not align with the Day 1 of cycle schedule. Nominal imaging days are Day 182 (26 weeks) and Day 364 (52 weeks).; Brain imaging is excluded from the standard count as it is 'as clinically indicated' or 'only if participant has signs and symptoms consistent with brain metastases'.; Follow-up visits (FU1, FU2, and subsequent 12-weekly assessments) occur after the 12-month treatment period and thus do not fall within the 12-month (Day 0 to Day 365) window.; PK/Immunogenicity samples and routine lab tests performed on infusion days are subsumed under the 'core_treatment' category due to tie-breaker precedence."
37845511,Placebo Q4W,control,1,2,4,7,11,15,0,2,4,7,10,13,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from first dose of study treatment,One screening visit. Infusions every 28 days for 12 months (13 doses). Body imaging at approximately 26 weeks and 52 weeks from Day 0.,"Treatment duration is assumed to be the maximum of 12 months (Day 0 to Day 365) for the blinded phase, as stated in the protocol summary and study design.; Cycle length is 28 days (Q4W).; The 'Screening Visit (Before Day 1, prior to Randomization)' is counted as a single contact day, with all listed procedures occurring on that day. The highest priority procedure (Body Imaging/ECG) determines the category for this day.; Body imaging scheduled 'Every 26 weeks (± 14 days)' is interpreted as separate contact days from the infusion days, as their nominal dates do not align with the Day 1 of cycle schedule. Nominal imaging days are Day 182 (26 weeks) and Day 364 (52 weeks).; Brain imaging is excluded from the standard count as it is 'as clinically indicated' or 'only if participant has signs and symptoms consistent with brain metastases'.; Follow-up visits (FU1, FU2, and subsequent 12-weekly assessments) occur after the 12-month treatment period and thus do not fall within the 12-month (Day 0 to Day 365) window.; PK/Immunogenicity samples and routine lab tests performed on infusion days are subsumed under the 'core_treatment' category due to tie-breaker precedence."
37870976,Arm A (amivantamab plus chemotherapy),intervention,1,5,8,12,16,21,0,5,8,12,16,21,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression or discontinuation criteria are met,"Screening (1 day). Treatment: Cycle 1 (Days 1, 2, 8, 15), then Cycle 2+ (Day 1 of each 21-day cycle). Imaging on C3D1 and every 6 weeks thereafter (C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1).","A single day is assumed for all screening procedures within the Day -28 to Day -1 window.; Randomization is considered part of the single screening day.; All listed procedures in Table 1 marked with 'X' for a given visit column are considered in-person contact days.; Pre-infusion medications listed in Table 1 (Corticosteroid, Preinfusion medications for amivantamab) and detailed in Tables 5, 6, 7, 8, 9 are assumed to require an in-person visit on the days they are administered, even if some might be taken at home, as they are tied to specific visit days for study treatment.; The 'End of Treatment' and 'Follow-up' visits are not included in the 12-month calculation as treatment is assumed to continue until progression, and these visits occur after discontinuation.; For Arm A, PK/Immunogenicity samples are collected on C1D1, C1D2, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1, C18D1 based on Table 1, which is more comprehensive than Table 2 for the full 12-month period.; For Arm B, PK/Immunogenicity samples are not collected as per Table 1 and Table 2 (which specifies Arm A only)."
37870976,Arm B (chemotherapy alone),control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression or discontinuation criteria are met,"Screening (1 day). Treatment: Day 1 of each 21-day cycle. Imaging on C3D1 and every 6 weeks thereafter (C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1).","A single day is assumed for all screening procedures within the Day -28 to Day -1 window.; Randomization is considered part of the single screening day.; All listed procedures in Table 1 marked with 'X' for a given visit column are considered in-person contact days.; Pre-infusion medications listed in Table 1 (Corticosteroid) and detailed in Table 5 are assumed to require an in-person visit on the days they are administered, even if some might be taken at home, as they are tied to specific visit days for study treatment.; The 'End of Treatment' and 'Follow-up' visits are not included in the 12-month calculation as treatment is assumed to continue until progression, and these visits occur after discontinuation.; The optional crossover to amivantamab monotherapy for Arm B participants upon disease progression is not included in this calculation, as it is conditional on progression and optional."
37875143,Pembrolizumab + FP Chemotherapy,intervention,1,10,25,45,65,90,0,10,25,45,65,90,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression or up to 35 cycles (approx 2 years),"Screening (1 day). During intervention phase: Day 1 of each 21-day cycle for Pembrolizumab/Placebo and Cisplatin/Oxaliplatin IV infusions. Additionally, Days 2-5 of each 21-day cycle for 5-FU IV infusion (FP arm).","Screening is considered 1 contact day (e.g., Day -28), encompassing all procedures marked with 'X' in the 'Screening Phase' column of Table 1. This day is categorized as 'imaging_diagnostics' due to the presence of tumor imaging, 12-lead ECG, and tissue collection, which take precedence over labs and clinic visits.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; The cycle length is 21 days (Q3W).; Treatment is assumed to continue without progression or discontinuation for the full duration of the 12-month window (Day 0 to Day 365).; Post-treatment follow-up visits (Safety and Efficacy) are not included in the 12-month window as treatment is assumed to continue until Day 365, placing these follow-up visits beyond Day 365.; Capecitabine (oral administration for CAPOX regimen) is not counted as an in-person healthcare contact day.; All Day 1 visits of each cycle involve IV infusions (Pembrolizumab/Placebo and Cisplatin/Oxaliplatin). These are categorized as 'core_treatment' due to active treatment delivery, taking precedence over any imaging, lab, or clinic visit procedures performed on the same day.; For the FP (cisplatin and 5-fluorouracil) chemotherapy regimen, 5-fluorouracil is administered as a continuous IV infusion on Days 1 to 5 of each cycle. This means Day 1, Day 2, Day 3, Day 4, and Day 5 of each cycle are in-person contact days for 'core_treatment'. Day 1 is already accounted for as a cycle start day, so Days 2-5 are additional contact days."
37875143,Pembrolizumab + CAPOX Chemotherapy,intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression or up to 35 cycles (approx 2 years),Screening (1 day). During intervention phase: Day 1 of each 21-day cycle for Pembrolizumab/Placebo and Oxaliplatin IV infusions.,"Screening is considered 1 contact day (e.g., Day -28), encompassing all procedures marked with 'X' in the 'Screening Phase' column of Table 1. This day is categorized as 'imaging_diagnostics' due to the presence of tumor imaging, 12-lead ECG, and tissue collection, which take precedence over labs and clinic visits.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; The cycle length is 21 days (Q3W).; Treatment is assumed to continue without progression or discontinuation for the full duration of the 12-month window (Day 0 to Day 365).; Post-treatment follow-up visits (Safety and Efficacy) are not included in the 12-month window as treatment is assumed to continue until Day 365, placing these follow-up visits beyond Day 365.; Capecitabine (oral administration for CAPOX regimen) is not counted as an in-person healthcare contact day.; All Day 1 visits of each cycle involve IV infusions (Pembrolizumab/Placebo and Cisplatin/Oxaliplatin). These are categorized as 'core_treatment' due to active treatment delivery, taking precedence over any imaging, lab, or clinic visit procedures performed on the same day.; For the CAPOX (capecitabine and oxaliplatin) chemotherapy regimen, only Day 1 of each cycle is an in-person contact day for Oxaliplatin IV infusion. Oral capecitabine (Days 1-14) is not a contact day."
37875143,Placebo + FP Chemotherapy,control,1,10,25,45,65,90,0,10,25,45,65,90,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression or up to 35 cycles (approx 2 years),"Screening (1 day). During intervention phase: Day 1 of each 21-day cycle for Placebo and Cisplatin/Oxaliplatin IV infusions. Additionally, Days 2-5 of each 21-day cycle for 5-FU IV infusion (FP arm).","Screening is considered 1 contact day (e.g., Day -28), encompassing all procedures marked with 'X' in the 'Screening Phase' column of Table 1. This day is categorized as 'imaging_diagnostics' due to the presence of tumor imaging, 12-lead ECG, and tissue collection, which take precedence over labs and clinic visits.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; The cycle length is 21 days (Q3W).; Treatment is assumed to continue without progression or discontinuation for the full duration of the 12-month window (Day 0 to Day 365).; Post-treatment follow-up visits (Safety and Efficacy) are not included in the 12-month window as treatment is assumed to continue until Day 365, placing these follow-up visits beyond Day 365.; Capecitabine (oral administration for CAPOX regimen) is not counted as an in-person healthcare contact day.; All Day 1 visits of each cycle involve IV infusions (Pembrolizumab/Placebo and Cisplatin/Oxaliplatin). These are categorized as 'core_treatment' due to active treatment delivery, taking precedence over any imaging, lab, or clinic visit procedures performed on the same day.; For the FP (cisplatin and 5-fluorouracil) chemotherapy regimen, 5-fluorouracil is administered as a continuous IV infusion on Days 1 to 5 of each cycle. This means Day 1, Day 2, Day 3, Day 4, and Day 5 of each cycle are in-person contact days for 'core_treatment'. Day 1 is already accounted for as a cycle start day, so Days 2-5 are additional contact days."
37875143,Placebo + CAPOX Chemotherapy,control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression or up to 35 cycles (approx 2 years),Screening (1 day). During intervention phase: Day 1 of each 21-day cycle for Placebo and Oxaliplatin IV infusions.,"Screening is considered 1 contact day (e.g., Day -28), encompassing all procedures marked with 'X' in the 'Screening Phase' column of Table 1. This day is categorized as 'imaging_diagnostics' due to the presence of tumor imaging, 12-lead ECG, and tissue collection, which take precedence over labs and clinic visits.; Day 0 is defined as Cycle 1 Day 1 (C1D1).; The cycle length is 21 days (Q3W).; Treatment is assumed to continue without progression or discontinuation for the full duration of the 12-month window (Day 0 to Day 365).; Post-treatment follow-up visits (Safety and Efficacy) are not included in the 12-month window as treatment is assumed to continue until Day 365, placing these follow-up visits beyond Day 365.; Capecitabine (oral administration for CAPOX regimen) is not counted as an in-person healthcare contact day.; All Day 1 visits of each cycle involve IV infusions (Pembrolizumab/Placebo and Cisplatin/Oxaliplatin). These are categorized as 'core_treatment' due to active treatment delivery, taking precedence over any imaging, lab, or clinic visit procedures performed on the same day.; For the CAPOX (capecitabine and oxaliplatin) chemotherapy regimen, only Day 1 of each cycle is an in-person contact day for Oxaliplatin IV infusion. Oral capecitabine (Days 1-14) is not a contact day."
37935977,"Arm 1 (Standard Cytarabine plus Daunorubicin, 7+3)",intervention,1,9,21,34,35,36,0,7,13,19,19,19,1,2,2,2,2,2,0,0,6,13,14,15,0,0,0,0,0,0,28,"Induction, then up to 4 cycles of consolidation (112 days), followed by follow-up until 5 years after initial registration.","Induction (Day 0-6, Day 14, Day 28) followed by 4 cycles of Consolidation (Day 1, 3, 5 for treatment; Day 7, 14, 21 for labs/H&P within each 28-day cycle), then follow-up visits.","Consolidation starts on Day 42 (after induction and recovery).; Consolidation cycles are 28 days long, with a maximum of 4 cycles completed.; For consolidation, 'Wk2', 'Wk3', 'Wk4' refer to distinct weekly visits (Day 7, Day 14, Day 21) within each 28-day cycle.; Follow-up visits at Month 3, 6, 9, 12 occur after treatment completion. The Month 3 follow-up visit is subsumed by a consolidation visit.; CNS Assessment is categorized as imaging_diagnostics, assuming it involves a lumbar puncture or other diagnostic procedure when marked in the schedule.; Cytogenetics/FISH is an analysis performed on specimens collected during BM Asp/Bx or Peripheral Blood draws; the contact day is attributed to the specimen collection/diagnostic procedure (BM Asp/Bx or Peripheral Blood).; Vorinostat (PO) administration is not considered an in-person contact day unless other procedures are scheduled on the same day."
37935977,"Arm 2 (Idarubicin with High Dose Cytarabine, IA)",intervention,1,5,17,30,31,32,0,4,10,16,16,16,1,1,1,1,1,1,0,0,6,13,14,15,0,0,0,0,0,0,28,"Induction, then up to 4 cycles of consolidation (112 days), followed by follow-up until 5 years after initial registration.","Induction (Day 0-3, Day 28) followed by 4 cycles of Consolidation (Day 1, 2, 3 for treatment; Day 7, 14, 21 for labs/H&P within each 28-day cycle), then follow-up visits.","Consolidation starts on Day 42 (after induction and recovery).; Consolidation cycles are 28 days long, with a maximum of 4 cycles completed.; For consolidation, 'Wk2', 'Wk3', 'Wk4' refer to distinct weekly visits (Day 7, Day 14, Day 21) within each 28-day cycle.; Follow-up visits at Month 3, 6, 9, 12 occur after treatment completion. The Month 3 follow-up visit is subsumed by a consolidation visit.; CNS Assessment is categorized as imaging_diagnostics, assuming it involves a lumbar puncture or other diagnostic procedure when marked in the schedule.; Cytogenetics/FISH is an analysis performed on specimens collected during BM Asp/Bx or Peripheral Blood draws; the contact day is attributed to the specimen collection/diagnostic procedure (BM Asp/Bx or Peripheral Blood)."
37935977,"Arm 3 (IA with Vorinostat, IA+V)",intervention,1,8,20,33,34,35,0,4,10,16,16,16,1,2,2,2,2,2,0,2,8,15,16,17,0,0,0,0,0,0,28,"Induction, then up to 4 cycles of consolidation (112 days), followed by follow-up until 5 years after initial registration.","Induction (Day 0-2 for labs/H&P, Day 3-6 for treatment, Day 28) followed by 4 cycles of Consolidation (Day 4-6 for treatment; Day 7, 14, 21 for labs/H&P within each 28-day cycle), then follow-up visits.","Consolidation starts on Day 42 (after induction and recovery).; Consolidation cycles are 28 days long, with a maximum of 4 cycles completed.; For consolidation, 'Wk2', 'Wk3', 'Wk4' refer to distinct weekly visits (Day 7, Day 14, Day 21) within each 28-day cycle.; Follow-up visits at Month 3, 6, 9, 12 occur after treatment completion. The Month 3 follow-up visit is subsumed by a consolidation visit.; CNS Assessment is categorized as imaging_diagnostics, assuming it involves a lumbar puncture or other diagnostic procedure when marked in the schedule.; Cytogenetics/FISH is an analysis performed on specimens collected during BM Asp/Bx or Peripheral Blood draws; the contact day is attributed to the specimen collection/diagnostic procedure (BM Asp/Bx or Peripheral Blood).; Vorinostat (PO) administration is not considered an in-person contact day unless other procedures are scheduled on the same day."
37935977,Arm 3 (IA),intervention,1,5,17,30,31,32,0,4,10,16,16,16,1,1,1,1,1,1,0,0,6,13,14,15,0,0,0,0,0,0,28,"Induction, then up to 4 cycles of consolidation (112 days), followed by follow-up until 5 years after initial registration.","Induction (Day 0-3, Day 28) followed by 4 cycles of Consolidation (Day 1, 2, 3 for treatment; Day 7, 14, 21 for labs/H&P within each 28-day cycle), then follow-up visits.","Consolidation starts on Day 42 (after induction and recovery).; Consolidation cycles are 28 days long, with a maximum of 4 cycles completed.; For consolidation, 'Wk2', 'Wk3', 'Wk4' refer to distinct weekly visits (Day 7, Day 14, Day 21) within each 28-day cycle.; Follow-up visits at Month 3, 6, 9, 12 occur after treatment completion. The Month 3 follow-up visit is subsumed by a consolidation visit.; CNS Assessment is categorized as imaging_diagnostics, assuming it involves a lumbar puncture or other diagnostic procedure when marked in the schedule.; Cytogenetics/FISH is an analysis performed on specimens collected during BM Asp/Bx or Peripheral Blood draws; the contact day is attributed to the specimen collection/diagnostic procedure (BM Asp/Bx or Peripheral Blood)."
37980924,Apixaban,intervention,1,5,5,5,5,5,0,0,0,0,0,0,0,1,1,1,1,1,1,4,4,4,4,4,0,0,0,0,0,0,28,fixed duration of approximately 28 days,"Screening (Day -7), Randomization/C1D1 (Day 0), C1D8 (Day +7), C1D15 (Day +14), C1D22 (Day +21), C1D29 (Day +28).","Screening is one in-person visit at Day -7.; Randomization/C1D1 is one in-person visit at Day 0.; The Day 7 visit is not counted as a distinct in-person contact day, as it is conditional ('for in-patients only') and its procedures are largely covered by the Day 8 visit for outpatients.; The Day 35 follow-up is a telephone visit and not an in-person contact day, based on the explicit mention in the study schema (Supplemental Figure 1 and Figure -1).; The 'Dispense Study Drug' procedure is categorized as clinic_visits, as it represents drug logistics/instructions rather than active treatment delivery (e.g., infusion).; The study protocol only details in-person visits for the initial induction period (up to Day 29/35). No further mandated in-person visits are described for the longer trial duration, so counts for 3, 6, 9, and 12 months reflect only the initial induction phase visits."
37980924,No systemic anticoagulation prophylaxis,control,1,5,5,5,5,5,0,0,0,0,0,0,0,1,1,1,1,1,1,4,4,4,4,4,0,0,0,0,0,0,28,fixed duration of approximately 28 days,"Screening (Day -7), Randomization/C1D1 (Day 0), C1D8 (Day +7), C1D15 (Day +14), C1D22 (Day +21), C1D29 (Day +28).","Screening is one in-person visit at Day -7.; Randomization/C1D1 is one in-person visit at Day 0.; The Day 7 visit is not counted as a distinct in-person contact day, as it is conditional ('for in-patients only') and its procedures are largely covered by the Day 8 visit for outpatients.; The Day 35 follow-up is a telephone visit and not an in-person contact day, based on the explicit mention in the study schema (Supplemental Figure 1 and Figure -1).; The 'Dispense Study Drug' procedure is categorized as clinic_visits, as it represents drug logistics/instructions rather than active treatment delivery (e.g., infusion).; The study protocol only details in-person visits for the initial induction period (up to Day 29/35). No further mandated in-person visits are described for the longer trial duration, so counts for 3, 6, 9, and 12 months reflect only the initial induction phase visits."
38039991,Durvalumab + SoC CCRT,intervention,1,24,32,35,38,42,0,24,32,35,38,42,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,"until completion of planned therapy (24 doses), clinical progression, unacceptable toxicity, or withdrawal","Screening (1 day); Treatment: Durvalumab/Placebo infusion q28d (14 doses within 12 months), concurrent SoC CCRT including EBRT (25 fractions over 5 weeks), Cisplatin (6 weekly doses), and Brachytherapy (3 sessions). Tumor assessments (imaging + pelvic exam) q12w from Week 20.","All procedures marked 'X' for a given visit column in Table 1 (Schedule of assessments for durvalumab/placebo ± chemoradiation therapy screening and treatment and retreatment periods) occur on that single day.; For the screening visit, multiple procedures (ECG, FFPE tumor sample, Tumor radiological assessments, labs, physical exams, etc.) are listed. Applying the tie-breaker precedence, this day is categorized as 'imaging_diagnostics' due to imaging procedures.; The SoC CCRT (EBRT, Cisplatin, Brachytherapy) is assumed to be completed within 59 days as per protocol. EBRT is assumed to be 25 fractions over 5 weeks (5 days/week), starting C1D1 (Day 0). Cisplatin is 6 doses, weekly, starting C1D2 (Day 1). Brachytherapy is 3 fractions, assumed to occur on Day 35, Day 42, and Day 49, not on cisplatin days, and after week 3 of EBRT.; Durvalumab/Placebo infusions occur every 28 days (q4w) for 24 doses, starting C1D1 (Day 0).; All treatment days (Day 0 onwards) involve active treatment (durvalumab/placebo infusion, cisplatin, EBRT, or brachytherapy). Even if other assessments (e.g., labs, physical exams, PROs, imaging) occur on these days, the day is categorized as 'core_treatment' due to precedence.; Tumor radiological assessments and pelvic exams (q12w from Week 20 post-randomization) fall on Durvalumab/Placebo infusion days within the 12-month window (Day 140, Day 224, Day 308), and are thus categorized as 'core_treatment'.; Patient follow-up contacts/reviews for safety on C1D14, C2D14, C3D14 are assumed to be non-in-person (e.g., phone calls) and are not counted as contact days.; Follow-up visits from Table 2 (Schedule of assessments for patients who have completed or discontinued treatment) are not included as they occur after the last dose of IP, which extends beyond the 12-month window (24 doses * 28 days = 672 days).; Optional or 'as clinically indicated' visits are not counted."
38039991,Placebo + SoC CCRT,control,1,24,32,35,38,42,0,24,32,35,38,42,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,"until completion of planned therapy (24 doses), clinical progression, unacceptable toxicity, or withdrawal","Screening (1 day); Treatment: Placebo infusion q28d (14 doses within 12 months), concurrent SoC CCRT including EBRT (25 fractions over 5 weeks), Cisplatin (6 weekly doses), and Brachytherapy (3 sessions). Tumor assessments (imaging + pelvic exam) q12w from Week 20.","All procedures marked 'X' for a given visit column in Table 1 (Schedule of assessments for durvalumab/placebo ± chemoradiation therapy screening and treatment and retreatment periods) occur on that single day.; For the screening visit, multiple procedures (ECG, FFPE tumor sample, Tumor radiological assessments, labs, physical exams, etc.) are listed. Applying the tie-breaker precedence, this day is categorized as 'imaging_diagnostics' due to imaging procedures.; The SoC CCRT (EBRT, Cisplatin, Brachytherapy) is assumed to be completed within 59 days as per protocol. EBRT is assumed to be 25 fractions over 5 weeks (5 days/week), starting C1D1 (Day 0). Cisplatin is 6 doses, weekly, starting C1D2 (Day 1). Brachytherapy is 3 fractions, assumed to occur on Day 35, Day 42, and Day 49, not on cisplatin days, and after week 3 of EBRT.; Placebo infusions occur every 28 days (q4w) for 24 doses, starting C1D1 (Day 0).; All treatment days (Day 0 onwards) involve active treatment (placebo infusion, cisplatin, EBRT, or brachytherapy). Even if other assessments (e.g., labs, physical exams, PROs, imaging) occur on these days, the day is categorized as 'core_treatment' due to precedence.; Tumor radiological assessments and pelvic exams (q12w from Week 20 post-randomization) fall on Placebo infusion days within the 12-month window (Day 140, Day 224, Day 308), and are thus categorized as 'core_treatment'.; Patient follow-up contacts/reviews for safety on C1D14, C2D14, C3D14 are assumed to be non-in-person (e.g., phone calls) and are not counted as contact days.; Follow-up visits from Table 2 (Schedule of assessments for patients who have completed or discontinued treatment) are not included as they occur after the last dose of IP, which extends beyond the 12-month window (24 doses * 28 days = 672 days).; Optional or 'as clinically indicated' visits are not counted."
38039993,Arm A: Lenvatinib plus Pembrolizumab,intervention,1,5,13,26,39,53,1,3,9,17,26,35,0,0,0,0,0,0,0,0,0,0,0,0,0,2,4,9,13,18,21,Lenvatinib until progression or intolerable toxicity; Pembrolizumab/placebo for up to 35 cycles (approx. 2 years) or until disease progression/unacceptable toxicity.,"Screening (1 day), then 3 visits per 21-day cycle: Day 1 (core_treatment), Day 8 (clinic_visits), Day 15 (core_treatment).","The 'Screening' column in the Schedule of Activities (SoA) table represents a single in-person contact day, categorized as 'core_treatment' due to Lenvatinib Dispensing being present on that day, taking precedence over other procedures.; Randomization is considered to occur on C1D1 (Day 0) and is part of the C1D1 visit.; Lenvatinib is administered orally once daily, and its dispensing is considered a 'core_treatment' activity.; Pembrolizumab/placebo is administered intravenously on Day 1 of each 21-day cycle, which is a 'core_treatment' activity.; Procedures marked with 'X' in the SoA table for a given visit are assumed to occur on that day.; Optional visits (e.g., 'Stool analysis (optional)') are excluded from contact day counts.; Tele-visits or phone calls for follow-up (e.g., 'Survival status' if clinic visit not feasible) are not counted as in-person contact days.; All procedures occurring on a day with 'core_treatment' activities (Pembrolizumab/placebo administration or Lenvatinib Dispensing) are subsumed under the 'core_treatment' category due to precedence rules.; On days without 'core_treatment' or 'imaging_diagnostics', if 'labs' and 'clinic_visits' occur, the day is categorized as 'clinic_visits' due to precedence.; Treatment is assumed to continue for the entire 12-month (365-day) period, following the 'until progression' rule for Lenvatinib and the maximum 35 cycles for Pembrolizumab/placebo (which extends beyond 365 days, so we count visits up to Day 365). Post-treatment follow-up visits are not included in the 12-month window as treatment is assumed to continue until Day 365.; Imaging assessments (e.g., CT/MRI, ECG, MUGA/ECHO) and lab collections (e.g., blood draws, urine tests) that coincide with core treatment days are categorized as 'core_treatment'."
38039993,Arm B: Lenvatinib plus Placebo,control,1,5,13,26,39,53,1,3,9,17,26,35,0,0,0,0,0,0,0,0,0,0,0,0,0,2,4,9,13,18,21,Lenvatinib until progression or intolerable toxicity; Placebo for up to 35 cycles (approx. 2 years) or until disease progression/unacceptable toxicity.,"Screening (1 day), then 3 visits per 21-day cycle: Day 1 (core_treatment), Day 8 (clinic_visits), Day 15 (core_treatment).","The 'Screening' column in the Schedule of Activities (SoA) table represents a single in-person contact day, categorized as 'core_treatment' due to Lenvatinib Dispensing being present on that day, taking precedence over other procedures.; Randomization is considered to occur on C1D1 (Day 0) and is part of the C1D1 visit.; Lenvatinib is administered orally once daily, and its dispensing is considered a 'core_treatment' activity.; Pembrolizumab/placebo is administered intravenously on Day 1 of each 21-day cycle, which is a 'core_treatment' activity.; Procedures marked with 'X' in the SoA table for a given visit are assumed to occur on that day.; Optional visits (e.g., 'Stool analysis (optional)') are excluded from contact day counts.; Tele-visits or phone calls for follow-up (e.g., 'Survival status' if clinic visit not feasible) are not counted as in-person contact days.; All procedures occurring on a day with 'core_treatment' activities (Pembrolizumab/placebo administration or Lenvatinib Dispensing) are subsumed under the 'core_treatment' category due to precedence rules.; On days without 'core_treatment' or 'imaging_diagnostics', if 'labs' and 'clinic_visits' occur, the day is categorized as 'clinic_visits' due to precedence.; Treatment is assumed to continue for the entire 12-month (365-day) period, following the 'until progression' rule for Lenvatinib and the maximum 35 cycles for Pembrolizumab/placebo (which extends beyond 365 days, so we count visits up to Day 365). Post-treatment follow-up visits are not included in the 12-month window as treatment is assumed to continue until Day 365.; Imaging assessments (e.g., CT/MRI, ECG, MUGA/ECHO) and lab collections (e.g., blood draws, urine tests) that coincide with core treatment days are categorized as 'core_treatment'."
38060199,Cohort 1 Arm A (Ipatasertib + Atezolizumab + Paclitaxel),intervention,1,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day). Treatment cycles (28-day cycle): Day 1, Day 8, Day 15 of each cycle. Tumor assessments (CT/MRI, bone scan, head scan) occur on Day 56, 112, 168, 224, 280, 336. Cardiac function and ECG at screening. Various labs and clinic visits occur on treatment days.","Treatment is assumed to continue 'until progression' for the entire 12-month period for calculation purposes.; All listed activities in Table 1 (Appendix 1) with an 'X' are considered in-person contact days unless explicitly stated otherwise (e.g., telephone calls, optional visits).; Placebo administration (oral or IV infusion) is considered a 'core_treatment' activity requiring in-person contact, similar to active drug administration, for blinding and logistical reasons.; PK and ADA samples are explicitly stated as 'no longer collected' as of protocol Version 5 (Page 97, Appendix 2) and are therefore not counted as contact days.; Long-term follow-up assessments are explicitly stated as 'no longer required' as of protocol Version 6 (Page 69, Page 84) and are therefore not counted.; The SDDV (Study Drug Discontinuation Visit) is a contact day, but if treatment continues up to Day 365, the SDDV would occur after Day 365 and thus falls outside the 12-month window.; All five arms (Cohort 1 Arm A, Cohort 1 Arm B, Cohort 1 Arm C, Cohort 2 Arm A, Cohort 2 Arm B) follow the identical schedule of in-person visits and assessments as outlined in Table 1 (Appendix 1) for the treatment phase, as the differences are in the active vs. placebo nature of the drugs, but the administration schedule and assessment schedule are maintained for blinding purposes. Therefore, the contact day counts are identical across all arms."
38060199,Cohort 1 Arm B (Ipatasertib + Paclitaxel),intervention,1,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day). Treatment cycles (28-day cycle): Day 1, Day 8, Day 15 of each cycle. Tumor assessments (CT/MRI, bone scan, head scan) occur on Day 56, 112, 168, 224, 280, 336. Cardiac function and ECG at screening. Various labs and clinic visits occur on treatment days.","Treatment is assumed to continue 'until progression' for the entire 12-month period for calculation purposes.; All listed activities in Table 1 (Appendix 1) with an 'X' are considered in-person contact days unless explicitly stated otherwise (e.g., telephone calls, optional visits).; Placebo administration (oral or IV infusion) is considered a 'core_treatment' activity requiring in-person contact, similar to active drug administration, for blinding and logistical reasons.; PK and ADA samples are explicitly stated as 'no longer collected' as of protocol Version 5 (Page 97, Appendix 2) and are therefore not counted as contact days.; Long-term follow-up assessments are explicitly stated as 'no longer required' as of protocol Version 6 (Page 69, Page 84) and are therefore not counted.; The SDDV (Study Drug Discontinuation Visit) is a contact day, but if treatment continues up to Day 365, the SDDV would occur after Day 365 and thus falls outside the 12-month window.; All five arms (Cohort 1 Arm A, Cohort 1 Arm B, Cohort 1 Arm C, Cohort 2 Arm A, Cohort 2 Arm B) follow the identical schedule of in-person visits and assessments as outlined in Table 1 (Appendix 1) for the treatment phase, as the differences are in the active vs. placebo nature of the drugs, but the administration schedule and assessment schedule are maintained for blinding purposes. Therefore, the contact day counts are identical across all arms."
38060199,Cohort 1 Arm C (Paclitaxel alone),intervention,1,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day). Treatment cycles (28-day cycle): Day 1, Day 8, Day 15 of each cycle. Tumor assessments (CT/MRI, bone scan, head scan) occur on Day 56, 112, 168, 224, 280, 336. Cardiac function and ECG at screening. Various labs and clinic visits occur on treatment days.","Treatment is assumed to continue 'until progression' for the entire 12-month period for calculation purposes.; All listed activities in Table 1 (Appendix 1) with an 'X' are considered in-person contact days unless explicitly stated otherwise (e.g., telephone calls, optional visits).; Placebo administration (oral or IV infusion) is considered a 'core_treatment' activity requiring in-person contact, similar to active drug administration, for blinding and logistical reasons.; PK and ADA samples are explicitly stated as 'no longer collected' as of protocol Version 5 (Page 97, Appendix 2) and are therefore not counted as contact days.; Long-term follow-up assessments are explicitly stated as 'no longer required' as of protocol Version 6 (Page 69, Page 84) and are therefore not counted.; The SDDV (Study Drug Discontinuation Visit) is a contact day, but if treatment continues up to Day 365, the SDDV would occur after Day 365 and thus falls outside the 12-month window.; All five arms (Cohort 1 Arm A, Cohort 1 Arm B, Cohort 1 Arm C, Cohort 2 Arm A, Cohort 2 Arm B) follow the identical schedule of in-person visits and assessments as outlined in Table 1 (Appendix 1) for the treatment phase, as the differences are in the active vs. placebo nature of the drugs, but the administration schedule and assessment schedule are maintained for blinding purposes. Therefore, the contact day counts are identical across all arms."
38060199,Cohort 2 Arm A (Ipatasertib + Atezolizumab + Paclitaxel),intervention,1,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day). Treatment cycles (28-day cycle): Day 1, Day 8, Day 15 of each cycle. Tumor assessments (CT/MRI, bone scan, head scan) occur on Day 56, 112, 168, 224, 280, 336. Cardiac function and ECG at screening. Various labs and clinic visits occur on treatment days.","Treatment is assumed to continue 'until progression' for the entire 12-month period for calculation purposes.; All listed activities in Table 1 (Appendix 1) with an 'X' are considered in-person contact days unless explicitly stated otherwise (e.g., telephone calls, optional visits).; Placebo administration (oral or IV infusion) is considered a 'core_treatment' activity requiring in-person contact, similar to active drug administration, for blinding and logistical reasons.; PK and ADA samples are explicitly stated as 'no longer collected' as of protocol Version 5 (Page 97, Appendix 2) and are therefore not counted as contact days.; Long-term follow-up assessments are explicitly stated as 'no longer required' as of protocol Version 6 (Page 69, Page 84) and are therefore not counted.; The SDDV (Study Drug Discontinuation Visit) is a contact day, but if treatment continues up to Day 365, the SDDV would occur after Day 365 and thus falls outside the 12-month window.; All five arms (Cohort 1 Arm A, Cohort 1 Arm B, Cohort 1 Arm C, Cohort 2 Arm A, Cohort 2 Arm B) follow the identical schedule of in-person visits and assessments as outlined in Table 1 (Appendix 1) for the treatment phase, as the differences are in the active vs. placebo nature of the drugs, but the administration schedule and assessment schedule are maintained for blinding purposes. Therefore, the contact day counts are identical across all arms."
38060199,Cohort 2 Arm B (Atezolizumab + Paclitaxel),intervention,1,4,10,20,30,40,0,4,10,20,30,40,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day). Treatment cycles (28-day cycle): Day 1, Day 8, Day 15 of each cycle. Tumor assessments (CT/MRI, bone scan, head scan) occur on Day 56, 112, 168, 224, 280, 336. Cardiac function and ECG at screening. Various labs and clinic visits occur on treatment days.","Treatment is assumed to continue 'until progression' for the entire 12-month period for calculation purposes.; All listed activities in Table 1 (Appendix 1) with an 'X' are considered in-person contact days unless explicitly stated otherwise (e.g., telephone calls, optional visits).; Placebo administration (oral or IV infusion) is considered a 'core_treatment' activity requiring in-person contact, similar to active drug administration, for blinding and logistical reasons.; PK and ADA samples are explicitly stated as 'no longer collected' as of protocol Version 5 (Page 97, Appendix 2) and are therefore not counted as contact days.; Long-term follow-up assessments are explicitly stated as 'no longer required' as of protocol Version 6 (Page 69, Page 84) and are therefore not counted.; The SDDV (Study Drug Discontinuation Visit) is a contact day, but if treatment continues up to Day 365, the SDDV would occur after Day 365 and thus falls outside the 12-month window.; All five arms (Cohort 1 Arm A, Cohort 1 Arm B, Cohort 1 Arm C, Cohort 2 Arm A, Cohort 2 Arm B) follow the identical schedule of in-person visits and assessments as outlined in Table 1 (Appendix 1) for the treatment phase, as the differences are in the active vs. placebo nature of the drugs, but the administration schedule and assessment schedule are maintained for blinding purposes. Therefore, the contact day counts are identical across all arms."
38103088,Arm 1: F-627 (all cycles),intervention,1,27,58,58,58,58,0,4,8,8,8,8,1,0,1,1,1,1,0,23,49,49,49,49,0,0,0,0,0,0,21,4 cycles or until Day 84,"Screening (1 day), C1D1, C1D2, C1D3-21 (daily), C2D1, C2D2, C2D3-21 (EOD), C3D1, C3D2, C3D3-21 (EOD), C4D1, C4D2, C4D3-21 (EOD), End of Study Day 84.","One in-person screening day is assumed to occur within the 'Screening Days -15 to -1' window, e.g., Day -1.; Chemotherapy administration occurs on Day 1 of each 21-day cycle (Day 0, 21, 42, 63).; Study drug (F-627 or Placebo) administration occurs on Day 2 of each 21-day cycle (Day 1, 22, 43, 64).; ANC monitoring for Cycle 1 (Day 3-21) is assumed to be daily (19 days).; ANC monitoring for Cycles 2-4 (Day 24-42, Day 45-63, Day 66-84) is assumed to be every other day for the full duration of the cycle (10 days each cycle), representing a conservative lower estimate for the variable 'until ANC recovery + 3 days' schedule.; The End of Study visit is on Day 84 as explicitly stated in the Study Flow Chart (Page 36), overriding other text suggesting '3 weeks after last drug administration' (which would be Day 86)."
38103088,"Arm 2: Placebo (Cycle 1), then F-627 (Cycles 2-4)",intervention,1,27,58,58,58,58,0,4,8,8,8,8,1,0,1,1,1,1,0,23,49,49,49,49,0,0,0,0,0,0,21,4 cycles or until Day 84,"Screening (1 day), C1D1, C1D2, C1D3-21 (daily), C2D1, C2D2, C2D3-21 (EOD), C3D1, C3D2, C3D3-21 (EOD), C4D1, C4D2, C4D3-21 (EOD), End of Study Day 84.","One in-person screening day is assumed to occur within the 'Screening Days -15 to -1' window, e.g., Day -1.; Chemotherapy administration occurs on Day 1 of each 21-day cycle (Day 0, 21, 42, 63).; Study drug (F-627 or Placebo) administration occurs on Day 2 of each 21-day cycle (Day 1, 22, 43, 64).; ANC monitoring for Cycle 1 (Day 3-21) is assumed to be daily (19 days).; ANC monitoring for Cycles 2-4 (Day 24-42, Day 45-63, Day 66-84) is assumed to be every other day for the full duration of the cycle (10 days each cycle), representing a conservative lower estimate for the variable 'until ANC recovery + 3 days' schedule.; The End of Study visit is on Day 84 as explicitly stated in the Study Flow Chart (Page 36), overriding other text suggesting '3 weeks after last drug administration' (which would be Day 86)."
38159809,Pembrolizumab Monotherapy,intervention,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,up to 35 cycles or until discontinuation,"Screening (2 days), then Cycle Day 1 (C_D1) every 21 days for treatment. Tumor scans occur at Day 63, 126, 189, 252, 315. Full physical exams occur at C1D1, C5D1, C9D1, C13D1, C17D1. ECGs occur at C1D1, C2D1, C6D1, C10D1, C14D1, C18D1. Thyroid function tests occur at C1D1, C2D1, C4D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1.","As of Amendment 007-06, lenvatinib and matching placebo arms were removed, and all remaining participants continue on open-label pembrolizumab monotherapy. Therefore, only one arm is considered.; Assumed a minimum of 2 distinct in-person screening days to accommodate the various screening procedures and their timing requirements (e.g., 'within 7 days before C1', 'within 10 days before first dose', 'within 28 days of randomization'). One day is primarily for initial administrative tasks and specific lab collections (categorized as 'labs'), and another day closer to C1D1 for physical assessments, imaging, and other labs (categorized as 'imaging_diagnostics' due to precedence).; The treatment duration is 'up to 35 cycles or until discontinuation'. For calculation purposes, treatment is assumed to continue through the 12-month window (365 days).; All Cycle 1 Day 1 (C1D1) and subsequent Cycle Day 1 (C_D1) visits include pembrolizumab IV infusion, which is categorized as 'core_treatment'. Due to precedence, any other procedures on these days are subsumed under 'core_treatment'.; Survival follow-up visits (e.g., 'Every 12 weeks') are explicitly noted to potentially occur via telephone or e-mail, and thus are not counted as in-person healthcare contact days.; 12-lead ECG at Safety Follow-up is noted as 'only required at the EOT Visit for those participants that had received lenvatinib'. Since lenvatinib is removed, this is not counted as a contact day in the post-treatment phase."
38252907,Arm A: Nivolumab plus Platinum-doublet Chemotherapy,intervention,2,2,6,13,19,26,0,2,5,9,13,18,2,0,1,4,6,8,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (Nivolumab max 24 months),"Screening (2 days: Day -14 for biopsy, Day -7 for main screening). Treatment on Day 1 of each 21-day cycle (Nivolumab + Pemetrexed/Platinum for 4 cycles, then Nivolumab + Pemetrexed maintenance). Dedicated tumor assessments at Week 7, 13, 19, 25, 31, 37, 43, 49.","Arm B enrollment is closed, so only Arm A and Arm C are considered.; A fresh biopsy is assumed to be performed during screening, adding one contact day (imaging_diagnostics).; The main screening visit (including CT/MRI, ECG, Labs, and Clinic procedures) is consolidated into a single day (imaging_diagnostics due to precedence).; Cycle 1 Day 1 (C1D1) is designated as Day 0.; All agents are assumed to be administered on Day 1 of each cycle.; Treatment is assumed to continue until progression for the purpose of calculating contact days up to 12 months, noting Nivolumab has a 24-month maximum duration.; Tumor assessments (Week 7, 13, 19, 25, 31, 37, 43, 49) are considered dedicated imaging visits (imaging_diagnostics) as they do not coincide with Day 1 of a 21-day cycle.; EQ-5D-3L/LCSS questionnaires and TSH lab draws are performed on Day 1 of cycles and do not add separate contact days."
38252907,Arm C: Platinum Doublet Chemotherapy,control,2,2,6,13,19,26,0,2,5,9,13,18,2,0,1,4,6,8,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (2 days: Day -14 for biopsy, Day -7 for main screening). Treatment on Day 1 of each 21-day cycle (Pemetrexed/Platinum for 4 cycles, then Pemetrexed maintenance). Dedicated tumor assessments at Week 7, 13, 19, 25, 31, 37, 43, 49.","Arm B enrollment is closed, so only Arm A and Arm C are considered.; A fresh biopsy is assumed to be performed during screening, adding one contact day (imaging_diagnostics).; The main screening visit (including CT/MRI, ECG, Labs, and Clinic procedures) is consolidated into a single day (imaging_diagnostics due to precedence).; Cycle 1 Day 1 (C1D1) is designated as Day 0.; All agents are assumed to be administered on Day 1 of each cycle.; Treatment is assumed to continue until progression for the purpose of calculating contact days up to 12 months.; Tumor assessments (Week 7, 13, 19, 25, 31, 37, 43, 49) are considered dedicated imaging visits (imaging_diagnostics) as they do not coincide with Day 1 of a 21-day cycle.; EQ-5D-3L/LCSS questionnaires are performed on Day 1 of cycles and do not add separate contact days."
38319255,Ibrutinib + Venetoclax (I+VEN),intervention,3,2,5,11,13,14,0,2,5,11,13,14,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,Arm A: 15 cycles (420 days) fixed duration. Arm B: 6 cycles (168 days) fixed duration. Disease evaluation visits continue after treatment completion.,"Arm A: Screening (3 days). Treatment: C1D1, C2D1, C3D1, C3D26, C4D1, C4D8, C4D15, C4D22, C5D1, C6D1, C7D1, C8D1, C10D1, C13D1. (C9D1, C11D1, C12D1, C14D1 are not in-person contact days). Arm B: Screening (3 days). Treatment: C1D1, C1D2, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1. Post-treatment DE visits: DE2 (Day 168), DE3 (Day 252), DE4 (Day 336).","Cycle length is 28 days for treatment cycles.; Day 0 is Cycle 1 Day 1 (C1D1).; Screening is considered to include a primary screening visit plus separate days for bone marrow aspirate and biopsy, as these are listed in Table 3 for 'Up to 30 days prior to randomization' but not explicitly on the main screening day in Table 1 or 2, and are typically distinct procedures.; Any day with 'Clinic visit for study medication dispensation and accountability check' is categorized as 'core_treatment' due to drug dispensation.; Obinutuzumab IV infusion is categorized as 'core_treatment'.; The first dose of Venetoclax on C4D1 (Arm A) is explicitly stated to be delivered in the clinic, hence categorized as 'core_treatment'.; For Arm A, days C9D1, C11D1, C12D1, C14D1, C15D1 are explicitly stated as 'do not require clinic attendance' in Table 1 footnote, therefore no in-person contact days are counted for these specific cycle days.; For Arm B, C2-6 D15 laboratory tests are explicitly stated in footnote 'b' of Table 2 as 'may be done outside the treating institution', therefore no in-person contact days are counted for these specific cycle days.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits).; Disease Evaluation (DE) visits are counted as in-person contact days, and their procedures are categorized. If a DE visit coincides with a treatment day involving drug administration, the day is categorized as 'core_treatment'."
38319255,Chlorambucil + Obinutuzumab (G-Clb),control,3,4,7,10,11,12,0,4,7,9,9,9,3,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,28,Arm A: 15 cycles (420 days) fixed duration. Arm B: 6 cycles (168 days) fixed duration. Disease evaluation visits continue after treatment completion.,"Arm A: Screening (3 days). Treatment: C1D1, C2D1, C3D1, C3D26, C4D1, C4D8, C4D15, C4D22, C5D1, C6D1, C7D1, C8D1, C10D1, C13D1. (C9D1, C11D1, C12D1, C14D1 are not in-person contact days). Arm B: Screening (3 days). Treatment: C1D1, C1D2, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1. Post-treatment DE visits: DE2 (Day 168), DE3 (Day 252), DE4 (Day 336).","Cycle length is 28 days for treatment cycles.; Day 0 is Cycle 1 Day 1 (C1D1).; Screening is considered to include a primary screening visit plus separate days for bone marrow aspirate and biopsy, as these are listed in Table 3 for 'Up to 30 days prior to randomization' but not explicitly on the main screening day in Table 1 or 2, and are typically distinct procedures.; Any day with 'Clinic visit for study medication dispensation and accountability check' is categorized as 'core_treatment' due to drug dispensation.; Obinutuzumab IV infusion is categorized as 'core_treatment'.; The first dose of Venetoclax on C4D1 (Arm A) is explicitly stated to be delivered in the clinic, hence categorized as 'core_treatment'.; For Arm A, days C9D1, C11D1, C12D1, C14D1, C15D1 are explicitly stated as 'do not require clinic attendance' in Table 1 footnote, therefore no in-person contact days are counted for these specific cycle days.; For Arm B, C2-6 D15 laboratory tests are explicitly stated in footnote 'b' of Table 2 as 'may be done outside the treating institution', therefore no in-person contact days are counted for these specific cycle days.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits).; Disease Evaluation (DE) visits are counted as in-person contact days, and their procedures are categorized. If a DE visit coincides with a treatment day involving drug administration, the day is categorized as 'core_treatment'."
38319892,Durvalumab 1500 mg monotherapy (Arm 1),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Treatment visits on Day 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Additional safety check visits on Day 14, 42, 70.","Cycle length is 28 days (Q4W) based on the nominal days in the schedule tables.; Treatment continues until progression, so visits are counted up to Day +365 based on the repeating cycle schedule.; Screening and randomization procedures are considered to occur on a single in-person day within the screening window, with the highest priority procedure determining the category.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, C3 are counted as distinct in-person clinic visits.; Health resource use (HOSPAD module) is excluded as it's 'to be completed at each hospitalization' and not a scheduled routine visit.; Optional genetic sample collection is included as it has an 'X' in the screening table and patient consent for genetic research is mandatory.; Archived tumor sample submission is considered part of the screening day's clinic visit activities."
38319892,Durvalumab 1500 mg plus tremelimumab 75 mg×4 doses combination therapy (Arm 2),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Combination therapy visits on Day 1, 29, 57, 85. Durvalumab monotherapy visits on Day 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Additional safety check visits on Day 14, 42, 70.","Cycle length is 28 days (Q4W) based on the nominal days in the schedule tables.; Treatment continues until progression, so visits are counted up to Day +365 based on the repeating cycle schedule.; Screening and randomization procedures are considered to occur on a single in-person day within the screening window, with the highest priority procedure determining the category.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, C3 are counted as distinct in-person clinic visits.; Health resource use (HOSPAD module) is excluded as it's 'to be completed at each hospitalization' and not a scheduled routine visit.; Optional genetic sample collection is included as it has an 'X' in the screening table and patient consent for genetic research is mandatory.; Archived tumor sample submission is considered part of the screening day's clinic visit activities.; Tremelimumab is administered on Day 1, 29, 57, 85. Durvalumab is administered on Day 1, 29, 57, 85, and then continues as monotherapy Q4W from Day 113 onwards."
38319892,Durvalumab 1500 mg plus tremelimumab 300 mg×1 dose combination therapy (Arm 3),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Combination therapy visit on Day 1. Durvalumab monotherapy visits on Day 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Additional safety check visits on Day 14, 42, 70.","Cycle length is 28 days (Q4W) based on the nominal days in the schedule tables.; Treatment continues until progression, so visits are counted up to Day +365 based on the repeating cycle schedule.; Screening and randomization procedures are considered to occur on a single in-person day within the screening window, with the highest priority procedure determining the category.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, C3 are counted as distinct in-person clinic visits.; Health resource use (HOSPAD module) is excluded as it's 'to be completed at each hospitalization' and not a scheduled routine visit.; Optional genetic sample collection is included as it has an 'X' in the screening table and patient consent for genetic research is mandatory.; Archived tumor sample submission is considered part of the screening day's clinic visit activities.; Tremelimumab is administered on Day 1. Durvalumab is administered on Day 1, and then continues as monotherapy Q4W from Day 29 onwards."
38319892,Sorafenib 400 mg BID therapy (Arm 4),control,1,3,7,10,13,17,0,0,0,0,0,0,1,0,1,3,4,6,0,2,3,4,6,8,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Treatment visits on Day 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Additional safety check visits on Day 14, 42, 70.","Cycle length is 28 days (Q4W) based on the nominal days in the schedule tables.; Treatment continues until progression, so visits are counted up to Day +365 based on the repeating cycle schedule.; Screening and randomization procedures are considered to occur on a single in-person day within the screening window, with the highest priority procedure determining the category.; Patient follow-up contact/Patient review for safety on D14 of C1, C2, C3 are counted as distinct in-person clinic visits.; Health resource use (HOSPAD module) is excluded as it's 'to be completed at each hospitalization' and not a scheduled routine visit.; Optional genetic sample collection is included as it has an 'X' in the screening table and patient consent for genetic research is mandatory.; Archived tumor sample submission is considered part of the screening day's clinic visit activities.; Sorafenib is oral, so no core_treatment days for drug administration. The highest priority procedure on each visit day determines the category."
38320161,Intervention Arm (Lumicell imaging directed tissue resection after standard of care),intervention,1,2,3,4,5,6,0,1,1,1,1,1,1,0,0,0,0,0,0,1,2,3,4,5,0,0,0,0,0,0,,until no further surgical intervention is required,"Single screening day, single surgery day (Day 0), single post-operative visit (~2-14 days), and routine follow-up visits at 3, 6, 9, and 12 months.","All screening procedures (Informed consent, Medical History, Radiologic evaluation, Physical exam, Pregnancy test, CBC, Serum chemistry, Concomitant Medications) are assumed to occur on a single in-person day during the screening window.; Radiologic evaluation at screening is considered a study-mandated in-person diagnostic visit.; The 'Day 1 / Enrollment' column represents a single in-person day (Day 0, the day of surgery) where LUM015 administration, intraoperative imaging, blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation occur.; The '~2-14 days after surgery' column represents a single in-person post-operative visit, assumed to occur within the 1-month window, which includes blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation.; The 'Routine follow up visit' column in the Schedule of Events table is interpreted as in-person visits occurring at approximately 3, 6, 9, and 12 months post-surgery, each including blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation.; Patient Reported Outcome Measures (PROMs) surveys are collected electronically and are not counted as in-person contact days.; Margin assessment is a pathology procedure on resected tissue and does not require an in-person patient contact day.; Both arms receive LUM015 administration (core_treatment) on Day 0.; Only the Intervention Arm receives 'Intraoperative imaging' (core_treatment) on Day 0.; Category tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38320161,Control Arm (Standard of care alone),control,1,2,3,4,5,6,0,1,1,1,1,1,1,0,0,0,0,0,0,1,2,3,4,5,0,0,0,0,0,0,,until no further surgical intervention is required,"Single screening day, single surgery day (Day 0), single post-operative visit (~2-14 days), and routine follow-up visits at 3, 6, 9, and 12 months.","All screening procedures (Informed consent, Medical History, Radiologic evaluation, Physical exam, Pregnancy test, CBC, Serum chemistry, Concomitant Medications) are assumed to occur on a single in-person day during the screening window.; Radiologic evaluation at screening is considered a study-mandated in-person diagnostic visit.; The 'Day 1 / Enrollment' column represents a single in-person day (Day 0, the day of surgery) where LUM015 administration, blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation occur. Intraoperative imaging is NOT performed for the control arm.; The '~2-14 days after surgery' column represents a single in-person post-operative visit, assumed to occur within the 1-month window, which includes blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation.; The 'Routine follow up visit' column in the Schedule of Events table is interpreted as in-person visits occurring at approximately 3, 6, 9, and 12 months post-surgery, each including blood draws (CBC, Serum chemistry), concomitant medication review, and adverse event evaluation.; Patient Reported Outcome Measures (PROMs) surveys are collected electronically and are not counted as in-person contact days.; Margin assessment is a pathology procedure on resected tissue and does not require an in-person patient contact day.; Both arms receive LUM015 administration (core_treatment) on Day 0.; Only the Intervention Arm receives 'Intraoperative imaging' (core_treatment) on Day 0.; Category tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38483412,Arm I (COPORT),intervention,3,23,37,38,38,39,0,23,37,37,37,37,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,2,,"Fixed number of radiation fractions, followed by long-term follow-up.","Screening (H&P/PSA, CT/MRI, Bone Scan); Daily RT for 37 fractions (approx. 7.4 weeks) with weekly H&P/AE on RT days; Follow-up visits at 6 months and 1 year from Day 0.","Radiation therapy (RT) fractions are administered 5 days a week (Monday-Friday).; Weekly History & Physical (H&P) and Adverse Event (AE) evaluations during RT occur on one of the RT treatment days.; The 'End of RT' visit, including physical exam, PSA, AE evaluation, EPIC, and EQ-5D, occurs on the last RT treatment day.; Pre-treatment assessments (H&P, PSA, EPIC, EQ-5D) are consolidated into a single clinic visit day in the screening window.; Optional specimen collections (whole blood, serum, plasma, urine) and optional ADT administration visits are not counted as mandatory contact days.; Day 0 is the first day of radiation therapy."
38483412,Arm II (HYPORT),intervention,3,23,25,26,26,27,0,23,25,25,25,25,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,2,,"Fixed number of radiation fractions, followed by long-term follow-up.","Screening (H&P/PSA, CT/MRI, Bone Scan); Daily RT for 25 fractions (approx. 5 weeks) with weekly H&P/AE on RT days; Follow-up visits at 6 months and 1 year from Day 0.","Radiation therapy (RT) fractions are administered 5 days a week (Monday-Friday).; Weekly History & Physical (H&P) and Adverse Event (AE) evaluations during RT occur on one of the RT treatment days.; The 'End of RT' visit, including physical exam, PSA, AE evaluation, EPIC, and EQ-5D, occurs on the last RT treatment day.; Pre-treatment assessments (H&P, PSA, EPIC, EQ-5D) are consolidated into a single clinic visit day in the screening window.; Optional specimen collections (whole blood, serum, plasma, urine) and optional ADT administration visits are not counted as mandatory contact days.; Day 0 is the first day of radiation therapy."
38499457,Pracinostat + AZA,experimental,1,11,31,55,79,104,0,11,29,50,71,92,1,0,1,3,4,6,0,0,1,2,4,6,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycle 1 (Day 0, 1, 2, 3, 4, 5, 6, 15); Subsequent Cycles (Day 1-7, Day 21-26). Cycle length is 28 days.","All screening procedures are consolidated into a single contact day within the screening window, with the highest priority category being 'imaging_diagnostics' due to the bone marrow aspirate/biopsy.; For 'Day 21-26' assessment windows, a single contact day is assumed within that period (e.g., Day 21 of the cycle).; Azacitidine administration follows the standard 'Days 1-7' schedule per cycle. The '5-2-2' schedule is not used for this calculation.; Pracinostat/placebo administration is considered an in-person contact day when administered by study personnel (C1D1, C1D3, C1D15, and Day 1 of all subsequent cycles). Otherwise, it is self-administered at home and not counted as a contact day.; The 'Pracinostat Population PK Sampling' is included for all patients. The 'Sub-study pracinostat/AZA PK sampling (ONLY IN SELECTED SITES)' is for a subset of patients and is not included in the general contact day count per arm.; Treatment is assumed to continue for the full 12 months (Day 365) for calculation purposes. Therefore, the End of Treatment and Long-Term Follow-up visits fall outside the 12-month window.; Overlapping visits on the same calendar day are counted as one contact day, with category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38499457,Placebo + AZA,control,1,11,31,55,79,104,0,11,29,50,71,92,1,0,1,3,4,6,0,0,1,2,4,6,0,0,0,0,0,0,28,until progression,"Screening (1 day); Cycle 1 (Day 0, 1, 2, 3, 4, 5, 6, 15); Subsequent Cycles (Day 1-7, Day 21-26). Cycle length is 28 days.","All screening procedures are consolidated into a single contact day within the screening window, with the highest priority category being 'imaging_diagnostics' due to the bone marrow aspirate/biopsy.; For 'Day 21-26' assessment windows, a single contact day is assumed within that period (e.g., Day 21 of the cycle).; Azacitidine administration follows the standard 'Days 1-7' schedule per cycle. The '5-2-2' schedule is not used for this calculation.; Placebo administration is considered an in-person contact day when administered by study personnel (C1D1, C1D3, C1D15, and Day 1 of all subsequent cycles). Otherwise, it is self-administered at home and not counted as a contact day.; The 'Pracinostat Population PK Sampling' is included for all patients. The 'Sub-study pracinostat/AZA PK sampling (ONLY IN SELECTED SITES)' is for a subset of patients and is not included in the general contact day count per arm.; Treatment is assumed to continue for the full 12 months (Day 365) for calculation purposes. Therefore, the End of Treatment and Long-Term Follow-up visits fall outside the 12-month window.; Overlapping visits on the same calendar day are counted as one contact day, with category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38531002,Pazopanib 800 mg,intervention,2,6,11,18,25,33,0,0,0,0,0,0,1,1,2,3,4,5,1,5,9,15,21,28,0,0,0,0,0,0,28,13 cycles,"Screening (2 days); Cycle 1 (Day 0, 7, 14, 15, 21, 28); Cycles 2-13 (Day 1 and Day 28 of each cycle); Every 3 months imaging/clinical tumor assessment; End of Treatment (Day 363).","Screening activities ('Prior to Randomization' column) are assumed to occur over two distinct in-person days: one for imaging procedures (CTs, MRI, ECG) and one for clinic visits and lab draws.; The 'Day 15 (± 2 days)' LFT assessment in Cycle 1 is considered a separate in-person visit from the weekly Cycle 1 Day 14 visit.; Assessments scheduled 'Every 3 months (±7 days)' for imaging and clinical tumor assessment are considered distinct in-person days, occurring at approximately Day 90, Day 180, Day 270, and Day 360.; Conditional visits (e.g., 'PRN', 'if clinically indicated', 'if patient has terminated treatment prior to cycle 7', 'for women of childbearing potential', 'for patients with elevated alkaline phosphatase') are excluded from the general contact day count.; Pill Count/Diary and Quality of Life (QOL) questionnaires are considered in-person activities at each scheduled clinic visit where they are listed, including baseline, end of each cycle, and End of Treatment.; Pharmacokinetic (PK) blood draws, specified as 'within 24 hours prior to start of treatment on Cycle X Day 1', are assumed to occur on Day 28 of the preceding cycle, making it an in-person lab visit.; All 'Day 1' visits for Cycles 1-13 and 'End of Treatment' visit are considered in-person healthcare contact days.; The category for Day 28 (C2D1) is imaging_diagnostics due to the required ECG, which takes precedence over labs and clinic visits scheduled for that day.; The category for the 'Every 3 months' assessment days (Day 90, 180, 270, 360) is imaging_diagnostics due to the required CT/MRI scans, which take precedence over clinical tumor assessment."
38531002,Placebo,control,2,6,11,18,25,33,0,0,0,0,0,0,1,1,2,3,4,5,1,5,9,15,21,28,0,0,0,0,0,0,28,13 cycles,"Screening (2 days); Cycle 1 (Day 0, 7, 14, 15, 21, 28); Cycles 2-13 (Day 1 and Day 28 of each cycle); Every 3 months imaging/clinical tumor assessment; End of Treatment (Day 363).","Screening activities ('Prior to Randomization' column) are assumed to occur over two distinct in-person days: one for imaging procedures (CTs, MRI, ECG) and one for clinic visits and lab draws.; The 'Day 15 (± 2 days)' LFT assessment in Cycle 1 is considered a separate in-person visit from the weekly Cycle 1 Day 14 visit.; Assessments scheduled 'Every 3 months (±7 days)' for imaging and clinical tumor assessment are considered distinct in-person days, occurring at approximately Day 90, Day 180, Day 270, and Day 360.; Conditional visits (e.g., 'PRN', 'if clinically indicated', 'if patient has terminated treatment prior to cycle 7', 'for women of childbearing potential', 'for patients with elevated alkaline phosphatase') are excluded from the general contact day count.; Pill Count/Diary and Quality of Life (QOL) questionnaires are considered in-person activities at each scheduled clinic visit where they are listed, including baseline, end of each cycle, and End of Treatment.; Pharmacokinetic (PK) blood draws, specified as 'within 24 hours prior to start of treatment on Cycle X Day 1', are assumed to occur on Day 28 of the preceding cycle, making it an in-person lab visit.; All 'Day 1' visits for Cycles 1-13 and 'End of Treatment' visit are considered in-person healthcare contact days.; The category for Day 28 (C2D1) is imaging_diagnostics due to the required ECG, which takes precedence over labs and clinic visits scheduled for that day.; The category for the 'Every 3 months' assessment days (Day 90, 180, 270, 360) is imaging_diagnostics due to the required CT/MRI scans, which take precedence over clinical tumor assessment."
38552197,Atezolizumab in combination with Cabozantinib,intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,Screening (1 day) + Day 1 of each 21-day cycle (18 days within 12 months).,"One single screening day is assumed for all screening procedures (informed consent, demographics, medical history, height, weight, ECOG, concomitant medications, adverse events, PROs, tumor tissue specimens/biopsy, ALK/EGFR assessment, viral serology, C-reactive protein, hematology, chemistry, pregnancy test, coagulation, TSH, urine chemistry, urinalysis, ECG, tumor response assessments). The highest priority activity on this day is imaging_diagnostics (CT/MRI scans and biopsy).; Treatment is assumed to continue for the full 12-month period (up to Day 365), based on the 'until progression' rule and the need to enumerate visits through Day +365. This results in 18 cycles of 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357).; All Day 1 visits of each cycle are considered in-person contact days due to the intravenous infusion of Atezolizumab. These days are categorized as core_treatment, subsuming any other assessments (ECG, labs, tumor assessments, clinic visits) that occur on the same day.; Cabozantinib is administered orally at the clinic only on Day 1 of Cycle 1. Subsequent doses are taken at home and are not counted as in-person contact days.; Optional visits, such as optional RBR blood samples and mobile nursing visits, are excluded from contact day counts.; Tumor response assessments (CT/MRI) are scheduled at baseline (screening) and every 6 weeks for the first 48 weeks (Day 42, 84, 126, 168, 210, 252, 294, 336). These days coincide with treatment days and are thus categorized as core_treatment.; The 'Post-Treatment Follow-Up Visit (30 days after final dose)' and 'Survival Follow-Up' visits are not counted within the 12-month window, as they would occur after the assumed 12 months of continuous treatment."
38552197,Docetaxel monotherapy,control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,Screening (1 day) + Day 1 of each 21-day cycle (18 days within 12 months).,"One single screening day is assumed for all screening procedures (informed consent, demographics, medical history, height, weight, ECOG, concomitant medications, adverse events, PROs, tumor tissue specimens/biopsy, ALK/EGFR assessment, viral serology, C-reactive protein, hematology, chemistry, pregnancy test, coagulation, TSH, urine chemistry, urinalysis, ECG, tumor response assessments). The highest priority activity on this day is imaging_diagnostics (CT/MRI scans and biopsy).; Treatment is assumed to continue for the full 12-month period (up to Day 365), based on the 'until progression' rule and the need to enumerate visits through Day +365. This results in 18 cycles of 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357).; All Day 1 visits of each cycle are considered in-person contact days due to the intravenous infusion of Docetaxel. These days are categorized as core_treatment, subsuming any other assessments (ECG, labs, tumor assessments, clinic visits) that occur on the same day.; Optional visits, such as optional RBR blood samples and mobile nursing visits, are excluded from contact day counts.; Tumor response assessments (CT/MRI) are scheduled at baseline (screening) and every 6 weeks for the first 48 weeks (Day 42, 84, 126, 168, 210, 252, 294, 336). These days coincide with treatment days and are thus categorized as core_treatment.; The 'Post-Treatment Follow-Up Visit (30 days after final dose)' and 'Survival Follow-Up' visits are not counted within the 12-month window, as they would occur after the assumed 12 months of continuous treatment."
38648575,Irinotecan Liposome Injection (ONIVYDE®),intervention,2,4,9,15,22,29,0,3,7,13,20,27,2,0,0,0,0,0,0,1,2,2,2,2,0,0,0,0,0,0,14,until progression,"Screening (Day -28, Day -7). Treatment cycles are 14 days long. Visits occur on Day 1 and Day 15 of each cycle for drug administration, labs, and clinic assessments. Additional lab visits on C1D8 and C2D22. Tumor assessments and QoL are every 6 weeks from C1D1 and coincide with D1 of cycles.","Screening visits are consolidated into two distinct days (Day -28 and Day -7) to minimize contact days while fulfilling all screening requirements.; Treatment continues until Day +365 (assuming no progression within this period). The 30-day follow-up visit is therefore not included in the 12-month window.; Monthly OS follow-up (LTFU) is assumed to be remote (phone/email) and thus not a contact day, as per protocol text allowing remote options and the definition of a non-contact day.; For procedures that the COVID-19 appendix states *can* be done remotely (e.g., Physical Exam, ECOG, QoL, Conmeds, Conprocs, AE reporting), these are only counted as in-person contact days if another explicitly in-person procedure (e.g., drug administration, labs, imaging, ECG, consent, randomization) is scheduled on the same day.; Biobanking samples are collected at C1D1, C3D1 (Week 6), and C6D1 (Week 12) as per Page 21, which aligns with core treatment days and does not add new contact days.; PK samples are collected on C1D1 (4 samples), C1D8 (1 sample), C1D15 (1 sample), and C2D22 (1 sample) as per Table 6. C1D1 and C1D15 coincide with core treatment. C1D8 and C2D22 are standalone lab visits."
38648575,Topotecan IV,control,2,10,25,45,65,90,0,10,25,45,65,90,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -7). Treatment cycles are 21 days long. Topotecan is administered on Day 1-5 of each cycle. Day 1 of each cycle also includes labs and clinic assessments. Tumor assessments and QoL are every 6 weeks from C1D1 and coincide with D1 of cycles.","Screening visits are consolidated into two distinct days (Day -28 and Day -7) to minimize contact days while fulfilling all screening requirements.; Treatment continues until Day +365 (assuming no progression within this period). The 30-day follow-up visit is therefore not included in the 12-month window.; Monthly OS follow-up (LTFU) is assumed to be remote (phone/email) and thus not a contact day, as per protocol text allowing remote options and the definition of a non-contact day.; For procedures that the COVID-19 appendix states *can* be done remotely (e.g., Physical Exam, ECOG, QoL, Conmeds, Conprocs, AE reporting), these are only counted as in-person contact days if another explicitly in-person procedure (e.g., drug administration, labs, imaging, ECG, consent, randomization) is scheduled on the same day.; Topotecan is administered for 5 consecutive days (Day 1-5) in each cycle, meaning 5 contact days per cycle.; Biobanking samples are collected at C1D1, C3D1 (Week 6), and C5D1 (Week 12) as per Page 21, which aligns with core treatment days and does not add new contact days."
38683596,ARM 1: Aspirin 300 mg daily x 5 years,intervention,1,0,0,1,1,2,0,0,0,0,0,0,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,,5 years of study treatment,"One screening visit, followed by in-person visits every 6 months for the 5-year treatment duration, and then annually for follow-up.","One in-person screening day is assumed for all baseline procedures (History and Physical, Weight, BMI, PS, Height, Pulse/BP, AE Assessment, Lifestyle Questionnaires, Tissue/Blood/Urine samples) as they are all listed under 'Prior to Registration/Randomization' and 'After consent signed, prior to treatment start' columns.; The 'Evaluation of Disease Recurrence or new invasive disease' procedure, mandated at 6-month visits and end of treatment, is classified as 'imaging_diagnostics' due to its nature as a disease assessment in a cancer trial, which often involves imaging or diagnostic biopsies for confirmation as per Section 11.1.; Day 0 (C1D1) is not counted as an in-person contact day, as no specific in-person procedures are listed for it in the Schedule of Events, and the study drug is taken daily at home.; The 'Every 6 months from start of study treatment +/- 28 days' visits are interpreted as nominal Day 180, Day 360, Day 540, etc.; BMI, Lifestyle Measures, and Blood/Urine samples are collected at baseline (screening) and specifically at the 24-month visit, as indicated by footnotes and specific tables (Page 10, Footnote 1; Page 12, Section 6.2 table; Page 13, Section 6.3 table). For other 6-month visits, these specific procedures are not included."
38683596,ARM 2: Placebo daily x 5 years,control,1,0,0,1,1,2,0,0,0,0,0,0,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,,5 years of study treatment,"One screening visit, followed by in-person visits every 6 months for the 5-year treatment duration, and then annually for follow-up.","One in-person screening day is assumed for all baseline procedures (History and Physical, Weight, BMI, PS, Height, Pulse/BP, AE Assessment, Lifestyle Questionnaires, Tissue/Blood/Urine samples) as they are all listed under 'Prior to Registration/Randomization' and 'After consent signed, prior to treatment start' columns.; The 'Evaluation of Disease Recurrence or new invasive disease' procedure, mandated at 6-month visits and end of treatment, is classified as 'imaging_diagnostics' due to its nature as a disease assessment in a cancer trial, which often involves imaging or diagnostic biopsies for confirmation as per Section 11.1.; Day 0 (C1D1) is not counted as an in-person contact day, as no specific in-person procedures are listed for it in the Schedule of Events, and the study drug is taken daily at home.; The 'Every 6 months from start of study treatment +/- 28 days' visits are interpreted as nominal Day 180, Day 360, Day 540, etc.; BMI, Lifestyle Measures, and Blood/Urine samples are collected at baseline (screening) and specifically at the 24-month visit, as indicated by footnotes and specific tables (Page 10, Footnote 1; Page 12, Section 6.2 table; Page 13, Section 6.3 table). For other 6-month visits, these specific procedures are not included."
38833658,Arm A: Lenvatinib Plus Pembrolizumab Treatment,intervention,1,3,7,14,20,27,1,3,7,14,20,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,"until progressive disease or unacceptable toxicity (Pembrolizumab up to 18 administrations, approx. 2 years)","Screening (1 day) + Intervention visits every 2 weeks (Day 0, 14, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336, 350, 364).","All screening procedures marked 'X' in the 'Screening -ing' column are assumed to occur on a single contact day within the screening window.; The 'Archival or Newly Obtained Tissue Collection' (biopsy) during screening is considered a core_treatment procedure, making the screening day a core_treatment day.; For Arm A, Pembrolizumab administration is assumed to be Q6W (every 42 days) as explicitly stated in the 'Intervention Groups and Duration' table (page 6), overriding conflicting information in Table 1 (page 13).; Lenvatinib dispensing (Arm A) and Regorafenib/TAS-102 administration/dispensing (Arm B) are assumed to require an in-person visit every 2 weeks based on notes such as 'Dispensed every 2 weeks' and 'Participants must return to the site every 2 weeks'. These are categorized as core_treatment days.; All other procedures (imaging, labs, clinic visits) that fall on a day with drug administration/dispensing are subsumed under core_treatment due to precedence.; Treatment is assumed to continue until progression for the entire 12-month period, thus post-treatment follow-up visits are not included in the counts for the 12-month interval.; The 'Telephone Contact Visit' on C1D8 is explicitly excluded as an in-person healthcare-contact day."
38833658,Arm B: Regorafenib Treatment,control,1,3,7,14,20,27,1,3,7,14,20,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progressive disease or unacceptable toxicity,"Screening (1 day) + Intervention visits every 2 weeks (Day 0, 14, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336, 350, 364).","All screening procedures marked 'X' in the 'Screening -ing' column are assumed to occur on a single contact day within the screening window.; The 'Archival or Newly Obtained Tissue Collection' (biopsy) during screening is considered a core_treatment procedure, making the screening day a core_treatment day.; Regorafenib administration/dispensing is assumed to require an in-person visit every 2 weeks based on the note 'Participants must return to the site every 2 weeks'. These are categorized as core_treatment days.; All other procedures (imaging, labs, clinic visits) that fall on a day with drug administration/dispensing are subsumed under core_treatment due to precedence.; Treatment is assumed to continue until progressive disease or unacceptable toxicity for the entire 12-month period, thus post-treatment follow-up visits are not included in the counts for the 12-month interval.; The 'Telephone Contact Visit' on C1D8 is explicitly excluded as an in-person healthcare-contact day."
38833658,Arm B: TAS-102 Treatment,control,1,3,7,14,20,27,1,3,7,14,20,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progressive disease or unacceptable toxicity,"Screening (1 day) + Intervention visits every 2 weeks (Day 0, 14, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336, 350, 364).","All screening procedures marked 'X' in the 'Screening -ing' column are assumed to occur on a single contact day within the screening window.; The 'Archival or Newly Obtained Tissue Collection' (biopsy) during screening is considered a core_treatment procedure, making the screening day a core_treatment day.; TAS-102 administration/dispensing is assumed to require an in-person visit every 2 weeks based on the note 'Participants must return to the site every 2 weeks'. These are categorized as core_treatment days.; All other procedures (imaging, labs, clinic visits) that fall on a day with drug administration/dispensing are subsumed under core_treatment due to precedence.; Treatment is assumed to continue until progressive disease or unacceptable toxicity for the entire 12-month period, thus post-treatment follow-up visits are not included in the counts for the 12-month interval.; The 'Telephone Contact Visit' on C1D8 is explicitly excluded as an in-person healthcare-contact day."
38838287,Arm A: NKTR-214 + Nivolumab,intervention,1,3,6,10,14,19,0,3,6,10,14,19,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,42,maximum of 2 years from Cycle 1 Day 1,"Screening (1 day). On-treatment cycles (6 weeks/42 days each): C1D1, C1D8, C1D22. Subsequent cycles: Day 1, Day 22. Imaging (Body/Brain) on C2D22, C4D1, C5D22, C7D1, C8D22. PK/CVA on C1D1, C1D8, C1D22, C3D1, C3D22, C6D1, C6D22, C9D1, C9D22.","All screening procedures are assumed to occur on a single in-person screening day. The highest priority procedure (imaging) determines the category for this day.; Oral hydration follow-up visits (C1D3, C1D5, C2+D22) are not counted as in-person contact days as the protocol states they can be conducted by telephone.; Optional visits (e.g., optional tumor tissue sample) are not counted.; Treatment for Arm A is for a maximum of 2 years (Day 0 to Day 730). Calculations are performed up to Day 365.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits).; IV drug administration (NKTR-214 and Nivolumab) and IV fluids are categorized as core_treatment.; Body Imaging, Brain Imaging, ECG, and Echocardiogram/MUGA are categorized as imaging_diagnostics.; Clinical labs, urinalysis, pregnancy tests, PK samples, and CVA biomarkers are categorized as labs.; Physical exams, vital signs, Karnofsky Performance Status, AE assessments, concomitant medication review, hydration guidelines review, patient-reported outcomes (EQ-5D-3L, FKSI-19, PRO-CTCAE), and Health Care Resource Utilization are categorized as clinic_visits.; Follow-up visits (Safety Follow-Up 1 & 2, Survival Follow-Up) are not included in the 12-month window as treatment is assumed to continue for the full 12 months, placing these visits outside the 12-month interval. Survival Follow-Up is explicitly stated as possibly telephone, so not counted anyway."
38838287,Arm B: Sunitinib or Cabozantinib,control,1,3,6,10,14,19,0,0,0,0,0,0,1,0,1,2,4,5,0,0,0,0,0,0,0,3,5,8,10,14,42,until progression (assumed 12 months for calculation),"Screening (1 day). On-treatment cycles (6 weeks/42 days each): C1D1, C1D8, C1D22. Subsequent cycles: Day 1, Day 22. Imaging (Body/Brain) on C2D22, C4D1, C5D22, C7D1, C8D22.","All screening procedures are assumed to occur on a single in-person screening day. The highest priority procedure (imaging) determines the category for this day.; Optional visits (e.g., optional tumor tissue sample) are not counted.; Treatment for Arm B is 'until progression'. For calculation purposes, this is assumed to cover the full 12-month period.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits).; Oral drug dispensation (Sunitinib or Cabozantinib) is not considered a core_treatment activity, but rather part of the clinic visit on that day.; Body Imaging and Brain Imaging are categorized as imaging_diagnostics.; Clinical labs, urinalysis, and pregnancy tests are categorized as labs.; Physical exams, vital signs, Karnofsky Performance Status, AE assessments, concomitant medication review, Pill Diary review, patient-reported outcomes (EQ-5D-3L, FKSI-19, PRO-CTCAE), and Health Care Resource Utilization are categorized as clinic_visits.; Follow-up visits (Safety Follow-Up 1 & 2, Survival Follow-Up) are not included in the 12-month window as treatment is assumed to continue for the full 12 months, placing these visits outside the 12-month interval. Survival Follow-Up is explicitly stated as possibly telephone, so not counted anyway."
38872480,Bevacizumab + Chemotherapy arm,intervention,1,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,2,2,21,"maximum of 6 cycles for chemotherapy, maximum of 21 cycles for bevacizumab (starting from C2), or until disease progression/unacceptable toxicity, whichever occurs first.","Screening (1 day); Cycle 1 (Day 0, Day 7, Day 14); Cycles 2-6 (Day 1 of each 21-day cycle); Cycles 7-22 (Day 1 of each 21-day cycle). Radiographic assessments and PROs occur on specific cycle Day 1 visits.","All screening activities (Informed consent, H&P, ECOG PS, Vital signs, Hematology, Urinalysis, Serum chemistry, Serum pregnancy test, PT/INR/aPTT, ECG, Radiographic disease assessment, HIV/HBV/HCV serology, CA-125, PROs, Concomitant medications) are assumed to occur on a single in-person day within the screening window. This day is categorized as 'imaging_diagnostics' due to the presence of ECG and Radiographic disease assessment, which take precedence over other activities.; Cycle 1 Day 1 (Day 0) is the anchor date for all subsequent cycle calculations.; All cycle-based visits (Day 1 of each cycle) are assumed to occur on Day 1 of the respective cycle for calculation purposes, as allowed by the '± 3 days' window for drug administration and 'within 3 days prior' for other assessments.; Weekly vital signs in Cycle 1 (Day 7, Day 14) are counted as in-person 'clinic_visits' days, as the option for home assessment is at the investigator's discretion and not explicitly stated as non-contact for all patients.; Conditional visits (Audiogram, Incision check, PT/INR/aPTT for patients on anticoagulation only) are excluded from the general contact day count.; For days with multiple activities, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied. Therefore, imaging, labs, and clinic visits occurring on a treatment day are subsumed under 'core_treatment'.; The maximum number of chemotherapy cycles (Paclitaxel/Carboplatin) is 6. The maximum number of Bevacizumab/Placebo cycles is 21 (starting from Cycle 2, so C2-C22). Calculations assume patients continue for the maximum specified cycles.; Study Completion/Early Termination Visit and Post-Treatment follow-up visits are outside the 12-month window (Day +365) and are not included in the counts."
38872480,Placebo + Chemotherapy arm,control,1,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,2,2,21,"maximum of 6 cycles for chemotherapy, maximum of 21 cycles for placebo (starting from C2), or until disease progression/unacceptable toxicity, whichever occurs first.","Screening (1 day); Cycle 1 (Day 0, Day 7, Day 14); Cycles 2-6 (Day 1 of each 21-day cycle); Cycles 7-22 (Day 1 of each 21-day cycle). Radiographic assessments and PROs occur on specific cycle Day 1 visits.","All screening activities (Informed consent, H&P, ECOG PS, Vital signs, Hematology, Urinalysis, Serum chemistry, Serum pregnancy test, PT/INR/aPTT, ECG, Radiographic disease assessment, HIV/HBV/HCV serology, CA-125, PROs, Concomitant medications) are assumed to occur on a single in-person day within the screening window. This day is categorized as 'imaging_diagnostics' due to the presence of ECG and Radiographic disease assessment, which take precedence over other activities.; Cycle 1 Day 1 (Day 0) is the anchor date for all subsequent cycle calculations.; All cycle-based visits (Day 1 of each cycle) are assumed to occur on Day 1 of the respective cycle for calculation purposes, as allowed by the '± 3 days' window for drug administration and 'within 3 days prior' for other assessments.; Weekly vital signs in Cycle 1 (Day 7, Day 14) are counted as in-person 'clinic_visits' days, as the option for home assessment is at the investigator's discretion and not explicitly stated as non-contact for all patients.; Conditional visits (Audiogram, Incision check, PT/INR/aPTT for patients on anticoagulation only) are excluded from the general contact day count.; For days with multiple activities, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied. Therefore, imaging, labs, and clinic visits occurring on a treatment day are subsumed under 'core_treatment'.; The maximum number of chemotherapy cycles (Paclitaxel/Carboplatin) is 6. The maximum number of Placebo cycles is 21 (starting from Cycle 2, so C2-C22). Calculations assume patients continue for the maximum specified cycles.; Study Completion/Early Termination Visit and Post-Treatment follow-up visits are outside the 12-month window (Day +365) and are not included in the counts."
38889373,Amcenestrant (SAR439859) plus palbociclib,intervention,4,2,6,9,12,16,0,1,3,5,7,10,2,0,1,2,3,4,1,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (4 days), then D1 and D15 of Cycles 1 & 2. From Cycle 3 onwards, D1 of each cycle. Tumor assessments (CT/MRI) every 12 weeks from randomization. Radionuclide bone scans every 24 weeks for the first 18 months, then every 12 weeks. PK samples on C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C7D1, C10D1. FSH on C1D1 and every 4th cycle. Estradiol on C1D1 and C3D1. HRQL on C1D1, C2D1, C3D1, C4D1, then every 3 cycles from C6D1. cfDNA on C4D1.","Goserelin administration (subcutaneous injection by staff) is considered an in-person core_treatment contact day. It is assumed the participant is eligible for goserelin (pre/perimenopausal woman or man).; Screening procedures are consolidated into a minimum of 4 distinct contact days based on logical grouping of activities (e.g., all initial clinic assessments on one day, all labs on another, all imaging on a third, and fresh biopsy if required on a fourth).; An 'X' in the Schedule of Activities table indicates an in-person contact day.; Procedures marked with '(X)' (e.g., Urine dipstick testing on C1D15) are considered optional/conditional and are excluded from the base contact day count unless explicitly stated as mandatory under certain conditions that are assumed to occur (e.g., fresh biopsy if archived tissue is unavailable).; Oral drug administration (Amcenestrant, Letrozole, Palbociclib) is not considered an in-person contact day unless combined with other procedures requiring a clinic visit.; Treatment is assumed to continue until disease progression.; The Schedule of Activities is identical for both treatment arms."
38889373,Letrozole plus palbociclib,intervention,4,2,6,9,12,16,0,1,3,5,7,10,2,0,1,2,3,4,1,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (4 days), then D1 and D15 of Cycles 1 & 2. From Cycle 3 onwards, D1 of each cycle. Tumor assessments (CT/MRI) every 12 weeks from randomization. Radionuclide bone scans every 24 weeks for the first 18 months, then every 12 weeks. PK samples on C1D1, C1D15, C2D1, C2D15, C3D1, C4D1, C7D1, C10D1. FSH on C1D1 and every 4th cycle. Estradiol on C1D1 and C3D1. HRQL on C1D1, C2D1, C3D1, C4D1, then every 3 cycles from C6D1. cfDNA on C4D1.","Goserelin administration (subcutaneous injection by staff) is considered an in-person core_treatment contact day. It is assumed the participant is eligible for goserelin (pre/perimenopausal woman or man).; Screening procedures are consolidated into a minimum of 4 distinct contact days based on logical grouping of activities (e.g., all initial clinic assessments on one day, all labs on another, all imaging on a third, and fresh biopsy if required on a fourth).; An 'X' in the Schedule of Activities table indicates an in-person contact day.; Procedures marked with '(X)' (e.g., Urine dipstick testing on C1D15) are considered optional/conditional and are excluded from the base contact day count unless explicitly stated as mandatory under certain conditions that are assumed to occur (e.g., fresh biopsy if archived tissue is unavailable).; Oral drug administration (Amcenestrant, Letrozole, Palbociclib) is not considered an in-person contact day unless combined with other procedures requiring a clinic visit.; Treatment is assumed to continue until disease progression.; The Schedule of Activities is identical for both treatment arms."
38942046,Arm A: Perioperative Nivolumab,intervention,1,3,5,9,13,15,0,2,4,7,11,11,1,0,0,1,1,2,0,1,1,1,1,2,0,0,0,0,0,0,28,"1 neoadjuvant dose, followed by 9 adjuvant doses every 4 weeks for 9 months","Screening (Day -28) -> Day +1 (Neoadjuvant Nivolumab + Biopsy) -> Day +10 (Pre-Surgery) -> Day +15 (Nephrectomy) -> Day +43, +71, +99, +127, +155, +183, +211, +239, +267 (Adjuvant Nivolumab) -> Day +140 (Month 4.5 Imaging) -> Day +280 (Month 9 Imaging) -> Day +308 (FU1)","Day 0 is the date of randomization.; The 'After Amendment #4' schedule for Nivolumab administration (1 neoadjuvant dose, 9 adjuvant doses every 4 weeks) is used.; The neoadjuvant nivolumab infusion (Day 1) and mandatory core biopsy (if needed post-randomization) are assumed to occur on the same day (Day +1 relative to randomization). This day is categorized as 'core_treatment' due to the infusion.; Nephrectomy for Arm A is assumed to occur on Day +15 (mid-point of 7-28 days after neoadjuvant dose on Day +1).; The pre-surgery visit for Arm A is assumed to occur on Day +10 (within 5 business days prior to nephrectomy).; The first adjuvant nivolumab dose is assumed to occur on Day +43 (4 weeks after nephrectomy on Day +15). Subsequent adjuvant doses occur every 28 days.; Month 4.5 (Week 20) visit is approximated as Day +140.; Month 9 (Week 40) visit is approximated as Day +280.; The 'Within 6 Weeks after Final Treatment' visit is approximated as Day +308 (6 weeks after the last adjuvant dose on Day +267).; All screening procedures listed under 'Baseline' in the Therapeutic Parameters Table are consolidated into a single in-person contact day in the screening window, prioritized as 'imaging_diagnostics' due to CT/MRI and potential biopsy.; QOL assessments are performed on clinic visit days and do not add separate contact days.; Optional visits (e.g., DXA, clinically indicated bone imaging/EKG/echo) and recurrence visits are excluded from fixed schedule counts.; Telephone calls are not counted as in-person contact days."
38942046,Arm B: Observation,control,1,3,5,6,6,7,0,1,1,1,1,1,1,0,0,1,1,2,0,1,3,3,3,3,0,1,1,1,1,1,,observation after nephrectomy,Screening (Day -28) -> Day +1 (QOL) -> Day +24 (Pre-Surgery) -> Day +28 (Nephrectomy) -> Day +70 (FU1) -> Day +84 (Week 12) -> Day +140 (Month 4.5 Imaging) -> Day +280 (Month 9 Imaging),"Day 0 is the date of randomization.; Nephrectomy for Arm B is assumed to occur on Day +28 (mid-point of within 8 weeks after randomization).; A QOL assessment is assumed to occur on Day +1 (post-randomization, prior to nephrectomy).; The pre-surgery visit for Arm B is assumed to occur on Day +24 (4 days prior to nephrectomy).; The 'Within 6 Weeks after Surgery' visit is approximated as Day +70 (6 weeks after nephrectomy on Day +28).; The Week 12 visit is approximated as Day +84.; Month 4.5 (Week 20) visit is approximated as Day +140.; Month 9 (Week 40) visit is approximated as Day +280.; All screening procedures listed under 'Baseline' in the Therapeutic Parameters Table are consolidated into a single in-person contact day in the screening window, prioritized as 'imaging_diagnostics' due to CT/MRI and potential biopsy.; QOL assessments are performed on clinic visit days and do not add separate contact days.; Optional visits (e.g., DXA, clinically indicated bone imaging/EKG/echo) and recurrence visits are excluded from fixed schedule counts.; Telephone calls are not counted as in-person contact days."
